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Background: Malignant Mesothelioma (MM) is a malignancy related to asbestos 
exposure which causes a wide variety of molecular aberrations. MM has a very dismal 
treatment outcome with an overall survival of fewer than 12 months, with less than 
five drugs available for its treatment. MM recurrence is unavoidable due to 
chemoresistance. Long-term inflammation triggered by asbestos activates a key 
transcription factor, nuclear factor-κB (NF-κB), which is further upregulated in cancer 
stem cells (CSCs) by hypoxia. Both hypoxia and NF-κB pathway plays a pivotal role 
in the maintenance of stemness in hypoxia-induced CSCs leading to upregulation of 
anti-apoptotic signalling, chemo-radiation resistance and metastasis. Therefore, the 
development of drugs targeting hypoxia-NF-κB-CSCs axis is of clinical significance 
for MM treatment. Our previous studies have shown that Disulfiram (DS), a clinically 
used anti-alcoholism drug, in combination with Copper (II) (Cu) has substantial 
toxicity in CSCs in a wide range of cancer types. The clinical application of DS in 
Cancer is limited by its very short half-life (< 2 minutes) in the bloodstream. MM is 
Cancer which mainly infiltrates local organs and tissues with rare distant metastasis. 
Considering this growing feature of MM, we developed a biodegradable and 
controlled released poly (lactic-co-glycolic acid) microparticle-encapsulate disulfiram 
(PLGA-DS) for local treatment of MM. This study aims to examine the anti-MM 
effect of PLGA-DS and elucidate its molecular mechanisms.  
Methodologies: In order to determine drug sensitivity, stemness, apoptosis, 
invasiveness and NFNB status, the following methodologies were performed in this 
study: MTT cytotoxicity assay, flow cytometry, analysis of CSC markers, hypoxic cell 
 
 iii 
cultures, western blot, stable transfection of MM cell line with NFκB, CRISPR-Cas9 
knock out of NF-kB-p65, CSC sphere reformation, invasion and migration assay.  
 
Results and conclusions: Two MM cell lines were examined and cultured in a hypoxic 
environment. MM cell lines were highly resistant to Pemetrexed (PMT) and Cisplatin 
(CIS), the first-line chemotherapeutic agents for MM. Hypoxia cultured MM cells 
showed high NF-κB activity and CSC markers and manifested strong 
migration/invasion ability. The NF-κB-p65 over expressed transfected cell lines did 
not demonstrate CSC traits along with no increase in resistance to first line drugs. 
PLGA-DS/Cu completely abolished CSC population in a culture which is 
demonstrated by sphere reformation assays and flow cytometry analysis of CSC 
markers such as CD24, CD133 and ABCG2. PLGA-DS/Cu also inhibited the hypoxia-
induced NF-kB expression and blocked the migration and invasion ability of MM 
cells. It showed substantial toxicity to MM cell lines and reversed hypoxia-induced 
chemoresistance. Also, PLGA-DS/Cu potentiated the cytotoxic effect of 
Cisplatin/Pemetrexed in vitro. Isobologram analysis indicates moderate synergistic 
effect between PLGA-DS and cisplatin and pemetrexed in MSTO 211 and JU77 cell 
lines, respectively. As an FDA approved a drug with all preclinical safety data 
available, further studies may quickly translate it into MM clinical treatment. This is 
very promising in vitro data and indicate that PLGA-DS could be a promising 
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Cancer is not a single disease and caused by the uncontrolled growth of abnormal or 
mutated cells in the body. Cancer cells have the potential to grow and divide rapidly 
and undergo unchecked proliferation (B Kalyanaraman.,2017). It is major cause of 
worldwide death and in countries of all income levels (Torre et al.,2015). According 
to the WHO, Cancer imposes the largest worldwide burden, i.e. 244.6 million 
Disability-adjusted life years (DALYs), both in men (137.4 million DALYs) and in 
women (107.1 million DALYs).The cancer-related burden is slightly but non-
significantly higher in men than in women (9.6% vs 8.6%; p = 0.219).  
 
 
Figure 1: Showing the estimated epidemiological trend of the five leading causes of 
cancer death from the years 2016 to 2060 (Mattiuzzi and Lippi.,2019). 
 
As per last WHO update, corresponding to the year 2016 states that cancer is the 
second leading cause of death, accounting for 8.97 million deaths worldwide. 
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Especially, the rank of cancer was among the leading reasons for mortality which 
differs in the different WHO regions. It remains first in the Western Pacific and 
America Regions, second in South-East Asia, Eastern Mediterranean Regions and 
European, but only fourth in the African Region (Mattiuzzi and Lippi.,2019)  
 
2.0 Mesothelioma 
Mesothelioma is characterised as an insidious neoplasm because of its long latency 
period, for about 40 years (Frank et al.,2012). Malignant Mesotheliomas (MM) are 
rare and aggressive tumors. It arises from the mesothelium of pleura and peritoneum 
and the rare sites are pericardium and tunica vagnilis testis. More than 80% of 
mesotheliomas localises in the pleura (Tischoff et al.,2017). Previous exposure to 
asbestos is the leading risk factor for MM. Clinical signs are late and unspecific 
(Delourme et al.,2018). The precise prevalence of the disease is not known, but MM 
expects to represent 1% of all the known cancers (Alastair J Moore et al., 2008). 
 
2.1 Epidemology 
Europe (Belgium, Malta, The Netherlands) and Oceania (New Zealand and Australia) 
have reported the highest MM incidence. Fifty-five countries have banned asbestos. 
However, only 16% of the inhabitants contribute to the world population. The second 
group includes a significant part of Europe and the USA. The incidence rates of MM 
are misleading as inside a single country; the incidence of the disease shows 
substantial variations depending on the areas (Bianchi et al.,2014).  
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The incidence and mortality rates of global mesothelioma are uncertain because there 
is no data available from developed countries which continue to use large quantities 
of asbestos. The accuracy of diagnosis for MM has improved due to novel molecular 
and immunohistochemical markers. However, still, 14 per cent (high-resource 
countries) to 50 per cent (developing countries) of diagnoses are incorrect, leading to 
insufficient diagnosis (Carbone et al., 2019). 
Men get affected even more often than women. The mean patient age is > 60 years. 
The most significant risk factor is asbestos exposure, which persists in 54 90% of all 
affected patients (Tischoff and Apple.,2017). In environmentally exposed subjects, the 
male to female ratio reports about 1.2: 1.4 (Marinaccio et al.,2018). In 9 countries 
(United Kingdom, Sweden, France, Germany, Netherlands, Canada, United States, 
Australia, and New Zealand), MM mortality has decreased dramatically among males. 
It was significantly rising in 5 countries (Poland, Spain, China-Hong Kong, Japan, and 
the Republic of Korea) over the last ten years.  
Among females and in the last ten years MM mortality has declined significantly in 
only one country (Italy); while in 3 countries (Poland, Argentina, and the Republic of 
Korea), it has increased substantially. In the remaining countries, APC (Annual 
Percentage Change) was stable. The burden and patterns of mesothelioma mortality 
are globally variable. Furthermore, MM is still a significant cause of mortality despite 
the ban on asbestos in many countries (Rahman. ,2018). 
 
2.2 Etiology 
Exposure to airborne asbestos fires is mainly associated with the development of MM  
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(Porpodis et al., 2013). Asbestos belongs to silicate family minerals which are further 
divided into two major groups: The serpentine form and the amphibole form. Asbestos 
is known to cause various diseases like laryngeal cancer, plaques/fibrosis and majorly 
Mesothelioma (Michele et al.,2012). Most pleural mesotheliomas are due to asbestos 
(70% to 90%) in men in Europe and North America. However, this proportion is lesser 
for peritoneal mesothelioma. In North America, asbestos exposure is lesser in women 
at any location, but in Europe, the ratio is higher and differs significantly by locale. 
Other types of mineral fibers (erionite, fluoro-edenite, and possibly balangeroite) can 
induce MM at specific geographic locations. For other malignancies, therapeutic 
radiation is a well-established cause of mesothelioma. Chronic pleural inflammation 
can cause MM, but there is insufficient data. A small number of mesotheliomas 
(probably 1%) is caused by germline mutations/deletions of BRCA1-associated 
protein 1 (BAP1). All of these alternative etiologies account for a small proportion of 
tumours, and most mesotheliomas are not caused by asbestos exposure (Attanoos et 
al.,2017).  
 
2.3 Types and features 
 
2.3.1 Anatomic classification 
Mesothelioma arises from mesothelial surfaces and can be classified by location and 
pathology. According to the site, mesothelioma occurs majorly in pleura (65%-70%), 




1.  Pleural Malignant Mesothelioma: It is the most common and accounts for the 
predominant subtype-80% of all cases. Pleural mesothelioma has an unusually 
dismal prognosis; its 5-year survival rate is only 10%, making it the most fatal 
among rare cancers (Tolani et al.,2018). 
2. Peritoneal Malignant Mesothelioma -Peritoneal Malignant Mesothelioma is a 
rare tumour, less common than its pleural equivalent. It emerges from the 
peritoneum overlying mesothelial cells, it occurs preferentially in males with 
an average age ranging from 47 to 60.5 years, clinical symptoms are not 
specific, and the imagery remains little or non-contributive (Mery et al.,2014). 
3. Primary cardiac and pericardial tumours - These are rare entities with an 
autopsy frequency of 0.001-0.03%. Cardiac and pericardial metastases are 
much more common than primary tumours. Pericardial malignant 
mesotheliomas account for up to 50% of primary pericardial tumours (Barroso 
et al.,2017). 
4. Mesothelioma of the tunica vaginalis - It arises from the serosal membranes of 
the tunica vaginalis testis (TVT) (Butnor et al.,2019). It represents 0.3 to 0.5% 
of all malignant mesotheliomas. Asbestos exposure is frequently accompanied 
by sickness. It is often mistakenly diagnosed during surgery for other causes, 
due to its low occurrence and non-specific clinical presentation, and the 
prognosis is typically low (Trenti et al.,2019). 
 
 2.3.2 Pathological classification 
According to pathology, malignant mesothelioma is divided into four histologic types:  
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1. Epithelioid: Composes roughly 60% of cases. Tumours of this kind have 
higher chances of survival since they are easier to be identified and removable 
with surgery. They are characterised by square-shaped cells with a visible 
nucleus and is the most common (50-70%) and tend to have a much more 
favourable prognosis (Boneli et al.,2017). 
2. Fibrous sarcomatoid: Roughly 25% of cases are more aggressive than 
epithelial, and patients often do not respond to the treatment. 10-20% with 
elongated and spindle-shaped cells is the most aggressive one (Boneli et 
al.,2017). 
3. Biphasic/mixed: They are most challenging to cure and thus with abysmal 
prognosis. It also contributes roughly to 15% of the total occurrence and 
consist of both epithelial and sarcomatoid cell types. It is a mixture of epithelial 
cells and sarcomatoid cells (20 35%) (Boneli et al.,2017). 
4.  Other (rare) histologies include desmoplastic, lymphohistiocytosis, 
deciduous, anaplastic, multicystic, and well-differentiated papillary 
mesothelioma (Terence et al.,2009). Papillary type is the most common which 
coexist with other patterns and mostly tubular design (Shavekke et al.,2017). 
 
2.3.3 Modified pathological classification 
Recently, a revised classification was also suggested (Blyth et al.,2018). The authors 
suggest that epithelioid and sarcomatoid classifications to be retained, but biphasic 
tumours were split into biphasic-E and biphasic-S. 68% of tumours are histologically 
classified as epithelioid; further molecularly classified as biphasic-E. Moreover, it had 




                  




           
 
  
Figure 2: Showing the median survival of mesothelioma patients depending upon the 




MM has reduced life expectancy, with median survival varying between 8 and 14 
months. For mesothelioma patients, the prognostic markers were categorised into the 
following four basic categories: clinical and patient-reported prognostic markers, 
predictive blood or serum markers, prognostic imaging markers, and molecular 
prognostic markers. Inflammatory markers like WBC, neutrophil to lymphocyte ratio 
(NLR) and C-reactive protein in various MM, prognosis studies have also found to be 
significantly elevated (Zandwijk et al.,2013). Multiple organisations have analysed 
quite a large number of MM patients who enrolled in the treatment trials and identified 
the following poor prognostic factors: WBC count - 8.3 × 109/L or higher, older age, 
i.e. more than 75, Male, chest pain, Non-epithelioid histology, Platelets greater than 
400,000 L, poor performance status, LDH greater than 500 IU/L (Alastair J Moore 
et al., 2008). Decreased levels of haemoglobin, thrombocytosis, and elevated serum 
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lactate dehydrogenase (LDH) also contributed to the poor prognosis (Zandwijk et 
al.,2013). Epithelioid is the most common amongst the subtypes and is associated with 
the best prognosis. The worst prognosis is of sarcomatoid variants consisting of 
spindle morphology (Frank et al., 2012). 
 
2.5 Symptoms 
MM was discovered incidentally during laparoscopy for other indications. Usually, 
MM is diagnosed between 40 and 65 years of age and can show ambiguous, non-
specific symptoms which may be quite variable depending on the degree and 
distribution of the disease in the peritoneum. Plaques are very common with 
mesothelioma patients. Patients most often complain of increased abdominal 
distension and abdominal pain (Enomoto et al., 2019. Typical patients with malignant 
pleural mesothelioma may have an unproductive cough, chest wall pain, dyspnea, 
pleural effusions mainly on the right side (60 per cent of cases)). The common 
symptoms are shortness of breath and pain (90%), while others include fatigue (36%), 
worry (29%), cough (22%), sweating (22%), and constipation (22%) (Porpodis et 
al.,2013). 
 
2.6 Staging of MM 
The staging method for TNM ((T) tumours, (N) nodes, and (M) metastases is primarily 
focused on surgical and pathological variables and cross-sectional imaging. Due to the 
impracticality of measuring tumours with irregular and highly variable morphology, 
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unlike TNM staging of most solid tumours, MM classification does not require 
consideration of tumour size. The lung cancer diagram, which suggests that tumours 
invade pulmonary lymphatics, follows the N classification of MM. M classification of 
MM is binary. M1 indicates documented blood-borne metastasis. Distant metastases 
to the brain, bone, kidney and adrenal glands have reported. Still, they are rarely 
diagnosed, likely due to the comparatively rapid and fatal progression of local T4 
disease involving vital intrathoracic organs (Richard et al.,2017). Tertemiz et al. found 
extrapleural dissemination in 87.7% of cases during postmortem studies. Tumour 
dissemination in extrathoracic sites seen in the liver (31.9%), spleen (10.8%), thyroid 
(6.9%), and the brain (3.0%) (Tertemiz et al.,2014) 
The precision and reproducibility of TNM staging for MM are impeded by the absence 
of a quantitative measure, representing the size of the tumour, the number and 
complexity of criteria for T classification, and the growing inclination to use lung-
sparing surgical procedures that leave many unassessed margins and lymph nodes. 
These facts led the International Association for the Study of Lung Cancer (IASLC) 
staging committee to suggest the concept of a "best" stage (bTNM) incorporating 
available staging data from multiple (clinical, surgical, pathological) evaluations to 
minimise missing data and increase the efficacy of TNM by using chest computed 
tomography (CT), magnetic resonance imaging (MRI) and fluorodeoxyglucose 
positron emission tomography (FDG - PET), clinical staging of MM usually requires 
radiographic evaluation of TNM classification criteria. Some groups used staging to 
monitor metastatic diseases which would avoid surgical resection and could be missed 
by imaging.  
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Pathological staging classifies cases from surgical resection based on gross and 
microscopic analyses of pathological specimens (Richard et al.,2017). Review of the 
database of MM by the IASLC indicated that therapeutic (cTNM) staging minimally 
stratified survival and was inconsistent with pathological (pTNM) staging. Alternative 
staging models based on quantitative parameters explored, to improve the prognostic 
classification of MM. The rarity of this disorder, the difficulty of its diagnosis and the 
general ineffectiveness of available treatment have impeded attempts to improve MM 
staging (Gill et al.,2018). RECIST (Solid Tumors Response Evaluation Criteria) is the 
most used MM measurement system. It is based on the unidimensional measurements 
of tumour thickness perpendicular to the chest wall or mediastinum. Tumour stage 
remains the most important prognostic factor in many malignancies, and it is often 
used to stratify patients in clinical trials. Since not every patient had both therapeutic 
and pathological stages, data was put together to obtain the best TNM.  
Beyond TNM, histology remains the most significant prognostic determinant (Bonomi 
et al., 2017). The peritoneal carcinomatosis index (PCI) is the most frequently used 
and accepted classification to measure the peritoneal disease burden. The eighth 
edition of the Staging Manual of the American Joint Committee on Cancer (AJCC) 
has a staging system for pleural mesothelioma. Still, it has no staging system for 
Malignant Peritoneal Mesothelioma (MPM). A new TNM staging method, proposed 
by Yan and colleagues, addresses this issue. T was allocated under this method based 
on the magnitude of the disease burden quantified by intraoperative PCI and classified 
into four subgroups: T1 (PCI 1 10), T2 (PCI 11 20), T3 (PCI 21 30), and T4 (PCI 
31 39). Node status (N) allocated for histopathology of surgical specimens based on 
the presence (N1) or absence (N0) of positive lymph nodes. Any extra-abdominal 
metastasis discovered on pre-operative imaging was assigned M1. Stage I disease 
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included T1N0M0, stage II included T2- 3N0M0, and stage III included T4N0M0 and 
N1 or M1 disease. Using this staging system, 5-year survival for stage I, II, and III 
was 87%, 53%, and 29%, respectively (Enomoto et al.,2019). Efforts are underway to 
further refine criteria and to validate 3-dimensional quantitative estimates of tumour 
size to potentially augment T classification in future editions of the staging system 
(Richard et al.,2017). 
 
2.7 Pathogenesis  
Asbestos has demonstrated to induce the production of reactive oxygen and nitrogen 
species from mesothelial cells and macrophages. These species are potent mutagens 
which can react with DNA, resulting in a plethora of damage (Quinna et al.,2015). The 
underlying pathogenesis of the disease is that the inhaled asbestos fibres enter the 
visceral pleura and the pleural space and then to the parietal pleura through the alveoli 
or retrograde through the lymphatic vessels (Roe and Stella.,2015). Molecular changes 
are also involved in the development of MM and accumulate over many decades, 
eventually resulting in malignant transformation of the mesothelial cell. The typical 
molecular landscape of MM consists of multiple chromosomal losses leading to loss 
or inactivation of several tumour suppressor genes. Mainly, chromosomes 3p, 9p and 
22q, harbouring tumour suppressor genes, are critically involved in the pathogenesis 
of MM, leading to loss of p16INK4A-p14ARF (CDKN2A) located at 9p21, 
neurofibromatosis type 2 (NF2) at 22q12 and BRCA1-associated protein 1 (BAP-1) 
at 3p21.31-p21.2 (Hjerpe, Own and Dobra.,2020). Several MM consists of very 
complex karyotypes along with extensive aneuploidy and the rearrangement of many 
chromosomes. The single most common karyotypic change found is the loss of one 
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copy of chromosome 22. Moreover, dysregulation in signal transduction pathways, 
related to cell survival and proliferation, has also been demonstrated (Boneli et 
al.,2017). The fibres themselves can also cause aberrant separation of chromosomes 
during mitosis and direct activation of tyrosine kinase receptors, in the absence of 
driver mutations (Abbott et al.,2020). 
 
2.8 Diagnosis  
As the clinical presentations and imaging are complex and non-specific, diagnosis of 
MM is difficult. Chest X-ray (CXR) typically starts with imaging and then goes on to 
computed tomography (CT). A novel approach may help differentiate malignant from 
benign lesions, such as quantitative textural and form analysis. Ultrasound is 
especially important to analyse pleural effusion. Thoracoscopy is used in the 
diagnostic phase as a standard procedure that allows good visualisation of the 
endothoracic anatomy with the direct evaluation of the locoregional tumour extension 
and to practice, where necessary, effective chemical pleurodesis (Abbott et al.,2020). 
It is a reliable diagnostic tool since it can give additional tissue confirmation. 
Computed tomography (CT) may show pleural-based nodularity. PET (Positron 
emission tomography) is very beneficial as mesothelioma has hypermetabolic 
characteristics. Thus, this technique cannot only be used for staging, but post-
treatment follows up as well (Frank et al., 2012). The ultra-structural features of MM 
can be revealed by using electron microscopy. As thin and tall microvilli on the surface 





2.9 Biomarkers  
Currently, there is no routine test used for testing prognostic or predictive biomarkers 
for MM. Emerging data suggest that the histologic type of mesothelioma show 
different associations with different predictive biomarkers (Brcic and Kern.,2020). 
Over the years, numerous candidate biomarkers have proposed the significance of 
screening, early diagnostic and prognostic markers. A combination of two positive 
(mesothelial) and two negatives (cancer-related) markers are considered the gold 
standard for immunohistochemical diagnosis of epithelioid and biphasic MM, while 
the rare sarcomatoid type has no specific markers. Among biomarkers in body fluids 
such as a serum, plasma, and pleural effusion (PE), soluble mesothelin-related peptide 
(SMRP), also known as mesothelin, is the best characterised and well known 
displaying high specificity for MM, but low sensitivity. Therefore, levels of SMRP in 
the body fluids cannot be considered as the sole modality of a diagnostic marker. 
Osteopontin has been reported as a promising biomarker to discriminate early-stage 
MM patients among an asbestos-exposed population, but its usefulness in screening is 
compromised by the low specificity (Lacerenza et al.,2020). 
Claudin-4 now viewed by many expert mesothelioma pathologists, and supported by 
the literature, as a superior marker of epithelial differentiation. While historically 
described mesothelial markers remain in use, more recently, HEG1 (heart 
development protein with EGF-like domains), is described as a sensitive and specific 
marker of mesothelial differentiation with an excellent discriminatory expression 
between mesothelial and epithelial proliferation (Schulte and Husain.,2020). MM 
stains were positive for cytokeratin 5/6 (CK 5/6), calretinin, vimentin, epithelial 
membrane antigen, Wilms tumour 1 (WT-1) (Enomoto et al.,2019). Until today the 
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only tumour biomarker to receive the approval of US Food and Drug Administration 
for clinical use is mesothelin. It has a very confined expression on non-cancerous 
healthy tissue; thus, it is a desirable therapeutic target for mesothelin-positive tumours. 
In a few situations, mesothelin can be shed from the surface of the cells by the action 
of tumour necrosis factor-a-converting enzyme and identified in the blood (Creaney 
et al.,2017). The low sensitivity of SMRPs for early MM limits its value; therefore, 
additional biomarkers are required (Santarelli et al.,2015). 
 
3.0 Treatment 
Unfortunately, few treatment options exist for MM (Abbott et al.,2020). Current 
treatments for MM are limited to surgery, radiation, and chemotherapy (Tolani et 
al.,2018). 
 
3.1 Surgery  
In terms of pleurectomy, surgical therapy is only for patients who can handle surgical 
risks and have a low tumour stage (Abbott et al.,2020). Various surgical procedures 
are surgical pleurodesis by video-assisted thoracoscopic surgery (VATS), debulking 
surgery and extrapleural pneumonectomy (EPP) (Alastair J Moore et al., 2008). 
Several non-randomised series reported long-term survivors following extra-pleural 
pneumonectomy (EPP), which involves removal of the diseased pleura in addition to 
the lung, pericardium and hemidiaphragm, usually as part of a multi-modality regime 
including neoadjuvant chemotherapy and adjuvant Hemi-thoracic radiotherapy (Blyth 
et al.,2018). In MM surgery, microscopic radical (R0) resection is not possible because 
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of the anatomy, and the target of MM surgery is full macroscopic resection (R1). 
Surgery alone is not effective, it is generally undertaken with chemotherapy and/or 
radiation therapy and reserved for a subset of patients with early tumour, epithelioid 
histology and good results (Cantini et al., 2020) 
 
3.2 Radiotherapy  
Radiation therapy (RT) may have a role in MM, as it can be used in combination with 
chemotherapy and can provide local tumour control if the patient has a good 
performance status (Abbott et al. ,2020). Intensity-modulated radiotherapy (IMRT) 
allows effective moulding of large RT doses, even to the complex morphology of the 
pleura. However, some of the apparent radio-resistance associated with MM may 
reflect intrinsic radio-resistant tumour biology and development of effective 
radiosensitisers which may be necessary for maximum effect. Combinations of RT 
with relevant agents, e.g. DNA-damage repair inhibitors and/or immunotherapies may 
deliver new treatment options (Blyth et al.,2018). Intensity-modulated radiotherapy 
(IMRT) is a sophisticated modality using small radiation beams at different angles in 
a 3-D conformal pattern, which allows more intense radiation at the target with high 
precision (Frank et al., 2012). However, the toxicity may be important and, thus, RT 
unless it helps to alleviate symptoms such as chest pain or bronchial/oesophagal 
obstruction, it alone has no benefit (Abbott et al. ,2020). 
 
3.3 Chemotherapy 
The combination of Cisplatin and Pemetrexed is floowed as a standard first line  
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therapy for MM. In 2003, a phase III randomised trial compared Cisplatin alone versus 
Cisplatin plus Pemetrexed in untreated malignant pleural mesothelioma with the 
combination, and the response rate was 41.3% compared to 16.7% for Cisplatin alone, 
Median time to progression was 5.7 vs 3.9 months. Median overall survival was 12.1 
vs 9.3 months, both in favour of the combination arm. Therefore, it has also become a 
standard recommendation in the adjuvant combined modality approach to resectable 
disease (Frank et al., 2012). The National Comprehensive Cancer Network's 
recommendations for 2018 identify that the first-line systemic therapy for MM is 
Pemetrexed combined with Cisplatin and probably Bevacizumab (Abbott et al. ,2020). 
 
3.3.1 Cisplatin  
Cisplatin is a small and surprisingly simple molecule made up of one atom of Platinum 
bound to two amides and two chlorides; it is a potent drug considering its size. 
Cisplatin undergoes a mechanism known as aquation, under conditions of low chloride 
concentration, as found in the cytosol, in which water molecules substitute one or two 
chlorides. By the process of aquation, Cisplatin becomes highly reactive and binds 
readily within the cell to a variety of biomolecules. Cisplatin covalently binds in its 
reactive form to the DNA bases, forming adducts of DNA. In a coordinated effort by 
the cells to remove the lesions, these DNA adducts block transcription and DNA 
synthesis, which in turn activates a complex intracellular signal transduction cascade. 
The cell cycle is arrested, providing adequate time for DNA repair mechanisms to 
remove the lesions. In cases of impaired repair or excessive damage, the cells undergo 
apoptosis (Rocha et al.,2018).  
 
Figure 1.3: Mechanism of Cisplatin action for mesothelioma treatment.  
Platinum responsiveness is high primarily, but many cancer patients will 
ultimately relapse with the Cisplatin-resistant disease. The major mechanisms 
leading to Cisplatin resistance inside the tumour cell is decreased drug import, 
increased drug export, increased drug inactivation by detoxification enzymes, 
increased DNA damage repair, and inactivated cell death signalling. Hence, drug 
resistance has been observed in many patients who relapsed from interactions 
between a cell, and its environmental components which promote these internal 
mechanisms and subsequent Cisplatin resistance (Chen and Chang.,2019). To 
overcome resistance, Cisplatin is commonly used in combination with some other 





Pemetrexed belongs to the class of antifolic agents, but it is distinguished from the 
other antifolates for its novel structure, possessing a unique 6-5 fused pyrrolo-[2,3-d] 
pyrimidine nucleus instead of the classical 6-6 core structure (pteridine or quinazoline) 
(Facchetti et al.,2017).  
 
 




Pemetrexed is an antagonist against folates. Because folate donate one-carbon units  
to the biosynthesis of purines, thymidine, and hence DNA, the interruption of folate 
metabolism by Pemetrexed contributes to ineffective DNA synthesis and failure of 
growth in tumour cells (Liang et al.,2019).  
Pemetrexed is rapidly converted to polyglutamate forms once the folylpolyglutamate 
enzyme synthetase enters the cell. The types of polyglutamate are stored in cells and 
are also more powerful Inhibitors of TS and GARFT. The process of polyglutamation 
is concentration and time-dependent process, which occurs in tumour and lesser in 
normal cells. Polyglutamated metabolites have prolonged drug action in malignant 
cells due to increased intracellular half-life., Therefore, Pemetrexed prevents the 
formation of DNA and RNA by inhibiting the formation of precursor purine and 
pyrimidine nucleotides, required for the growth and survival of both normal cells and 
cancer cells. 
The primary adverse effect of Pemetrexed is the dose-limiting toxicity of the drug and 
is associated with elevated pretreatment levels of plasma homocysteine which predicts 
severe myelosuppression (Xin et al.,2014). In first-line therapy, Pemetrexed is always 
administered in combination with other more emetogenic agents, such as Cisplatin; 
therefore, adequate antiemetic prophylaxis is necessary.  
 
3.3.3 Resistance of MM to Cisplatin and Pemetrexed 
A widely held misconception contends that all elderly patients, because of the toxicity 
of some chemotherapeutic agents, even with good performance status (performance 
status [PS] 0 1), are unable to tolerate aggressive chemotherapy (Xin et al.,2014). 
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However, the effect of this therapy is reversible; preclinical testing showed that 
exogenous hypoxanthine and thymidine were necessary to prevent growth inhibition 
by Pemetrexed (Curtin and Hughes 2001). In Pemetrexed-resistant cells, TYMS 
(Thymidylate Synthase) overexpression is one of the major factors leading to 
resistance and the regulation of DHFR (dihydrofolate reductase), RFC (Reduce folate 
carrier) and FPGS (folylpolyglutamate synthetase) expression is associated with 
acquired resistance to pemetrexed (Obata et al.,2013).  
Although Cisplatin is the most frequently used chemotherapeutic agent used, in 
association with Pemetrexed, usually the results are disappointing. Since the score of 
residual peritoneal seeding after cytoreductive peritonectomy is the principal 
prognostic indicator; selected patients can support it. Hyperthermic intraoperative 
intraperitoneal chemotherapy (HIPEC), followed by early postoperative 
intraperitoneal chemotherapy, is a good strategy for a much longer survival (Murinello 
et al.,2010). Therefore, despite the improvement shown with the combination of 
Cisplatin and Pemetrexed, nearly two-thirds of patients still fail to show a response to 
this regimen (Frank et al., 2012). 
MM treatment is not guided by histological or molecular features of the tumour. It 
mainly depends on the clinical stage and patient characteristics. Moreover, there are 
no other approved regimens for relapsed or refractory MM as Platinum-based 
chemotherapies and have also failed to show improvements in survival benefits and 
(Porpodis et al., 2013). There is no alternative when MM patients fail this treatment 
option as the combination confers a median progression-free survival (PFS) of 5.7 
months (Porpodis et al., 2013). Moreover, an overall Response rate of combination 
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chemotherapy is approximately 40%; almost half of all patients are primary resistant 
and develop resistance ultimately (Kim et al.,2018). 
 
4.0 Chemoresistance 
MM is incurable and chemoresistant cancer (Riedel et al.,2017). There is no standard 
chemotherapy for refractory or relapsing MM (Staumont et al.,2020). The standard of 
care in the first-line treatment is a combination of Platinum-based chemotherapy with 
antifolate Pemetrexed. Interestingly, Raz and collaborators showed that severe 
hypoxia-induced a complete antifolate resistance and caused simultaneous 
suppression of crucial genes in folate homoeostasis. Lactate production due to hypoxia 
also contributes to extracellular acidosis, thus supporting tumour invasiveness and 
exerting immunosuppressive effects (Petri et al.,2020). The genetic and molecular 
profiling of MM led to the discovery of pathways involved in the development and 
invasion of MM. Analyses of alterations in signalling pathway activities have 
identified consistent upregulation of the PI3K/AKT/mTOR pathway (Li et al.,2018). 
ROS are usually increased in MM cells due to oncogene activation and involved in the 
initiation and progression of MM. Overproduction of reactive oxygen and ROS, 
aberrant inflammatory cytokine and chemokine expression, increased 
cyclooxygenase-2 (COX-2), and nuclear factor kappa B (NF-kB) expression are just 
some of the molecular factors that contribute to inflammation-induced carcinogenesis 
(Benedetti et al.,2015).  
One of the multidrug resistance mechanisms (MDRs) is the overexpression of ATP-
binding cassette (ABC) transporters. Such as P-glycoprotein (Pgp) and multidrug-
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related proteins (MRPs), which extrude anti-cancer drugs, leading to a reduction in the 
accumulation of intracellular chemotherapy and its cytotoxic effects (Mungo et 
al.,2018). Cancer Stem Cells (CSCs) represent a small subpopulation of tumour bulk 
and are mainly responsible for tumour mass renewal, recurrence and chemoresistance. 
MM CSCs were first identified from commercial cell lines as a side population, 
ranging from 0.05 to 1.32% cells, positive for CD133, CD9, CD24, CD26, CD44, 
c a e b d  transcription factor 4 (Oct4), Nanog, e de e  region Y b  
2 (SOX2), ATP b d  cassette transporter G2 (ABCG2), aldehyde dehydrogenase 
(ALDH). A shared feature of CSCs is their resistance to Cisplatin and Pemetrexed 
(Milosevic et al.,2020). The utmost barrier for efficient drug delivery in solid tumours 
is the morphologically and functionally abnormal tumour vasculature characterised by 
chaotic angiogenesis and highly permeable blood vessels that lead to elevated tumour 
interstitial fluid pressure. High interstitial fluid pressure is believed to delay 
convection and, for this reason, to cause unfavourable drug transport conditions within 
tumours. The latter is is believed to be responsible for the inadequate response of 
tumours to chemotherapy and their recurrence (Riedel et al.,2017).  
 
4.1 Hypoxia  
 
The rapid proliferation of tumours makes them too large than their surrounding 
vasculature, resulting in a drop of normal oxygen levels of 2 9% to hypoxic levels of 
less than 2% (Jing et al.,2019) Oxygen can diffuse only 100-180Am from a capillary 
to the cells before completely metabolising (Powis et al.,2018). Regions with fewer 
oxygen levels are termed as hypoxic regions. Hypoxia plays a crucial role during 
embryonic development in determining cell fate (Saxena and Jolly.,2019). Oxygen 
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tension in tumours varies from 0.02 to 8%. Oxygen levels at about 3% induce EMT, 
while severe oxygen depletion (< 0.02%) inhibits DNA synthesis (Najafi et al.,2019).  
Normal cells cannot withstand prolonged hypoxia and undergo either apoptosis or 
necrosis depending on nutrient availability along with oxygen deprivation (Saxena and 
Jolly.,2020). Hypoxic cells become resistance to programmed cells death, convert to 
glycolytic metabolism and migrate to lesser hypoxic areas of the body. They relate to 
pro-angiogenic factors like VEGF (vascular endothelial growth factor) stimulating 
new blood vessel from existing vasculature leading to increased tumour oxygenation 
and, ultimately, tumour growth. For this reason, hypoxic tumours are the most pro-
angiogenic and aggressive tumour (Kim et al.,2020). Tumours are composed of 
regions with oxygenated cells which are situated near to the blood vessels. They 
become highly hypoxic with increased distance from a functional blood supply 
(Tameemi et al.,2019). Regions with extreme hypoxia are regarded as niches, where 
poorly differentiated and more aggressive cell types called cancer stem cells (CSCs) 
aggregated. CSC enrichment in these hypoxic regions finally causes tumour relapse at 
local or distant sites (Najafi et al., 2019). 
Hypoxia also generates intertumoral oxygen gradients, contributing to the plasticity 
and heterogeneity of tumours. Hypoxia-induced by the acidic TME leads to MDR by 
various mechanisms. It includes a decreased concentration of the drug caused by "ion 
trapping," reduced apoptotic potential, genetic alterations (such as p53 mutations), and 
elevated activity of a multidrug transporter p-glycoprotein (P-gp) (Jing et al.,2018).  
Mesotheliomas are particularly hypoxic solid tumour masses as evidenced by binding 
of pimonidazole as exogenous hypoxia markers and elevated levels of HIF-1  as 
endogenous hypoxia marker. Imaging evidence from [F-18] fluoromisonidazole 
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(FMISO) PET-CT scanning confirms hypoxia being integral to mesotheliomas 




Figure 1.5: Hypoxic regions of solid tumors  
 
Mechanistically, hypoxia shows to influence invasive and migratory behaviour of 
cancer cells via EMT (Epithelial to Mesenchymal Transition), a trans-differentiation 
of cells to acquire plastic and mobile abilities. This process alters its gene expression 
prior to migration. EMT is physiologically involved during embryogenesis and tissue 
regeneration, as well as in carcinogenesis in many forms of solid tumours and 
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haematological malignancies. Hypoxia-induced EMT is characterised by a decrease 
in epithelial-associated gene expressions, such as E-cad, -catenin and an increase in 
mesenchymal-like gene expressions, such as N-cad and vimentin. The TGF-  is the 
master regulator and promotes EMT. EMT is also increased by hypoxia inhibiting the 
expression of E-cad and increasing the expression of downstream transcription factors 
like Smads, Snail, Slug, and Twist. Interestingly, radio and chemoresistance have also 
shown to be associated with EMT phenotype; expression of Snail and Slug antagonises 
p53-mediated apoptosis and promotes resistance to radiation and chemotherapeutic 
agents such as Paclitaxel and Cisplatin in ovarian cancer cells (Barbara Muz et 
al.,2015).  
Hypoxia induces several complex intracellular signalling pathways such as the major 
hypoxia-inducible factor (HIF) pathway. Other hypoxia-associated pathways include 
PI3K/AKT/mTOR, MAPK is also known as ERK pathways, and the NF B. These 
pathways include cell proliferation, survival, apoptosis, metabolism, migration, and 
inflammation. PI3K / AKT / mTOR, MAPK, and NF-kB signalling pathways are also 
activated in a hypoxia-independent manner, which could eventually contribute to the 
activation of HIF (Barbara Muz et al.,2015). Hypoxia-inducible factors (HIFs) are 
mediators of hypoxia and responsible for monitoring cellular responses to oxygen 
levels (Najafi et al.,2019). They play a central role in cellular mechanisms triggered 
in response to hypoxia (Jing et al.,2019). HIF-1  and HIF-2  support formation of 
blood vessels, prevent cellular differentiation, regulate apoptosis and activate DNA 
repairing enzymes, all of which are related to therapy resistance (Najafi et al.,2019). 
HIF-1  is stabilised only during the acute phase, while HIF-2  is high and stable under 
the chronic hypoxia (Chen et al. 2018). Despite being highly homologous, HIF-1  and 
HIF-2  take diverse roles in chemoresistance; this is possibly due to the diversity of 
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oxygen demand for activation of HIF-1  and HIF-2 , different regulation over their 





 Figure 1.6: Hypoxic HIFa Stabilization and Transactivation  
Under non-hypoxic conditions, HIF1-a subunits (HIF-1a or HIF-2a) undergo O2-
dependent hydroxylation (-OH) catalysed by prolyl-4-hydroxylases (PHDs) that 
utilise 2-OG, ascorbate, and Fe2+ as co-substrates. This post-translational 
d ca  allows binding of HIF1-a to the von Hippel Lindau (pVHL) tumour 
suppressor, resulting in HIF1-a ubiquitination and proteasomal degradation. Hypoxia 
results in inhibition of PHD activity leading to stabilisation of HIF1-a, dimerisation 
with HIF1-b, nuclear translocation, and transactivation of target genes by consensus 
hypoxia-responsive elements (HREs) (Abbreviations: 2-OG, 2-oxoglutarate; Ub, 
ubiquitination). In well-oxygenated cells (>5% O2), HIFa undergoes enzymatic 
hydroxylation at proline residues by prolyl-4-hydroxylases (PHDs) which utilise O2 
as substrate and 2-oxoglutarate, Fe2+, and ascorbate as co-substrates. O2-dependent 
hydroxylation allows recognition of HIF1-a by the von Hippel Lindau (pVHL) 
tumour suppressor, recruiting E3-ubiquitin ligases which target HIF-1a for 
proteasomal degradation. Hypoxia inhibited HIF-1a hydroxylation (<1% O2), 
resulting in HIF-1a stabilisation, dimerisation with HIF-1b, and binding to cis-acting 
hypoxia-responsive elements (HREs) bearing the DNA consensus sequence 50-[A/G] 
CGTG-30, thereby inducing target gene transcription (Schito and Rey.,2018). 
 
HIF-1  induced genes are primarily involved in anaerobic glycolysis, angiogenesis, 
and apoptosis. On the other hand, HIF-2  regulates genes that promote invasion and 
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stemness (Saxena and Jolly.,2020). In a hypoxic environment, activated HIF-1  
increases the activity of Snail and Twist, two transcription factors that reduce E-
cadherin expression and promote EMT (Jing et al.,2019). Several studies 
demonstrated that HIF-1  and HIF-2  have a complementary action in angiogenesis: 
HIF-1  drives vessel growth whilst HIF-2  enhances vessel maturation (Tirpe et 
al.,2019). Tumour cells display an increase in glucose consumption, and for this, they 
make an essential metabolic switch to glycolysis; hence, the pyruvate is converted into 
lactate. This switch to glycolysis in tumour cells is present even in aerobic conditions 
and is called the Warburg effect. (Tirpe et al.,2019). This phenomenon is clinically 
assessed in mesotheliomas through PET/CT imaging with 2-[19F]-fluoro-2-deoxy-D-
glucose (F-FDG) tracers. HIF-1a activation increases glucose transport (via GLUT-1) 
as well as glutamine and L-type amino acid transport (via LAT1) in pleural 
mesotheliomas (Nabavi et al.,2016). 
Hypoxic cells within the tumour mass are distant from blood vessels, resistant to most 
anti-cancer drugs, and present a significant obstacle to the delivery of targeted 
therapies. Targeting hypoxia is a potential therapy to eradicate the progression of 
various cancers and enable long-term survival for patients. 
 
4.2 Cancer stem cells 
CSCs are a minor subpopulation of cancer cells located within the tumour and is 
another cellular source of chemoresistance. These cells have similar characteristics to 
non-transformed stem cells, such as the ability of self-renewal and expression of 
embryonic factors Oct4, Sox2 and Nanog. They can differentiate into committed 
tumour cells. Due to their inherent quiescent state, CSCs can evade the actions of drugs 
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which target rapidly proliferating cells and can limit drug toxicity due to increased 
expression of aldehyde dehydrogenase (ALDH), drug efflux pumps, and pro-survival 
proteins. Ultimately, these characteristics allow CSCs to re-populate the tumour, 
resulting in tumour relapse and chemoresistance (Chiodi and Mondello.,2020). 
 
 
Figure 1.7: Schematic representation of CSC genesis  
(A) Oncogenic insults can hit stem cells, leading to transformed stem cells, or  
(B) progenitor/differentiated cells, which then acquire stemness features through de-differentiation; 
(C) CSCs can be generated by de-differentiation of bulk tumour cells.  
 
CSCs are in specific niches and determined by tumour microenvironment (TME) 
peculiarities that empower them to be phenotypically better adapted and more 
susceptible to retrieve fitness. Moreover, these niches are thought to help protect CSCs 
from the immune system, resist conventional treatments by reducing their proliferation 
state and/or evading apoptosis, and facilitate their metastatic potential (Linden and 
Corbet.,2019). The main factor that phenotypically differentiates CSCs from 
embryonic or adult stem cells is their unregulated, and primarily symmetric, cell 
division. It has been observed that cancer stemness is exceptionally heterogeneous. 
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Different pathways may be indicated to varying times in different tumour types, 
resulting in distinct stemness characteristics. Activation of stemness pathways was 
identified in cells expressing distinct CSC markers (Lathia, Liu and Matei.,2020). 
As there is no clear CSC marker, one major challenge with regard to CSC is their 
accurate detection. However, there is some cell surface marker that seems robust 
enough to use them as indicators for CSC. Two of these biomarkers are CD44 and 
CD133. Naturally, there are more surface molecules, and usually, combinations of 
these markers are used to identify and isolate CSCs depending on the type of tumour 
that is investigated. It is important to emphasise that CSC differ between tumour 
entities, both phenotypically and functionally, results from one type of cancer should 
not translate to other types (Arnold et al.,2020). 
CSCs that can form spheres maintain their stem cell properties for many passages, 
whereas most differentiated cells die from anoikis. The high expression of telomerase 
in CSCs has also helped to preserve their ability to self-renew, thus enabling cells to 
proliferate indefinitely and promoting CSC EMT thus retaining their stem properties 
(Liu et al.,2020). HIFs are related to MDR, such as ABCG2, and influence drug 
efficacy. VEGF is also induced by hypoxia, leading to chemo/radiotherapy resistance 
(Sun et al.,2019).  
In tumours, hypoxia leads to a low ROS level that in turn can be protective for CSCs 
and lead to therapy failure. HIF's influence pathways that contribute to the quiescence 
of CSCs, such as cell cycle control via cyclin-dependent kinase, metabolic control via 
pyruvate dependent kinase, anti-apoptosis via BCL-XL, and self-renewal via OCT- 4 
(Sun et al.,2019). Traditionally, CSCs prefer hypoxic conditions and the CSC niche 
described as hypoxic and acidic. CSCs can create spheroids in blood circulation. The 
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ability to form spheroids is considered a unique feature of CSC's. The study concluded 
that CSCs containing spheroids in the blood of cancer patients might generate a 
"micro-niche" that supports CSC a  and adaptation in the bloodstream. 
Furthermore, CSCs up-regulate reactive oxygen species (ROS) scavengers and 
increase DNA-repair capabilities protecting them from the oxidative stress 
encountered in the blood circulation. CSCs become resistant to nutritive stress 
encountered in the blood circulation by increasing their capacity to produce ATP by 
oxidative mitochondrial metabolism. MET returns CSCs to a highly proliferative but 
less migratory phenotype, enabling the development of macrometastasis like the 
primary tumour (Steinbichler et al.,2020).  
CSCs are considered to have innately higher radio-resistance, invasive capacity and 
metastatic capacity than their differentiated cancer cell counterparts. Complex cellular 
and molecular mechanisms like stemness maintenance, reactive oxygen species (ROS) 
production epithelial-mesenchymal transition (EMT), are indulging in the process of 
CSC initiation and facilitation of cancer recurrence and metastasis after treatment (Liu 
et al.,2020). There is new evidence emerging which indicate that some of these anti-
cancerous drugs not only fail to remove CSCs but selectively enrich CSCs possibly by 
inducing de-differentiation or trans-differentiation (Ahmed et al.,2016).  
CSCs can switch between quiescent and proliferative state. Quiescence has found to 
be associated with the capacity of CSCs to survive anti-cancer treatments and escape 
from the immune system (Chiodi and Mondello.,2020). By becoming quiescent, CSCs 
up-regulate enzymes (such as ALDH), and multidrug resistance pumps to increase 
chemotherapy elimination from the cell and the upregulation of anti-apoptotic 
proteins. Given their link with tumour initiation and drug resistance, they have 
pushed to the forefront of cancer therapy (Cole et al.,2020).  
Figure 8: CSCs, carcinogenesis, tumorigenesis, and tumour resistance.  
(A)Tumours can arise from somatic cells through genetic mutations of cancer-critical 
genes. Also, dysregulation of microenvironmental factors can contribute to the 
carcinogenic process. (B) Such events might primarily affect long-lived somatic stem 
cells, which can illustrate the cancer cell of origin, (i) their ability for long-term self-
renewal, (ii) their capacity to differentiate into tumour bulk populations devoid of 
CSC characteristics, and (iii) their limitless potential for proliferation and 
tumorigenic growth. Further, CSCs in certain malignancies possess the capacity to 
drive tumour angiogenic responses and/or to retain in vasculogenic mimicry, 
potential means of promoting tumour growth. Also, immunoevasive features of CSC 
increase tumorigenesis and leads to tumour progression. (C) CSCs show high 
resistance to chemotherapeutic drugs and ionising radiation.  
Resistance to chemotherapy occurs by conversion of aldehydes into weak carboxylic 
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CSCs. This conversion is mediated by the activity of ALDHs in CSCs. High ALDH 
activity is a unique feature for CSCs that distinguish them from normal stem cells. 
Among 19 members of ALDHs, ALDH1 considered as a CSC biomarker primarily 
linked to stemness and chemotherapy resistance (Najafi et al.,2019).  
CSC plasticity is the main predicament in cancer targeted therapies. CSCs can 
sequentially transit between stem (an EMT phenotype) and non-stem (a mesenchymal-
epithelial transition [MET] phenotype), and between quiescence (drug resistance) and 
proliferation (drug-sensitive) states. It is for the promotion of a heterogeneous 
population of cells within a tumour, making it hard to combat by conventional 
chemotherapies (Najafi et al.,2019).  
There is growing evidence that CSC is also inherently resistant to radiation, by 
initiating DNA repair, re-distributing the cells in the cell cycle, raising activation of 
the DNA damage checkpoint, and re-populating and reoxygenating areas of hypoxia 
in the tumour (Das et al.,2020. Since they are the "seeds" of cancer, the way CSCs 
respond to treatment is crucial to the prognosis of tumours (Liu et al. ,2020). More 
attention should be focused on targeting stem cells by the use of the analogy of 
beehive, and the most efficient manner to destroy beehive is to target the queen bee. 
Likewise, the most effective way to remove a tumour would be to target the cancer 
stem cell, which is the queen bee.  
 
 
4.3 NF-KB  
The nuclear factor- B (NF- B) pathway plays a vital role in regulating immune and 
a a  responses. NF-kB pathway is also involved in cellular survival, 
proliferation, and differentiation. The process of tumour development and progression 
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produces cytokines, growth, angiogenic factors and proteases to activate NF B 
signalling. I a a  has been recognised as a hallmark of cancer. However, in 
human cancers, direct or altered molecular mutations in NF-kB have rarely been 
identified. Based on recent research, NF- B regulates several genes implicated in cell 
survival, proliferation, metastasis, and tumorigenesis of cancer. NF- B activation is 
also directly or indirectly linked to the expression of key angiogenesis factors and 
adhesion molecules, such as growth-regulated oncogene and IL-8, vascular 
endothelial growth factor (VEGF). The NF- B pathway has an essential connection in 
regulating a a , self-renewal, or maintenance and metastasis of CSCs (Yang 
et al.,2019).  
The half-life of NF-kB is less than 30min, and maintenance of its activity requires 
ongoing protein synthesis and continuous stimuli. Thus, the high NF-kB activity in 
drug-resistant cells is a constitutive and intrinsic feature of the resistant cell lines (Lin 
et al.,2010). High NF-kB activity has been observed in drug-resistant cancer cell lines. 
Ectopic overexpression of NF-kB blocks apoptosis (Wang et al., 2003, 2004; Guo et 
al., 2010; Yip et al., 2011).  
In MM different fiber types are found in various areas of the lung, where they can 
interrupt the phagocytosis of the mesothelial cells, which causes cytotoxicity, 
damaging DNA through oxidative stress and hence leads to an inflammatory response. 
The deposition of asbestos fibres causes the release of pro-inflammatory molecules 
such as HMGB-1 (High Mobility Group Box -1) and TNF-a, contributing to the 
carcinogenesis of asbestos (Quinna et al.,2015). HMGB-1 is the master switch that 
starts the inflammatory process. HMGB-1 release causes macrophage accumulation 
and the secretion of TNF-alpha, which in turn activates NF-kB. Activation of the NF-
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kB pathway can stimulate proliferation and reduce the effectiveness of chemotherapy 
and ionising radiation (Bianchi et al.,2007). Thus, it leads to the survival of HM 
(Human Mesothelial) cells that have accumulated genetic damage because of asbestos 
exposure (Michele et al. .2012). HMGB1 acts as a 'master switch' which initiates and 
maintains the chronic inflammation and drives mesothelioma formation. Overall 
HMGB1 plays a crucial role in MM onset, and progression relative to the following 
mechanisms: (i) asbestos-induced effector as its secretion by mesothelial or immune 
cells is highly responsive to asbestos fibre stimulation (ii) inflammatory and epithelial-
to-mesenchymal transition mediator (Abbott et al.,2020).  
The in vitro studies of MM cells exposed to asbestos had cytotoxic effects. Still, these 
effects were negated by TNF- , which acts by the activation of (NF- B) translocation 
and activation pathway. Nuclear factor- B increases cell survival by inducing cellular 
proliferation and inhibition of apoptosis. It results in favour of tumorigenesis. This 
study provided a mechanistic rationale to the observation by Liu et al. (1998) that 
asbestos did not show any pathogenesis in transgenic mice which do not express TNF-
alpha receptor. On the one hand, TNF-alpha protects HM cells from asbestos-induced 
cell death, and on the other hand, it promotes the growth of HM that have accumulated 
DNA damage following asbestos exposure (Michele et al.,2012).  
NF- B consists of e different proteins (p65, RelB, c-Rel, NF- B1, and NF- B2). 
The primary physiological function of NF- B is the p50-p65 dimer. The primary mode 
of NF- B regulation takes place at the level of subcellular localisation (Yang et 
al.,2019). To release the NF- B complex, signalling pathways are activated by pro-
inflammatory cytokine receptors, such as IL-1 receptor (IL-1R), tumour necrosis 
factor receptor (TNFR) and toll-like receptor (TLR) family members(TLR3, TLR4, 
TLR7); antigen receptors, such as B cell receptor (BCR) and T cell receptor 
(TCR); and, growth factors, like (EGFR) Epidermal growth factor receptor, 
family members. All these receptors can initiate the IkB kinase (IKK) complex 
(IKKα, IKKβ and IKKγ) NF-kB essential modulator (NEMO), which further 
phosphorylates and facilitates the ubiquitination of IkB and its subsequent 
degradation by the 26s proteasome. The dimers p65/p50, and c-Rel/p50 is then 
translocated into the nucleus and activate target gene expression.  
  




In the non-canonical pathway, there is no I B, but the RelB/p100 complex is inactive 
in the cytoplasm. Signaling from the cluster of differentiation 40 ligands (CD40L), 
lymphotoxin  receptor (LT R), and (BAFFR) B cell-activating factor receptor leads 
to NF- B-inducing kinase (NIK) activation, phosphorylating the homodimer 
IKK /IKK , which further transfers the phosphate group to the C-terminal residues of 
p100 to be ubiquitinated and proteasomal processed into p52. It finally leads to the 
nuclear translocation of RelB/p52 and the induction of target gene expression (Pires 
et L.,2018). 
The NF- B complex attached to sequence-specific target DNA, known as B sites in 
the nucleus, (5 -GGGRNYYYCC-3 , where R: purine, and N: any nucleotide and Y: 
pyrimidine ), further which exist in promoters of the target genes, gather with the basal 
transcriptional machinery, and associate with other transcription factors, including 
AP-1 (c-Jun/c-Fos complex) and chromatin remodelling proteins, such as CREB-
binding protein (CBP) and p300. Also, NF- B can be influenced by other transcription 
factors that can associate physically, changing its ability to bind to the DNA and genes 
that will be activated. This diversity of players who can control and activate NF-kB 
nuclear translocation will be responsible for the different and often competing 
functions of NF-kB as both a pro- and an anti-inflammatory mediator (Pires et 
L.,2018). 
NF- B is a crucial mediator of inflammation (acute and chronic) in tumours linking 
inflammation with stemness. NF- B activates hypoxia-related stemness signalling and 
is associated with both early (through induction of EMT) and late stage of 
tumorigenesis. NF- B reverts ROS-induced apoptotic cell death in CSCs (Najafi et 
al.,2019). Among the broad range of NF- B target genes and associated pathways, 
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epithelial-to-mesenchymal transition (EMT) is one of the most well-known ones in 
regulating CSC-functionality. Here, NF- B regulates transcription of SNAIL, Slug, 
ZEB1, ZEB2, and Twist, which repress the epithelial phenotype and are directly 
associated with cancer invasiveness and aggressiveness as well as poor patient 
survival. 
NF- B also regulates expression of Matrix metalloprotease MMP-2 and MMP-9, as 
well as vimentin. Particularly Vimentin-positive CSCs seem to represent the end-stage 
progression of EMT, concomitant with a completely dedifferentiated state, which is 
highly proliferative and invasive. In line with these observations, EMT shows to 
generate cells with properties of stem cells from human mammary epithelial cells. 
Stem-like cells have shown increased expression of stem cell markers, sphere 
formation ability, and more efficient capability for tumour formation (Kaltschmidt et 
al.,2019). 
 
4.3.1 Hypoxia - CSC- NF-kB  
Hypoxia functions to increase CSC number and helps maintaining their stem-like state 
allowing the subsequent growth and metastasis and hence considered as a critical 
physiological component of CSC niche (Yadav and Desai.,2019). Hypoxia-induced 
HIF overexpression and NF-kB pathway activation is responsible for chemoresistance 
and also determines the factors responsible for maintaining the stemness in CSCs 
(Conley et al., 2012). Increasing evidence suggests intracellular signalling pathways 
mediated by NF- B to be of particular importance for CSC characteristics and 
functionality (Kaltschmidt et al.,2019). Studies have also demonstrated that CSCs 
drive cancer cell proliferation, aggressiveness, and recurrence through the activation 
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of specific signalling pathways, such as the Notch, Hedgehog, Wingless (WNT) and 
NF-kB circuits (Castagnoli et al.,2020). NF- B activates hypoxia-related stemness 
signalling and is associated with both early (through induction of EMT) and late stage 
of tumorigenesis (Najafi et al.,2019). Together with the ability to neutralise ROS more 
efficiently, CSCs are, more resistant to radiation treatment. NF-kB is essential for 
CSCs to withstand stress exerted by ROS (Schulz et al.,2019). NF- B also reverts 
ROS-induced apoptotic cell death in CSCs (Najafi et al.,2019). 
HIFs also regulates the stemness of CSCs. Previous studies have shown that HIF-1 
alpha and HIF-2 alpha need to be activated by CSCs to maintain their self-
sustainability under hypoxic conditions and achieve pluripotency by up-regulation of 
Sox2 and Oct4 genes. HIF-1  manages the proliferation and fate of CSCs in 
medulloblastoma and glioblastoma multiforme and activates the NF- B pathway to 
nurture CSC survival and tumorigenesis. HIF-2  retains the survival and phenotype 
of CSCs (Yang et al.,2019). In tumours, hypoxia leads to a low ROS level that in turn, 
can be protective for CSCs and lead to therapy failure (Sun et al.,2019). HIF-1  
maintains the CSC niche and directly modulate the CSC population. It also protects 
CSCs from DNA damage and enhances stemness by slowing down cell cycle 
progression by acting as an antagonist to c-Myc activation (Yadav and Desai.,2019).  
 
5.0 Drug Repurposing and Disulfiram  
5.1 Drug repurposing  
Drug repurposing, repositioning, re-profiling, or re-directing defines the process of 
identifying a novel application of already approved drugs. Drug repurposing can 
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surpass several challenges associated with de-novo drug discovery. The traditional 
drug discovery involves a cost of ∼2.5 billion US dollars, which represents a loss of 
about 85 % as compared to drug repositioning which costs ∼ 300 million US dollars 
(Kaushik et al.,2020). Moreover, searching for specific molecules for a novel drug 
target may be perceived as unrealistically slow, especially during emerging disease 
outbreaks (Dinic et al.,2020). Drug repurposing is dependent on two major 
approaches: 1) Activity-based reporting, where drugs are assessed in cancer models in 
vitro and in vivo 2) In silico drug repurposing, where the drug interactions and their 
molecular targets are modelled in silicon by the use of bioinformatics tools and public 
databases. By the usage of these approaches, several drugs showed potent anti-
cancerous effects and successfully repurposed to target specific pathways (Boyer et 
al.,2018). Strategising drug repurposing involves three significant steps before taking 
the drug across the development pipeline: recognition of the right drug, i.e. hypothesis 
generation; systematic evaluation of the drug effect in clinical models; and estimation 
of usefulness in phase II clinical trials these steps are accomplished by various 
computational and experimental approaches (Kirtonia et al.,2020). For example, in 
tumours such as breast cancer, genomics-based tools have been used to identify Food 
and Drug Administration (FDA)-approved drugs and repurpose them to treat patients 
through targeting CSCs within the tumour. Also, data-driven computational methods 
were utilised in glioblastoma multiforme (GBM) to identify compounds and drugs that 
repositioned to inhibit GBM CSCs (Bahamad et al.,2020). 
Drug repositioning arises from the exploitation of the promiscuity of small molecule 
drugs, i.e., the ability to disturb two or more independent proteins causing undesired 
side effects. The growing appreciation of network pharmacology as the next drug 
discovery paradigm encourages scientists to understand better and make use of such 
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polypharmacological effects of promiscuous compounds (Chaudhari et al., 2017). 
Polypharmacological effects offer significant advantages for finding novel 
therapeutics, particularly for the treatment of complex and multifactorial diseases such 
as cancer (Dinic et al.,2020). Repurposing can be on-target, i.e. validation of already 
identified drug target for its potential anti-cancer activity or off-target effects that 
identifies novel molecular targets for already FDA approved drugs. Several clinical 
and non-clinical studies have revealed that among 200 off target drugs, 50 % of drugs 
have efficacy against Cancer (Kaushik et al.,2020). 
Moreover, once the cancer target has been identified and validated for a repositioned 
drug, and pharmacokinetic data from the literature, indicate that the in vitro antitumor 
activity of the candidate drug is pharmacologically achievable, proceeding to clinical 
trials can be faster as there is knowledge on safety and toxicity, including rare adverse 
events. Also, there is an extensive clinical experience derived from its original 
indication. Most importantly, repurposing candidates usually are of low cost, 
particularly those who are generic and have multiple manufacturers. Finally, drug 
candidates have widespread availability if they are included in the WHO Essentials 
Medicine list (Gonzalez-Fierro et al.,2019).  
The majority of the biochemical and clinical proprieties such as bioavailability and 
safety profiles, proven formulation and manufacturing routes, and reasonably 
characterised pharmacology, are known for most approved molecules which favour 
the inclusion of these repositioned drugs in clinical phases more rapidly and at a lower 
cost than novel therapeutic agents. For rare diseases such as MM that are understudied 
at the preclinical and clinical levels, the development of new compounds is 
problematic. It needs worldwide collaboration from numerous clinical trial centres to 
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achieve a successful outcome from innovative drugs. Drug repositioning may be an 
attractive strategy for diseases such as MM, by offering a reduced timeframe from 
preclinical research to the bedside. Furthermore, with the expected increase in the 
incidence of MM in developing countries, drug repositioning could provide solutions 
for patients living in these countries. Repositioning may apply to a wide variety of 
drugs and perform in a variety of ways. Recent research used the DRUGSURV 
database to target individual genes/proteins that identified as important for 
mesothelioma based on computational modelling of TP53 and stratified patient data 
(Guazzeli et al.,2020). 
 
5.2 Disulfiram  
Disulfiram is the oxidised form of two diethyldithiocarbamate molecules, linked 
together by a central disulphide bond. It has a molecular weight of 296.4 Da and 
consists of sulfhydryl group, thiuram structure and the ethyl groups. (Papaioannou et 
al., 2014). The earliest clinical evidence that showed DS has anti-cancer activity traced 
back to the 1970s. It reported that DS could induce apoptosis, reduce angiogenesis, 
and show metal ion-dependent antineoplastic activity. These findings attracted 
significant interest (McMahon Chen, and Li.,2020). DS is an established FDA-
approved agent to treat alcoholism dependent on its activity to inhibit acetaldehyde 
dehydrogenase (ALDH) for decades (Ren et al.,2020). In vivo, DS is rapidly 
metabolised to diethyldithiocarbamate (DDTC), which further gets converted to S-
methyl-N, N-diethyldithiocarbamate (DETC) and S-methyl-N, N-
diethyldithiocarbamate (Me-DDTC). Subsequent P450-catalyzed oxidation of DETC 
and Me-DDTC produces DETC-sulfoxide (DETC-SO) and S-methyl-N, N-
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diethyldithiocarbamate-sulfoxide (Me-DTC-SO) and sulfone (Me-DTC-SO2), 
metabolites that are most likely involved directly in ALDH inhibition. Importantly, 
when a chemical P450 inhibitor blocks downstream steps of DS metabolism, liver 
ALDH remains uninhibited, thus unambiguously proving that metabolites of DS are 
genuine inhibitors of ALDH in vivo. Even though this knowledge is published and 
accepted in some research fields, most cancer-focused studies regard DS as a direct 
ALDH inhibitor (Skrott et al.,2019). 
DS is widely researched due to its relatively good safety profile and reasonable 
financial cost (Li et al., 2015). In the conclusion of high-throughput cell-based drug 
screening, Disulfiram is found to be an anti-cancer drug as it shows reducing tumour 
growth (Turanli et al., 2018). Prolonged treatment with this drug has negligible side 
effects and thus considered safe by the FDA (Rae et al., 2013). Disulfiram is postulated 
to form carbamate complex with Cupric ions, resulting in the inhibition of proteasome 
activity, activation of apoptosis leading to cell death (Georgewill et al.,2014).  
DS is a member of the dithiocarbamate family comprising a broad class of molecules 
possessing an R1R2NC(S)SR3 functional group, which gives them the ability to 
complex metals and react with sulfhydryl groups (Li et al., 2015). It can respond with 
redox-sensitive sulfhydryl groups (thiols) and bind Copper (Cu), an essential cofactor 
for key cellular enzymes (e.g. cytochrome c oxidase and superoxide dismutase 1 
(SOD1)) involved in oxidative stress response. Notably, DS is a redox modulator 
whose induction of ROS is enhanced by the addition of Cu, and it has reported to 
inhibit the activity of NF-kB (Allensworth et al., 2015). 
The anti-cancerous activity of Disulfiram is dependent on Copper (Cu). DS quickly 
gets reduced to diethyldithiocarbamate (DDC), a potent chelator of Copper (II). The 
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biological activity of Disulfiram is dependent on binding divalent cations and thus 
disrupting processes dependent on these metals, particularly Copper and Zinc. 
Disulfiram treatment removes essential Copper and Zinc ions from the enzymes which 
regulate the extracellular matrix degradation and metabolism of oxygen, leading to 
cancer suppression, cancer invasion and angiogenesis in vitro and in vivo. Current 
literature of DS focuses on its capacity to bind copper ions by metal-binding regions 
in its structure (Wiggins et al., 2015). 
Suggested mechanisms for DS toxicity include inhibition of proteasome activity, 
G2/M cell cycle arrest, induction of apoptosis, inhibition of Nrf2 expression, inhibition 
of TGF-beta induced EMT transitions, and inhibition of the p97-NPL4 pathway 
(Hubert et al.,2020). Moreover, DS shows high toxicity to CSCs in a copper (Cu)-
dependent manner (Li et al., 2015). Also, DS as cancer therapeutic is well tolerated, 
with few toxicities at blood levels of 1.3 M. Clinical trials in cancer patients suggest 
that dosing up to 500 mg is possible and well-tolerated in combination with 
chemotherapy (Hubert et al.,2020). 
 
5.2.1 Disulfiram toxicity is copper dependent  
Cellular Copper in excess causes cytotoxicity and damages different types of 
biomolecules by mediating generation of highly reactive hydroxyl radicals. There is 
growing evidence that Copper plays a vital role in inflammation and the growth of 
tumours (Li et al., 2015). Copper plays an essential role in inflammation and the 
growth of tumours. Copper can stimulate the proliferation and migration of endothelial 
cells at high concentrations (Li et al., 2017). Copper has a long history for treating 
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cancer, but intracellular transport is still a significant hurdle for its clinical efficacy (Li 
et al., 2015). 
Since Copper is required for DS cytotoxicity and DS acts as a copper ionophore, the 
intracellular deposition of Copper can be cytotoxic through the generation of oxidative 
stress, resulting from Fenton reactions or enzymatic inhibition due to copper binding 
to peptide bonds. Further, Copper complexes tend to intercalate between the base pairs 
of DNAs due to their planar conformation (Tesson et al., 2017).  
As Copper is a bivalent metal ion chelator, DS forms a complex with Cu (DS/Cu) 
which is more readily taken up by cells. Also, DS and its metabolite 
diethyldithiocarbamate (DDC) inhibit superoxide dismutase (SOD) by Cu chelation. 
By shifting the thiol redox balance, both DS and DDC may also induce oxidative 
stress. Cellular thiol pools have proven to be important in regulating redox status of 
the cells, resulting in a sizeable antioxidant pool which consists of free thiols, thiols 
bound to proteins and thiols bound to disulfide bonds (Wu et al., 2018).  
This Cu (DDC)2 complex is believed to play a significant role in DSF-based cancer 
therapy. A stated above the anti-cancer efficacy of DS is copper ion dependent. Since 
many cancers have higher levels of Copper ions than normal tissues, it is hypothesised 
that DS could form relatively higher levels of Cu (DDC)2 in cancer and selectively 
kill cancer cells (McMahon, Chen, and Li.,2020). Cu-DDC is damaging to lung cancer 
cells by targeting CSC-like cells. It was observed that along with the thiol groups, 
thiuram structure is also essential for the anti-cancer activity of DS and DDC (Butcher 
et al., 2018). Studies indicated that Cu (DDC)2 killed cancer cells through the 
induction of paraptosis. Paraptosis is a non-apoptotic cell death that does not need the 
activation of caspases. Therefore, it is a promising approach to kill resistant cancer 
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cells with defective apoptotic pathways. Besides, DS or DS/Cu could effectively 
overcome drug resistance caused by multiple other mechanisms, including cancer 
stem cells (CSCs) and over-expression of drug-resistant transporters (McMahon Chen 
and Li.,2020). DDC-Cu is more cytotoxic than Ds/Cu as the IC50 for Ds/Cu is 449 
nM, and IC50 for DDC-Cu shown to be 238.7 nM, p < 0.01). It indicates that the final 
product of DS/Cu might play an essential role in DS/Cu induced cell death (Tawari et 
al., 2015).  
Cells treated with Cu (DDC)2 showed similar phenotypic characteristics as those 
treated with proteasome inhibitors, including the accumulation of poly-ubiquitinated 
proteins in the cytoplasm. Because of these observations, early studies believed that 
DS was a proteasome inhibitor. Recent studies revealed that Cu (DDC)2 did not 
directly inhibit proteasome but instead targeted the p97-NPL4-UFDI pathway. The 
binding of Cu (DDC)2 to the zinc (II) binding thiolate site present in NPL4 proteins 
resulted in the aggregation of NPL4. The aggregation of NPL4 caused the deactivation 
of P97 segregase, which caused the accumulation of misfolded proteins in the 
endoplasmic reticulum (ER) and eventually cell death (McMahon Chen, and 
Li.,2020). 
Cu (II) interacts directly with various molecules and promotes their oxidation in redox 
reaction leading to the formation of Cu (I). This Cu (I) further reacts with molecular 
oxygen and generates superoxide anion O2, which disputes to O2 and H2O2, 
producing hydroxyl radicals and other reactive oxygen species (ROS). ROS causes 
oxidative damage to DNA and is accountable for clastogenic property of Copper, 
resulting in cell death. Although the half-life of ROS is merely 10 9 s (HO ) to 1 ms 
(H2O2) But when equal molar of Disulfiram and Copper is mixed, the reaction is 
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triggered immediately and completed in 150 minutes. The study suggests that the 
cytotoxicity from Ds/Cu is due to the following actions: (1) Disulfiram and Copper 
reaction-generated ROS (2) toxic effect of DDC-Cu. The chelation of DS with Cu is 
indispensable for both two actions. (Tawari et al., 2015).   
The observation by Rae et al., 2013, have suggested that apart from the presence of 
Copper, the concentration of Copper relative to Disulfiram is also a significant 
determinant of the cytotoxicity of Disulfiram. The equimolar level of Copper and DS 
resulted in a maximum clonogenic kill. Presence of surplus DS resulted in the 
competition amongst DS/Cu and free DS complexes for cellular uptake or intracellular 
binding. This competition explains the increased survival, observed after increasing 
the concentration of Copper beyond DS (Rae et al., 2013).  
Recently, DTC copper complex CuET was detected by Skrott et al. in DS treated cell 
cultures. It is a complex that spontaneously develops in vivo and cell cultures and is 
present in tumour counterparts at higher concentrations than the corresponding natural 
liver and brain tissues of CuET is enhanced in humans undergoing DS treatment for 
alcoholism. They showed that Copper anion supplementation allowed its 
development, exerting a further deteriorating effect on cancer cells, precisely at the 
stage when DS is introduced.  
The copper transporter, Ctr1 regulate the transport of Cu into cells. To maintain redox 
homoeostasis, intracellular Cu levels are strictly controlled. As a strong bivalent metal 
ion chelator, DS and its derivative, N, N-diethyldithiocarbamate (deDTC), can form a 
complex [Cu(deDTC)2] with Copper. This DS/Cu complex can transport Cu into 
cancer cells in a Ctr1 independent manner, thus overcoming the transporter-controlled 
regulation of intracellular Cu homoeostasis (Liu et al., 2012). 
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Disulfiram and Copper also target cells by simultaneous modulation of ROS and NF-
KB (Peng Liu et al.,2014). Moreover, it has been found that the induction of apoptosis 
mediates the anti-cancer effect of DS/Cu. It also is seen that DS/Cu induces autophagy, 
which impedes DS/Cu-induced apoptosis. Cancer cells contain a high level of Cu in 
vivo. However, it is reported that Cultured cancer cells possess low to trace levels of 
Cu (Wu et al., 2018). Addition of Cu to DS was needed for CSC targeting and 
induction of cancer cell apoptosis in vitro. However, exogenous Cu may not be 
required for DS to work in vivo. Therefore, elevated Cu serves as a specific cancer 
target for Cu-chelating agents, such as DS (Cong et al., 2017). In comparison with Cu, 
the DS/Cu complex is a more potent ROS inducer. Reactive oxygen species even have 
a crucial role in signalling transduction in cancer cells. Considering the higher ROS 
load in cancer cells, it has been proposed that further ROS exposure induced by ROS-
generating agents will exhaust their cellular antioxidant capacity and selectively lead 
cancer cells into apoptosis (Liu et al., 2012). 
 
5.2.2 Mechanism of action of Disulfiram by Targeting NF-KB pathway  
An essential mechanism of DS-induced cell death involves proteasome inhibition. 
Proteasome activity was elevated in cancer cells. DS inhibits proteasome activity and 
induces selective apoptosis in the cancer cells and spare normal healthy cells. The 
copper-binding ability of DS can also be responsible for this action as the formation 
of Copper complexes tend to be accountable for pro-apoptotic proteasome inhibition 
(Rae et al., 2013). Proteasome inhibition in cancer cells leads to accumulation of pro-
apoptotic target proteins and induction of cell death (Owunari et al.,2014). NF-kB is a 
protein complex found in most animal cells. Activated NF-kB can induce a large 
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number of anti- apoptosis-related genes, thereby inducing drug resistance and 
rendering cells insensitive to chemotherapeutic drugs. Thus, NF-kB is considered one 
of the major drug resistance-related anti-apoptotic factors. Notably, DS/Cu combined 
with chemical drugs, can not only inhibit NF-kB activity but also enhance the 
cytotoxicity of an anti-cancer drug (Li et al.,2020). 
Chemotherapeutic agents and radiation activate NF- B, and both constitutive and 
therapy-induced NF- B activation is generally anti-apoptotic. Blocking NF- B has 
been tested and found to sensitise cancer cells to radiotherapy and a variety of 
chemotherapeutics in numerous tumour cell types. As discussed above, the induction 
of anti-apoptotic factors is one of the primary mechanisms involving NF- B in cancer 
cell resistance to therapy (Lin et al.,2010). Dithiocarbamates are widely used as 
inhibitors of canonical NF-kB pathway both in vitro and in vivo despite their lack of 
specificity. Since the beginning of this research in the early 1990s, it has suggested 
that dithiocarbamates can block the release and degradation of IkB. A popular 
explanation that persists is that the dithiocarbamate effect NF-kB pathway through 
oxidative stress attenuation. The canonical NF-kB pathway is (in a cell-free system) 
blocked by dithiocarbamates via E3 ubiquitin ligase inhibition, and this ligase depends 
on CSN5 (COP9 signalosome subunit 5) also known as Jab1 (Jun activating binding 
protein 1). CSN5 and the key proteasome subunit Poh1/Rpn11 both have the JAMM 
domain, the active site sensitive to both metals and ligands (1,10-phenanthroline). 
Taking all these into consideration, dithiocarbamates would seem to be primarily 
proteasome inhibitors, and their ability to inhibit NF-kB inhibition is secondary (cvek 
et al.,2008).  
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DS regulates NF-kB and mitogen-activated protein kinase (MAPK) signalling 
pathways, leading to the death of various types of the cancer cell. Activation of NF-
kB signalling associated with the epithelial-mesenchymal transformation (EMT) and 
tumorigenesis. Ying et al. confirmed that DS could potently inhibit osteoclast 
differentiation by attenuating NF-kB activity in vitro. Chiba et al. found that 90 % of 
cells showed an increase in phosphorylated p38 level when tumour-initiating 
hepatocellular carcinoma (HCC) treated with DS. It indicates that p38 MAPK 
activated in HCC cells, and DS inhibits tumour-initiating HCC cells in a p38-
dependent manner. Therefore, DS could exert antitumor effects in part by 
downregulating the NF-kB and MAPK signalling pathways (Li et al.,2020). 
Zeng et al. found that both the Wnt and NF-kB pathways, which are involved in cancer 
cell proliferation, apoptosis, and progression, were inhibited by Disulfiram (Zhang et 
al.,2020). Further, DS generates oxidative stress through the inhibition of NF- B 
activation and inhibition of superoxide dismutase (SOD) and because of its induction 
of an increased ratio of oxidised glutathione to its reduced form (Tesson et al., 2017). 
DS/Cu inhibits both NF-kB and TGF-b signalling, including the nuclear translocation 
of NF-kB subunits and the expression of Smad4, leading to down-regulation of Snail 
and Slug, which contributed to phenotype epithelial-mesenchymal transition (EMT). 
In the field of metastasis, studies showed that DS inhibits invasion of both tumour 
cells and endothelial cells at non-toxic concentrations by inhibiting MMP-2 and 
MMP-9 activity (Li et al., 2017).  
 
5.2.3 PLGA - Disulfiram 
In many other clinical studies, DS was used in combination with Copper which can  
Increase the intratumor Copper concentrations and generate higher levels of Cu 
(DDC)2 to kill cancer cells more effectively. In most of these clinical trials, the 
oral administration of DS yields low concentrations of Cu (DDC)2 in tumour 
regions because DS has low bioavailability and it is rapidly metabolised and 
degraded in the body (McMahon Chen, and Li.,2020). 
Figure 1.10.  Comparison between the action of free Disulfiram and PLGA 
- coated Disulfiram on tumor cells  
The underlying reason is that DS is instantly reduced to DDC in the bloodstream 
in vivo, which is also very unstable and promptly gets converted into the 





products. Thus, the functional group, i.e. sulfhydryl group of DDC is destroyed, 
making DDC lose its chelating ability (Tawari et al., 2015). The half-life of DS pH 
7.4 is 1-1.5 minutes. It may introduce the discrepancy between the anti-cancer 
activities in vitro, in vivo and the clinic (Wang et al.,2017).  
 
 
Figure 1.11 Proposed model for treating Mesothelioma by PLGA-coated 
Disulfiram + Copper by local injection. 
 
Therefore, advanced delivery systems are much needed for DS-based cancer therapy. 
Delivery systems should have the promise to enhance intratumor drug delivery,  
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improve anti-cancer potency and reduce toxicity. Nanomedicine can protect and 
deliver drugs in the bloodstream. Porous microparticles based on polymers are useful 
for the pulmonary administration due to its unique properties such as low density, 
adaptive aerodynamic diameter, and favourable lung deposition. PLGA, which is a 
biodegradable polymer, has been widely used as constructing porous-microparticle to 
deliver many types of drugs to lungs, such as proteins and plasmid DNA. (Wang et 
al.,2017).  
Thus, in vivo anti-cancer efficacy of DS can be improved by liposomal encapsulation 
(half-life~25 min). Therefore, our group prepared porous PLGA microparticle, 
through the emulsion solvent evaporation method, where ammonium carbonate was 
used as a porogen. PLGA encapsulation has improved DS half-life. In serum, from 
less than 2 minutes to 7 hours. DS-PLGA, in conjunction with Copper, was 
significantly inhibited by cancer stem cells population in the liver. Therefore, 
nanomedicine may be a novel strategy for protection of the sulfhydryl group in DS 
and translation of DS into cancer treatment (Wang et al.,2017). 
Since mesothelioma is known to metastasize rarely, we propose a local treatment by 
injecting PLGA-Disulfiram and Copper to the affected sites. The anti-cancerous 
properties of PLGA Microparticles were evaluated on mesothelioma cell lines MSTO 









Aims: I aim to determine the effect of microparticles encapsulated Disulfiram on 
malignant mesothelioma cells. The success of my project will lead to future animal 
study and potentially clinical trials. 
 
Objectives : My study intends to elucidate the following phenomena. 
1. Hypoxia induces chemoresistance and invasiveness in MM cell lines  
 
   2. Hypoxia induces cancer stem cell and invasiveness-related markers in   
            malignant Mesothelioma cell lines 
 
 3. PLGA-DS and Copper targeted MM CSCs, reversed chemoresistance and 
blocked MM cell invasiveness in vitro 
  4. The status of NF-kB activity on drug sensitivity and invasiveness in MM cell 
lines. 
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 2.1 Materials 
 
2.1.1. Mesothelioma cell lines 
The MM cell lines MSTO-211H and JU77 were very kindly provided by Professor 
Peter Sziosarek from the Queen Mary University of London. 
2.1.2. Reagents, Enzymes and Kits  
•   copper chloride (CuCl2), poly-2-hydroxyethyl methacrylate (Poly-HEMA), 
insulin, D-Glucose, human EGF, heparin, LB Broth, sodium chloride, trizma 
base, hydrogen peroxide, methanol, 100% ethanol, 99.9% dimethyl sulfoxide 
(DMSO), tween 20, tetramethyl ethylenediamine (TEMED), DL-dithiothreitol 
solution (DTT), fixative, developer, crystal violet solution, propidium iodide 
(powder), agarose, tris HCl, SDS, Triton X-100, sodium deoxycholate, NaCl, 
5% glycerol (Sigma, Dorset, UK) 
•    Dulbecco's Modified Eagle's Medium (DMEM), Dulbecco's Modified Eagle’s 
Medium/nutrient mixture F12 (DMEM-F12), L-Glutamine, Penicillin-
Streptomycin, Amphotericin B Mix (Lonza, Basel, Switzerland)  
•    RPMI-1640, Trypsin-EDTA (10x), Sterile phosphate buffer saline (PBS) -        
Biowhittaker®, USA 
•     Fetal Bovine Serum (FBS) - Hyclone®, USA 
•     B-27 Supplement, DNase/RNase free water (Gibco, Thermo fisher scientific 
Inc, UK)  
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•     99.9% Dimethyl sulfoxide (DMSO), N, N,N′,N′-Tetramethyl 
ethylenediamine -   Sigma®, UK 
•   99.7% Dimethyl sulfoxide (DMSO)- Fisher bioreagents, UK 
•  RL buffer, wash solution A – Norgen Biotek Corporation, Canada 
•  Vector shield (Vector Laboratories Inc, Burlingame, CA)  
•  Reverse Transcription kit (Applied Biosystems, CA, USA) 
•  Total RNA purification kit (Norgen Biotek Corp, Ontario, Canada)  
•  Hypoxyprobe Kit (Hypoxyprobe, Massachusetts, USA)  
•  ActinRedTM, LipofectamineTM 2000 Reagent, S.O.C. Medium, DH5 
competent E. coli bacterial cells (Invitrogen, Thermo fisher scientific Inc, UK)  
•  Image-it Fix-Perm kit (Molecular probes by life technologies, Massachusetts, 
USA)  
• QuantiPro™ BCA Assay Kit (BIO-RAD, Hertfordshire, UK) 
•  EZ-ECL chemiluminescence detection kit for horse radish peroxidases solution 
A and B - (Thermo Fisher Scientific Inc., UK) 
•  AccuGel 19:1 40%(w/v) 19:1 Acrylamide: Bis-Acrylamide Solution, 4X 
ProtoGel Resolving Buffer (1.5M Tris-HCl, 0.4% SDS, pH 8.8), ProtoGel 
Stacking Buffer (0.5 Tris-HCl, 0.4% SDS, pH 6.8), Pre-stained Blue Protein 
Ladder (Gene Flow, Lichfield, UK)  
•  Matrigel (BD biosciences). 
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•  Crystal violet solution, Contains 2.3% certified crystal violet, 0.1% ammonium 
oxalate and 20% ethyl alcohol, (Sigma – Aldrich) 
• PLGA-DS stock solution (1mM) was prepared in H2O. 
 
2.1.3 Antibodies  
Table 2.1. Primary monoclonal antibodies used for Western blot analysis  
 
Conjugated secondary antibodies used for Western blot analysis:  
ECLTM Anti-Rabbit IgG Horseradish Peroxidase (HPR) linked whole antibody (from 
donkey), ECLTM Anti-Mouse IgG HPR linked whole antibody (from sheep) (GE 
Healthcare, Life Sciences, Buckinghamshire, UK)  
Fluorescently labelled antibodies used for flow cytometry:  
FITC Mouse Anti-Human CD44, APC Mouse Anti-Human CD338 (BD Biosciences, 
New Jersey, USA) CD133/2 VioBrightTM FITC human (Macs Miltenyi Biotec, 
Surrey, UK)  
Antibody                    Reference No.            Company             Dilution in 
buffer 
    NF-kB p 65 Ab 16502 Abcam 1:1000 
IKB alpha Ab32518 Abcam 1:1000 
Beta Actin A2228 Sigma 1:5000 
Tubulin T5168 Sigma 1:5000 
Vinculin V9131 Sigma 1:5000 
HIF -2 Alpha Ab199 Abcam 1:1000 
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2.1.4. Buffers  
Phosphate Buffered Saline (PBS)  
Prepared by dissolving 5 abets of PBS in 1 litre of deionised water.  
Freezing Buffer  
Prepared by adding 10% DMSO in FBS. Used to suspend cell lines for storage in 
liquid nitrogen. 
 Flow Buffer  
Used for staining cells with antibody for flow cytometric analysis. Prepared by adding 
4% FBS in PBS.  
RIPA buffer  
RIPA is used for whole protein extraction. Stock buffer was prepared from the 
following reagents detailed in Table 2.2 to make a volume of 100 mL and pH 7.4. 
RIPA buffer protease and phosphatase inhibitors were added to an aliquot of 5 ml.  
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Sorensen’s glycine buffer  
Prepared by dissolving 3.75 g glycine and 2.92 g NaCl in deionised water. NaOH (5 
M) was used to adjust the pH to 10.5.  
10× Tris-buffered saline (10×TBS)  
Prepared by dissolving 12.11 g tris base and 81.8 g NaCl per 1 litre of deionised water. 
HCl (1 M) was used to adjust the pH to 7.4 
1×Tris-buffered saline-Tween-20 (TBS-T)  
Prepared by mixing 100 mL 10×TBS with 900 mL of deionised water and 500 μL of 
Tween-20. Used for washing membrane in Western blot technique.  
Running Buffer  
Used for gel electrophoresis in Western blot analysis. Prepared by mixing 100 mL of 
10x stock (tris/glycine/SDS), with 900 mL of deionised water.  
Transfer buffer  
Prepared by mixing 200 mL methanol, with 100 mL of 10x stock (tris/glycine) and 
700 mL of deionised water. Used in western blot analysis for blotting proteins onto a 
nitrocellulose membrane.  
Blocking buffer  
Prepared by dissolving 5 g of milk powder in 100 mL of TBS-T. 5% (w/v) milk in 
TBS-T was used to prevent non-specific binding on the nitrocellulose membrane in 
western blot analysis. 
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2.1.5. Equipment Consumables  
  
 
  •       Microamp Optical 96-well Plate (Applied Biosystems, CA, USA)   
  •        Sterile pipette ZAP filter tips (Alpha laboratories, Eastleigh, UK)  
 • Fixative procedure tray (Cell Path PLC, Newton, UK)  
 • Blotting papers, Amersham Hybond P 0.45 polyvinylidine difluoride (PVDF) 
(GE Healthcare Life Sciences, Buckinghamshire, UK)  
 • 0.5, 1.5 mL Eppendorf tube, 10, 25 mL serological pipette, 10, 20 50 and 100 
mL tubes, 6-well, 12-well, 24-well, 96-well flat bottom tissue culture plates, 
T25, T75, T175 tissue culture flask, with vented caps, vacuum filter, cell 
scrapper (Sarstedt Ltd., Leicester, UK)  
 • Cryogenic vials, Black 96-well Immuno plate, EZ single Cyto funnel with 
white filter cards (Thermo Scientific, Massachusetts, USA)  
 Primer 
(Thermofisher) 
TaqMan Gene Expression 
Assays ID Assay 
Cat no (4331182) 
1 P65 Hs01042014_m1 
2 HIF1a Hs00936371_m1 
3 HIF2a Hs01026149_m1 
4 SOX2 Hs01053049_s1 
5 NANOG Hs02387400_g1 
6 OCT4 Hs00999632_g1 
7 MMP2 Hs01548727_m1 
8 MMP7 Hs01042796_m1 
9 MMP9 Hs00957562_m1 
10 SNAIL 1 Hs00195591_m1 
11 SNAIL 2 Hs00161904_m1 
12 TWIST Hs01675818_s1 
13 ZEB 1 Hs00232783_m1 
14 HPRT1 hs99999909_m1 
16 E-CAD Hs01023895_m1 
17 VIM Hs00958111_m1 
18 N-CAD Hs00983056_m1 
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 • PolysineTM (VWR International, Pennsylvania)  
 
            Scientific instruments   
 • Quant Studio 6 Flex (Applied Biosystems, CA, USA)  
 • TE70 ECL Semi-Dry Transfer Unit, Hyper cassette (Amersham, Biosciences)  
 • BD Accuri C6 Flow Cytometer (BD, New Jersey, USA)  
 • Mini protein electrophoresis chamber kit, tank with lid, gel plate gaskets, 
1.5mm glass plate and 1.5mm 10 well combs, gel cutter, buffer dam, power 
pack (BIO- RAD, Hertfordshire, UK)  
 • BioMAT2 Class 2 microbiological safety cabinet (Contained Air Solutions, 
Manchester, UK)  
 • PIPETBOY (Integra, Hudson, USA)  
 • Evos FL Cell Imaging System (Invitrogen, California, USA)  
 • Multifuge 3 S-R (Heraeus, Hanau, Germany)  
 • Spectrafuge mini centrifuge, Micropipette for volumes: 0.1-2 μL, 0.5-10 μL, 
2- 20 μL, 10-100 μL, 20-20 μL, 100-1000 μL (Labnet, New Jersey, USA)  
 • MP220 pH meter (Mettler Toledo, Ohio, USA)  
 • Eclipse TS1000 (4×, 10×, 20× lenses) (Nikon, Amsterdam)  
 • CO2 Incubators, O2/CO2 Incubators (Panasonic, Leicestershire, UK)  
 • Refrigerated centrifuge sigma 6-16KS (Sigma, Dorset, UK)  
 • Block heater, see-saw rocker, heat-stir UC152 (Stuart, Staffordshire, UK)  
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 • Multichannel pipette, Transfer pipette S-8  
 • Multidrop 384, Multiskan Ascent, Fluoroskan Ascent FL, Nanodrop 2000, 
Shandon Cytospin 4 (Thermo Scientific, Massachusetts, USA)  
 • Ultrasonic Cleaner (VWR, Pennsylvania, USA)  
         Cell culture inserts, transparent PET membrane 24 well 8.0µM Pore size,   










2.2 Methods  
 
 
2.2 .1 Cell Culture of adherent cells  
 







Serum containing medium (SCM) 
 
RPMI media was used which consists of Fetal bovine serum 1% (v/v) L - 
Glutamine 1% (v/v) and antibiotics i.e. penicillin and streptomycin 1% (v/v) 
 
Serum free medium (SFM) 
 






Working stock i.e. 10x is prepared from 1x stock solution by diluting with sterile PBS. 
 
 
Freezing medium (To store cells at -180 °C in liquid nitrogen) 
 
The Medium was prepared by adding 10% DMSO to 90% fetal calf serum. 
 
 
2.2.2 Recovering cells from liquid Nitrogen 
 
The labelled cell lines were collected from liquid Nitrogen, quickly defrosted at 37 °C 
and transferred to T-75 vented flask containing 19 ml of RPMI (serum-containing 
medium). The cells were incubated overnight at room temperature, i.e. 37°C. It was 
followed by changing media the next day to ensure that the trace amounts of DMSO 
was removed and no unattached or dead cells remained.  
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2.2.3 Trypsinization of healthy adherent cells 
The cells were observed for ~90% confluency under the microscope, which should 
also relate to the colour change of media; the cells were then ready for Subculturing. 
The consumed media was aspirated, followed by washing with 5 mL sterile PBS. It 
was further followed by addition of 2 mL trypsin from working stock, and the cells 
were incubated at 37 °C for approximately 10 minutes. The flask was lightly tapped 
from the sides to detach the cells gently. After ten minutes, it was checked for 
complete detachment of the cells under the microscope. The trypsin was then 
neutralised with 2 mL serum-containing medium. The mixture should be mixed well 
in the flask to break any clumps left after trypsinisation. It was then transferred to the 
tube and centrifuged at 1200 r.p.m for 10 minutes; the pellet was collected and again 
suspended into fresh medium for subculturing. 
 
2.2.4 Maintenance of the cell lines 
 
The number of cells in the flask determines the number of days it should be a 
subcultured. The cells were checked for a change in the colour of media and 
confluency accordingly. When the cells were ~90% confluent, they are ready for 
subculture. The cells are again trypsinised, collected as pellet, counted, and added 
accordingly to the flask. 
 
 
2.2.5 Storage of cell lines in liquid nitrogen 
 
The fully confluent flask was trypsinised, and cells centrifuged at 1200 r.p.m for 5 
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minutes. The used media was aspirated. The cells were then counted using cell 
counter, and 1x106 cells were collected and released in 1 mL freezing medium. It was 
then aliquoted to carefully labelled cryovial mentioning details of the cell lines, date, 
passage number (if patient-derived). The cryovial is then wrapped in a thick layer of 
tissue paper and stored at -80 °C. It was followed by transfer of these vials to liquid 
nitrogen tank (-160 °C) to maintain long term viability of the cells. The location of the 




2 .2.6 Sphere Reformation 
 
 
Poly-HEMA coating for sphere cell culture 
 
 
• JU77 and MSTO-211H cell lines were stimulated to form spheres by using 
nutrient-rich media DMEM F12 supplemented with growth factors by using 
coated flask and plates with low adherence. These plates were prepared by using 
Poly-HEMA (poly-2-hydroxyethyl methacrylate) 10mg/mL mixed with 95% 
ethanol. The solution was sterilised using the filter and stored at 4°C. The 
following volumes used for coating the flasks/plates: 
• 2 ml for T 25 
• 0.4 ml/well for six wells 
  The coated flasks kept in the incubator at 50- 60 °C to form a coating of dried    
   polyhema on the bottom of the flask. Before using, the flasks were washed twice  




Growing sphere cells 
 
 
MSTO-211H and JU77 cell lines were trypsinised from T-75 cultured flask, and cells 
were counted using a cell counter. For sphere cells culture, 0.5x106 cells were grown 
in selective stem cell media with all the growth factors. The cells were grown in ploy-
HEMA coated flasks and incubated for seven days at 37 °C and the consumed media 
was changed carefully on Day-5 with fresh media. After incubation, the cells were 




Dosing the sphere cells 
 
The cultured cells were collected and centrifuged at 600 r.p.m for 5 minutes. The 
liquid was aspirated, and the pellet was mixed with 7 mL of stem cell media. 1 mL of 
media containing cells was distributed equally in 6 test tubes labelled for different 
treatments, i.e. Negative, Pemetrexed, Cisplatin, Copper, Disulfiram, Disulfiram + 
copper. The drug concentrations are as follows (according to the IC-50 values of cell 
lines): MSTO-211H and JU77: 
- PMT - 1 µM 
 
- CIS - 10 µM 
 
- PLGA-DS - 1 µM 
 
- Cu - 10 µM 
 
- PLGA- Ds/Cu - 1 µM/10 µM 
 
The labelled test tubes were then topped up with 3 mL SCM containing the above 
concentration of drugs making the volume to be 4 mL in all the six test tubes and 
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mixed well. 4 mL solution from the above mixture containing cells + drug was 
transferred to already prepared six-well plate coated with Poly-HEMA and washed 
twice with 2 mL PBS. The plate was incubated for 48 hours. 
 
 
Regrowing sphere cells 
 
Six test tubes were labelled carefully for different drugs (mentioned above). 
Individually collected content from each well (incubated for 48 hours) was transferred 
to each test tube. The test tubes were centrifuged at 600 r.p.m for 5 minutes, aspirated 
and 4 mL PBS was added to the pellet and centrifuged again at 600 r.p.m for 5 minutes. 
PBS was aspirated, and 200 µL of trypsin was added and mixed well until no spheres 
were visible. It was followed by a short incubation of 5 minutes and repeated twice 
making the volume of trypsin to 400 µL. The volume was made up to 1 mL by adding 
600 µL of serum-containing media. 5 mL of stem cell media was added further, and 
the volume was made up to 6 mL. Cells were counted for each test tube using the cell 
counter. Fifty thousand cells from each tube were collected and added to 2 mL to stem 
cell media. Poly-HEMA coated Six well plates were prepared by washing with 2 mL 
PBS. Stem cell media + cells were added to each labelled well with different drugs 
concentrations and placed in the incubator for seven days to identify the ability of 
spheres to regrow. The cells were observed under the microscope. Each well was then 






Graph pad prism analysis tool was used to perform all statistical data analysis. The 
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cut-off chosen for statistical significance between samples was p=0.05. Values less 
than 0.05 indicate that the difference between the samples is statistically significant. 
P-value<0.001 denotes that the difference between the samples is extremely 
significant, and p≥0.05 defines that the difference between the two samples is not 
statistically significant. The statistical "student t-test" was used for means to determine 
the statistical significance between MM cell lines that tested under the same conditions 
for two samples. The statistical test "One-Way Annova" used to determine the 
statistical significance of the same MM cell line that tested under the varying condition 
and more than two samples.  
 





 Table 2.4: showing gene of interest, lentiviral vector, and target sequences 
 
 
2.2.7.1 NF-kB knock out - All-in-One lentivector sets of sgRNA CRISPR/Cas9 for 
NF-KB (Rel A) purchased from Abm (BC, Canada). Each lentiviral set consists of 
multi-guide sgRNA that target the same gene but will introduce three fragment 










All in one Lentivector set (Human) 
  
 T1 57 GCTCAATGATCTCCACATAG 
   T2  98 GCTTCCGCTACAAGTGCGAG 
   T3  266 AGCTTGTAGGAAAGGACTGC 




 Preparation of LB plates  
LB (Luria -Bertani) agar medium (Sigma, UK) prepared by adding, 50 g of LB broth 
powder to 2 L of deionised water, 6 gm of agar medium was mixed in one of the 
aliquots and autoclaved. To select successfully transformed bacteria 100 μg/mL 
ampicillin (for antibiotic selection) added to the broth-agar autoclaved medium. Each 
10 cm2 petri dish prepared with 15 mL of medium containing ampicillin and allowed 
to set at room temperature and stored at 4°C.  
 
Transformation  
The JM109 E. coli strain (Promega USA) chosen as competent bacterial cells for 
transformation. They were stored as aliquots of 50 mL at -80°C. One aliquot of JM109 
was thawed on ice, 20 ng of each plasmid (T1, T2, T3) DNA was added to the 50 µL 
of competent cells and incubated on ice for 20 minutes. To enhance the uptake of DNA 
by bacterial cells, the tube containing JM109 and DNA were exposed to heat shock 
for one and a half minute at 42°C water bath. The samples were quickly placed on ice 
for 2 minutes. Subsequently, 950 µl of LB broth without containing ampicillin was 
added to the mixture and incubated at 37°C for 1 hour on a shaker. After incubation 
150 mL of each target was spread on the agar plate containing antibiotic ampicillin 
with the help of an L-rod and incubated overnight at 37°C to allow the formation of 
bacterial colonies which were not resistant to ampicillin. A single colony was picked 
per target and added to 20 ml of the sterile tube containing 3 mL of LB broth 
containing ampicillin to a final concentration of 100 mg/mL and incubated overnight 
in a shaker at 240 r.p.m, 37°C. The next day solution on each tube was divided into 
two 1 mL and 2 mL aliquots for mini-prep and maxi prep respectively.  
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The QIAGEN Kit, UK (QIAprep Spin Miniprep) was used for preparing high copy 
plasmid. The tubes with 1 ml of the transformed plasmid were centrifuged at 8000 
r.p.m. for 3 minutes at room temperature. The pellet was collected and suspended into 
250 mL of buffer P1 (composition: 50 mM Tris-Cl, pH 8.0; 10mM EDTA; 100 mg/mL 
RNase A). The mixture was transferred to a microcentrifuge tube, and 250 µL of buffer 
P2 was added (composition: 200 mM NaOH, 1% SDS (w/v) for cell lysis. The sample 
was mixed gently by inverting the tubes until the solution became clear. It was 
followed by adding chilled buffer P3 (composition: 3.0 M potassium acetate pH 5.5) 
and mixed well to neutralise cell lysis. The solution incubated on ice for 20 minutes. 
The mixture was centrifuged for 30 minutes at 13,000 r.p.m and 4°C. The supernatant 
was collected into a QIAprep and centrifuged again for 1 minute at 20,000 g, 4 °C. 
The flow-through was discarded. The QIAprep column was washed with buffer PB 
and centrifuged for one minute. The flow-through was discarded. The column was 
then washed a second time with 750 µL of buffer PE, centrifuged for 1 minute and 
flow-through was discarded. Additionally, centrifugation was repeated for 1 minute to 
remove any residual wash buffer. The column was transferred in a microcentrifuge 
tube, and 50 µL of buffer EB (pH-8.5) then added to the middle of the column and 
incubated for 1 minute at room temperature. The eluted DNA was quantified using 







1.5 mL of previously transformed plasmid was added into a 500 mL of a sterile glass 
bottle containing 9 mL of LB broth with ampicillin (100 µg/mL). The mixture was 
placed in a shaker at 37°C for 6 hours. After incubation, the mixture was transferred 
in a 500 mL sterile maxi prep bottle and centrifuged for 4,500 r.p.m. for 15 minutes. 
The supernatant was discarded, and the pellet resuspended and carefully combined 
into a 10 mL P1 buffer. The solution transferred into 50 mL maxi-prep flasks, 10 mL 
of Buffer P2 was added to the mixture for cell lysis, mixed well by inverting and 
incubated for 5 minutes at room temperature. The solution was incubated on ice for 
20 minutes. It was followed by centrifugation at 9,600 r.p.m for 30 minutes. 
Meanwhile, 10 mL buffer QBT was used to equilibrate maxi-prep columns. After 
centrifugation, the supernatant was collected and transferred in a maxi prep column 
and allowed to flow by gravity. 30 ml of buffer QC used to wash the QIAGEN 
columns. 15 mL of buffer QF was added to elute the DNA, and a 50 uL was placed 
under the column for collection. 10.5 mL of isopropanol (room temperature) was 
added to the collected elute and immediately mixed and centrifuged for 1-hour min at 
9,600 r.p.m, 4°C. Isopropanol aid in DNA precipitation. The supernatant was 
removed, and the pellet was washed with 1.5 mL of 70% ethanol (room temperature) 
and centrifuged for 10 min at 13,000 r.p.m, 4°C. The supernatant was decanted, and 
tubes were centrifuged again to remove the residual ethanol and pellet was left to air 
dry. DNA was dissolved in the TE buffer to measure the concentration of DNA by 
using nanodrop spectrophotometer. The three targets, i.e. T1, T2 and T3, were 




CRISPR -Cas9 knock out of MSTO-211H cell line with NFNB-p65 subunit  
 
Each target (T1, T2, T3) was diluted to a final concentration of 3 µg/µL of plasmid 
DNA, and 10 µL was added in a 1.5 mL tube. For stable transfection (knock out) 
Mesothelioma cell line (MSTO-211H) were seeded at a density of 0.4x106 and 
cultured in 6 well plates, in serum-containing media and incubated for 24 hours at 
37°C, 5% CO2. To determine the efficiency of transfection, scrambled (empty vector), 
and Negative (no plasmid) was used as controls. To perform transfection 250 μL of 
OPTIMEM was mixed with 10μL of lipofectamine 2000 in tube A. In tube B 250 μL 
of OPTIMEM was mixed with 3µg/µL of plasmid DNA (the plasmids containing the 
above sequences were mixed in equal proportions) In tube C 3 µg/µL of an empty 
plasmid (scrambled) was mixed with 250 μL of OPTIMEM and 10μL of lipofectamine 
2000. The tubes were incubated for 5 minutes at room temperature. After incubation, 
tube A and B were mixed and incubated for 20 minutes. 
The mixture was then transferred to well labelled six-well plates containing MSTO-
211H culture and incubated for 24 hours at 37°C and 5% CO2. The following day cell 
culture was trypsinised with 500 µL of trypsin and neutralised with 1.5 mL of serum 
containing media. Each transfection was then subcultured to well labelled petri dishes 
containing 15mL fresh RPMI media with 150 ng/mL puromycin as selecting agent. 
The cells were incubated at 37 °C and allowed to grow for a few days, according to 
preliminary screening. They were checked routinely, and media was changed 
approximately after every two days. The plates were observed for the presence of 
colonies. The Negative containing no resistance to puromycin died, and the 
successfully transfected cells formed colonies. The individual colonies were picked 
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by trypsinising and transferred to T-25 flask contains fresh RPMI with 150 ng/mL 
puromycin. The cells were then collected and screened by western blot for the 
expression of NF-kB on the protein level followed by screening by qRT-PCR on RNA 
level. For about, 40 colonies were picked and screened for no expression of NF-kB in 
the clones through western blot and RT-PCR. Amongst which only two clones for the 
best expression and one for scrambled was chosen for further experiments. 
 
2.2.7.2 NF-kB ectopic expression 
For stable transfection (overexpression) Mesothelioma cell line (MSTO-211H) were 
seeded at a density of 0.4x106 and cultured in 6 well plates, in serum-containing media 
and incubated for 24 hours at 37°C, 5% CO2. To determine the efficiency of 
transfection, mock (empty vector), and Negative (no plasmid) were used as controls. 
To perform transfection 250 μL of OPTIMEM was mixed with 10μL of lipofectamine 
2000 in tube A. In tube B 250 μL of OPTIMEM was mixed with 3µg/µL of plasmid 
DNA. In tube C 3 µg/µL of the empty plasmid (mock) was mixed with 250 μL of 
OPTIMEM and 10μL of lipofectamine 2000. The tubes were incubated for 5 minutes 
at room temperature. After incubation tube, A and B were mixed and incubated for 20 
minutes. 
The mixture was then transferred to well labelled six-well plates containing MSTO-
211H culture and incubated for 24 hours at 37°C and 5% CO2. The following day cell 
culture was trypsinised with 500 µL of trypsin and neutralised with 1.5 mL of serum 
containing media. Each transfection was subcultured to well labelled Petri dishes 
containing 15mL fresh RPMI media with 50 mg/mL hygromycin was the selecting 
agent. The cells incubated at 37°C and allowed to grow for a few days, according to 
 
74 
preliminary screening. The cells were checked routinely, and media was changed 
approximately every two days. The plates observed for the presence of colonies. The 
Negative containing no resistance to hygromycin died, and the successfully 
transfected cells formed colonies. The individual colonies were picked by trypsinising 
and transferred to T-25 flask contains fresh RPMI with 50 mg/mL hygromycin. The 
cells were then collected and screened by western blot for the expression of NF-kB on 
the protein level followed by screening by qRT-PCR on RNA level. For about, 40 
colonies were picked and screened for ectopic expression of NF-kB in the clones 
through western blot and RT-PCR. Amongst which only two clones for the best 
expression and one mock were chosen for further experiments  
 
2.2.8. SDS - PAGE / Western Bolt 
 
 
 Pellet Collection 
 
Cells were collected and centrifuged at 1200 r.p.m for 5 minutes. The collected pellet 
was washed with 1mL PBS and centrifuged. The washed pellet was transferred to 
Eppendorf (1.5 mL) and centrifuged with 1 mL PBS. PBS was removed, and the pellet 
was stored at -80 °C. 
 
Protein extraction  
 
For cell lysis 100-200 µL of RIPA buffer (with protease and phosphates inhibitors see 
Table 2.2 for its preparation) was added according to the pellet size and mixed every 
well. The samples were sonicated for 1 minute and centrifuged for 20 min (4°C) at 





The protein concentration was estimated with BCA assay, by comparing the values to 
a protein standard calibration curve, which is prepared by plotting absorbance versus 
protein concentration graph by using a serially diluted BSA in RIPA buffer. The 
protein sample was thawed and placed on ice. 2.5 µL of each protein sample aliquoted 
in duplicate in 96 well plates. Followed by the addition of reagent (A+S) which was 
prepared by mixing A:S = 20:1 µL (prepared according to the number of samples). 25 
µL of A+S solution aliquoted in the well-containing protein followed by addition of 
200 µL of reagent B. The mixture was incubated for 10 minutes at room temperature. 
The protein concentration was determined by using a multi-scan. BSA protein 
determination assay was followed which was prepared by serially diluting the 
3.0mg/mL BSA solution in RIPA buffer to the following concentrations: 3.0mg/mL, 
1.5 mg/mL, 1.0 mg/mL, 0.75 mg/mL, 0.50 mg/mL, 0.25 mg/mL and 0 mg/mL (30μL 
RIPA buffer). The absorbance was read at 650 nm, and protein concentration of the 
samples was calculated from plotting the absorbance versus protein concentration of 
the BSA. The protein estimates were used to equalise protein concentrations across 
the samples ranging between 30-150 μg/lane.  
 
Preparing samples for loading 
The samples were calculated using Excel software. A mixture of protein about 50-100 
µg, 1 µL of 0.5 M DTT, deionised water and 4x loading dye was prepared to the 
specified final volume (maximum loading volume 40 µL) and vortexed for 1 min. The 
labelled vials containing loading mixture was kept on heat block for 10 min at 96°C. 
The vials were removed after 10 minutes and vortexed for a few seconds. 
 
76 
Preparation of separating gel 
Before the preparation of gel mixture, 1.5 mm spacer plates were used and placed 
together and secured with clamps. The separating gel was prepared, as described in 
Table 2.3. TEMED was added in the end whilst preparing the mixture. The mixture 
was mixed thoroughly, and 7.5 mL added to the gel plates. After the addition of gel, 
approximately 200 µL of isopropanol was added to cover the top of separating gel 
solution to remove any bubbles. The gel was left undisturbed for 20 minutes. The 
isopropanol was removed once the gel was set. The solidified gel was washed thrice 
with distilled water.  
 
 Reagents: 
10% Ammonium persulphate: It was prepared by dissolving 0.1 g APS in 1 mL 
of distilled water. 
 
Table 2.5: Components of separating gel with corresponding volumes. 
 
SEPERATING GEL 10% GEL 6% GEL 
40% 19:1 acrylamide: bis (mL) 4.4 mL 4.4 mL 
Resolving Buffer (mL) 5.5 mL 5.5 mL 
H2O (mL) 5 mL 6.6 mL 
TEMED (µL) 15 µL 15 µL 




Preparation of stacking gel: The stacking gel was prepared, as shown in Table 2.4. 
The stacking gel mixture was added on top of the separating gel, and 1.5 mm comb 
was placed immediately but carefully to avoid the formation of bubbles. This comb 
helps in forming the required wells for protein loading. The combs were removed after 
solidification of the gel. 
 
Table 2.6: Preparation of stacking Gel SDS - PAGE electrophoresis 
 
Previously prepared SDS-PAGE gels were assembled into the electrophoresis tank, by 
using the cassette adapter and placed in the tank containing in 1x running buffer. Comb 
was removed, and the wells were cleaned with a syringe to remove any trapped gel 
inside the wells. The prepared protein samples were loaded into the wells, and 5µL of 
protein marker was added in one of the wells to monitor protein size. The gel was then 
run at 200 V, 300 mA for 1 hour. The current was maintained to allow protein 
separation by molecular weight.  
         REAGENTS                                           VOLUME   
30% 19:1 acrylamide: bis                        1.2 mL 
               Stacking Buffer (mL)                          4.2 mL 
                       H2O (mL) 6.6mL 
TEMED (µL) 20 µL 




3MM blotting paper was cut into 9 x 10 cm size. PVDF cut into 8 x 4.5 cm size and 
was soaked in transfer buffer for a while, and PVDF was dipped in methanol (to 
activate it for protein binding) for 5 minutes and then soaked in transfer buffer before 
being transferred. Four Blotting papers were dipped in transfer buffer and kept on top 
of each other on the semi-dry transfer unit. PVDF membrane was placed carefully on 
top of blotting papers. SDS gel was carefully removed from the casket and placed on 
top of the PVDF membrane and again covered by four blotting papers from the top. 
The sandwich was flooded with transfer buffer, and the lid was closed. The SDS-
PAGE was run for 1 hour 30 minutes at 20V and 200 mA. 
 
Blocking the PVDF membrane 
 
After botting was completed, the membrane was placed in a tray and submerged in 
blocking buffer. Blocking buffer was prepared by using 5% of fat-free milk in 1xTBS-
T solution. It was added to the freshly transferred protein-membrane for 1 hour and 
was used to prevent unspecific binding of antibodies. 
Staining by primary antibody 
PVDF membrane was incubated for 1 hour by using a primary antibody 
(Concentrations according to table 1.3) prepared in blocking buffer. The membrane 
was placed in a clean plastic bag and sealed around the corner using heat. The primary 
antibody was poured into the bag carefully without bubbles, sealed and was left 
overnight at 4°Con a shaker. The membrane was removed the next day and washed 
thrice with TBST for 10 minutes. It was then placed in 10 mL secondary antibody, 
prepared in blocking buffer (dilution from Table 1.3) and incubated for 2 hours at 
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room temperature. The PVDF membrane was then washed thrice with TBS -T (1x) 
for 10 minutes and prepared for signal detection. 
 










SECONDARY ANTI MOUSE 1:5000 






The ECL detection kit was used to detect the chemiluminescence signal. The washed 
membrane was placed in a hyper cassette layered with cling film. EZ-ECL solution 
was prepared by mixing solution A with solution B in 1:1 ratio and added to PVDF 
membrane for 4 minutes. The ECL solution was removed by tilting the cassette and 
draining off the solution without touching the membrane. For the extra sensitive 
proteins, the luminescence was detected using x-ray films in a completely dark room. 
The membrane was covered with cling film, and the x-ray was kept on the top. The 
lid of the cassette was closed, and it was left undisturbed in a completely dark room 
for 15 minutes. The film was developed by immersing in the developer solution briefly 
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rinsed with water, followed by brief exposure to the fixative solution. The bands were 
observed as dark spots due to chemiluminescent light affecting x-rays. The intensity 
of bands is directly proportional to the protein content, therefore darker the band more 
the protein and vice versa. The membrane was washed for 1 hour in TBS-T to remove 
any previously bound antibodies. The protein loading efficiency was determined by 
using b acting as a loading control. The membrane stained with b-actin primary 
antibody (1:5000) was prepared in blocking buffer. It was washed twice for 15 minutes 
and was followed by HPR conjugated secondary antibody (1:8000) in blocking buffer. 
The protein bands detected should be equivalent to all the samples. It further 
determines the accuracy of the technique throughout the western blot analysis.  
 
2.2.9. Quantification of RNA gene expression (qRT-PCR) 
 
RNA isolation 
Mesothelioma cells (0.25 x 106) were cultured in T-25 flask and placed in a hypoxic 
chamber for five days without changing media. Normoxic samples were collected by 
culturing 1x106 cells in overnight Normoxia. Media was aspirated, and cells were 
washed with 2 mL PBS. PBS was aspirated, and 300 µL of RL buffer was added and 
incubated for 2 minutes. The lysate was collected and placed in -80 °C if not processed 
further. RNA purification was performed by using total RNA purification kit (Norgen 
Biotek). To process the sample further, the solution was added to the genomic DNA 
column, and a collection tube was placed at the bottom of the column. It was then 
centrifuged at 10,000 r.p.m at room temperature for 1 minute. The column was 
disposed, and 200 µL of 100% ethanol was added to 300 µL of flow-through and 
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vortexed. This 500 µL of the solution was transferred to RNA purification tube with 
collection tube placed at the bottom and centrifuged at 10,000 r.p.m for 1 minute. The 
flow-through was discarded. 400 µL of wash solution A was added to the column and 
centrifuged for 1 minute at 10,000 r.p.m. The procedure was repeated three times. The 
column was carefully removed to prevent any ethanol binding to the column. The 
collection tube was discarded, and the column was placed into a fresh elution tube. 50 
µL of elution solution A was added to the column and left for 1 minute. The samples 
were centrifuged at 2000 r.p.m at room temperature for 2 minutes, followed by 
centrifugation at 10,000 rpm, room temperature for 1 minute. The final solution 




RNA concentration and quality of each sample were measured using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, UK). The ratio of absorbance at 260nm and 
280nm was used to assess the purity of RNA in the sample. To blank the machine, 1.5 
µL of the RNA samples were added and measured in ng/µL. 
Complementary DNA (cDNA) synthesis 
 
500 ng of the RNA required for RT (Reverse Transcriptase Chain Reaction), and 
therefore the obtained samples were diluted to 500 ng in 10µL using nuclease-free 
water (Invitrogen, UK). This 10μL of total RNA (50 ng/µL) mixed with 10μL of a 2x 
Reverse Transcription mixture containing 2x Transcription buffer, 8mM dNTP mix, 
2x random primers (as shown in table 2.6). This 2x RT master mix was used for 
reverse transcription, in thermocycler using the following conditions: 25°C for 10 
minutes, at 37°C for 120 minutes, 85°C for 5 minutes. The cDNA samples obtained 
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was placed on ice for immediate use or stored at -20ºC for long term storage. The 
cDNA product (20µL) was assumed to have 500 ng of DNA concentration and was 
diluted with 80 µL of DNase/Rnase free water (1:5 dilution) to make a final 
concentration of 5 ng/µL, cDNA stored at -80°C.  
 





VOLUME (µL) x 1Reaction 
10 x RT Buffer 2 
10 x RT Random Primers 2 
DNase/Rnase free Water 4.2 
25 x dNTP mix 0.8 





Quantitative real-time PCR (qRT-PCR) 
 
The quantification of gene-specific mRNA expression was determined by qRT-PCR 
using TaqMan Gene Expression Assays (Thermo Scientific, UK) with FAM reporter. 
The master mix was prepared for a calculated number of reactions required, as detailed 
in Table 2.7. The master mix was prepared for each specific TaqMan primer used, 
once these mixed 5.5 µL of the master mix added to one well of Microamp® fast 
optical 96-well reaction plates (Applied Biosystems, UK) followed by 4.5 µL of the 
required cDNA.  
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A negative control sample that contained 5.6 μL of nuclease-free water instead of 
cDNA solution was included in the assay to verify the fidelity of the PCR 
amplification—after setting up the reaction, the plates were sealed with an optically 
clear seal, gently tapped to remove any air bubbles and centrifuged at 200 r.p.m. for 1 
minute. The reaction plate was placed on a Real-Time PCR System (Applied 
Biosystems, UK). PCR cycling conditions consisted of an initial enzyme activation 
step at 95ºC for 10 minutes, following denaturation at 95ºC for 15 seconds and 
annealing and extension at 60ºC for 1 minute for 40 cycles. Data was exported to 
GraphPad Prism for statistical analysis. The expression of the GAPDH gene was 
determined and used for internal control and normalisation.  
Table 2.9: Showing the components for master mix for (qRT-PCR) and 





2.2.10. Detection of Cancer stem cell markers using Flow Cytometry 
 
Mesothelioma cells were collected and aliquoted at a density of 100,000 cells/well. 
They were plated in a six-well plate and incubated in the hypoxic chamber for four 
COMPONENT VOLUME 
2x TaqMan Universal Master Mix II 
 5 µL 
20x TaqMan Assay Primers 
 0.5 µL 
DNase/RNase free water 
 4.5 µL 
Total 10 µL 
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days. On third-day cell samples at a density of 250,000/well were plated in Normoxia 
and incubated overnight. The samples were trypsined by adding 500 µL of trypsin and 
neutralised with 1.5 mL of media. The solution was centrifuged at 1200 r.p.m for 5 
minutes. The pellet was washed with 2 ml flow buffer (4% FBS in PBS stored at 4°C) 
by centrifuging at 1200 rpm for 5 minutes. The cells were counted, and 200,000 cells 
suspended in each tube. The tube containing cells were washed with 2 mL of flow 
buffer at 2000 r.p.m for 5 minutes.  
 
Detection of CD133 positive population – The CD-133-FITC reagent was diluted 
(2.5 µL stain/100 µL of flow buffer). The cell pellet was resuspended in 100 µL of 
diluted CD133-FITC and incubated for 1 hour at 4°C. Followed by incubation, the 
cells were rinsed with flow buffer and centrifuged at 2000 r.p.m for 5 minutes. The 
medium was aspirated, and the pellet was resuspended in 200µl of flow buffer. The 
samples were analysed with FL-1 green filter to detect CD133 positive population.  
 
Detection of ABCG2 positive population – ABCG2 is also known as CD338w. The 
338w -APC reagent diluted (2.5 µL stain/100 µL of flow buffer). The cells were 
resuspended in 100 µL of diluted CD338w and incubated for 30minutes at 4°C. 
Followed by incubation, the cells were rinsed with flow buffer and centrifuged at 2000 
r.p.m for 5 minutes. The medium was aspirated, and the pellet was resuspended in 
200µl of flow buffer. The samples were analysed with FL-3 red filter to detect positive 




Detection of CD 24 positive population – The CD 24-FITC reagent was diluted 
(2.5 µL stain/100 µL of flow buffer). The cell pellet was resuspended in 100 µL of 
diluted CD24 and incubated for 30 minutes at 4°C. Followed by incubation, the cells 
were rinsed with flow buffer and centrifuged at 2000 r.p.m. for 5 minutes. The medium 
was aspirated, and the pellet was resuspended in 200µl of flow buffer. The samples 
were analysed with the FL-1 filter to detect positive CD24 population by using BD 
flow cytometer. 
. 
2.2.10.1 Measurement of hypoxia in cell culture  
 
The hypoxic status of the cell was examined by immunohistochemistry and flow 
cytometry. The attached cells (10,000/dish) in hypoxia were cultured for four days 
using a HypoxyprobeTM-1 Plus Kit (HPP). On the fourth day, the consumed medium 
was replaced with HPP containing medium at a concentration of 100 μM. The cells 
were incubated overnight. Cells for Normoxia (50,000 cells/well) were plated on the 
third day, and HPP probe (100 μM) was added on the fourth day for overnight. The 
hypoxic and normoxic culture were processed together on day five. The media was 
removed, and cells were washed with PBS. The Image-it Fix-Perm kit was used to fix 
the cells and prepare a slide for staining purposes. Fixative (which contained 4% 
formaldehyde) was added to the cells and incubated for 15 minutes. 
The cells were washed three times for five minutes each and kept on see-saw rocker 
at room temperature. Permeabilisation solution (containing 0.5% Triton X-100 in 
DPBS) was then added to the cells and left for 15 minutes. The slide was then washed 
three times for 5 minutes each with 500 µL of washing buffer. The cells were treated 
with 200 µL of blocking buffer (containing 3% BSA in DPBS) for 60 minutes. 
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Blocking buffer was discarded, and the cells were stained with the fluorescently 
labelled primary antibody to bind to the HPP. FITC anti-HPP was conjugated 
monoclonal antibody prepared in blocking buffer in the ratio 1:1000 dilution. It was 
incubated in the dark at room temperature for 1 hour. The cells were then washed with 
wash buffer thrice for 5 minutes. Two drops of beta actin- PI antibody was added in 1 
mL blocking buffer to stain the cytoskeleton. After half an hour, the solution was 
discarded, and a solution of vector shield containing DAPI was added directly to the 
cells, and well covered by 12 mm coverslip. The dishes were covered with aluminium 
foil to prevent the loss of fluorescence. The cells were then analysed using the Evos 
microscope for high magnification images.  
HPP staining was also detected by using flow cytometric analysis. Mesothelioma cells 
(100,000 cells/well) were plated in a six-well plate and incubated in the hypoxic 
chamber for four days. On the third day, 250,000 cells /well were incubated in 
normoxic conditions overnight. On the fourth day, HPP (1:1000) was added to the 
respected wells (1µL/mL) in normal and hypoxia samples for 2 hours. The samples 
were trypsinised by adding 500 µL of trypsin, rinsed with PBS, collected and 
centrifuged at 1200 r.p.m for 5 minutes. The pellet was washed with 2 mL PBS and 
centrifuged twice at 1200 rpm for 5 minutes. The final pellet was resuspended in 200 
µL of sterile PBS and fixed adding 2 mL of ice-cold 70% ethanol (stored at - 80 °C) 
drop by drop whilst mixing, followed by incubation for 10 minutes. This ice-cold 
ethanol was slowly added to the test tubes whilst placing them on the vortex, and cells 
were left untouched for 10 minutes. The cells were rinsed with PBS and centrifuged, 
at 1200 r.p.m for 5 minutes, the ethanol was aspirated, and cells were washed with 9 
mL PBS. The PBS was removed, and the fixed cells stained with 200 µL of HPP- 
FITC conjugated antibody was prepared in blocking buffer (1:1000) and stored in the 
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dark for 2 hours at 4°C. The cells were washed with 2mL of PBS and centrifuged at 
1200 r.p.m for 5 min. The pellet was mixed in 200 µL of PBS, and cells were analysed 
using FACS. The positive hypoxic population was detected by FL-1 green filter using 
BD flow cytometer.  
 
 
2.2.11. Migration Assay 
 
MSTO-211H and JU77 cell lines (0.25 x 106) were cultured in hypoxia for four days. 
For normoxic culture, 1x106 cells were on the third day for 24 hours. The normoxic 
and hypoxic cells were trypsinised together on the fourth day, and a pellet was 
obtained. The cells were trypsinised, and the pellet was collected again. It was 
resuspended in fresh medium, and cells were counted. Ten thousand cells for MSTO-
211H and 50,000 for JU77 were taken per sample and transferred to 2 ml PBS. The 
solution was centrifuged at 1200 r.p.m for 5 minutes. The pellet was resuspended in 
50 µL serum-free media and mixed very well, and it was then topped up with 1950 µL 
serum-free media and mixed well. 
Boyden chambers were placed in 24 well plates. 200 µL of SFM containing cells were 
transferred to the chamber. 700 µL of serum-containing media was transferred to the 
well in which Boyden chamber was placed, to immerse the chamber in serum-
containing media from the bottom. The hypoxic cells were treated with 25 nM of 
PLGA - DS, which was added in 700 µL of the serum-containing medium. So, one 
cell line had four samples per condition, i.e. Normoxia, hypoxia and Treated. The 
plates were incubated overnight. Following day media was removed from the 
chambers, and the chamber containing cells were transferred to another 24 well plates 
containing 700 µL of crystal violet/well. Crystal violet was prepared in the ratio of 1:3 
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with PBS. The chamber was left untouched for 20 minutes and then washed twice with 
water and left to dry. The dried chambers were placed back in the fresh 24 well plates 
and observed under the microscope. The cells were counted for different conditions 
and were analysed using INNOVA graph pad. 
 
2.2.12 Invasion Assay 
 
 
MSTO-211H and JU77 cell lines (0.25 x 106) were cultured in hypoxia for four days. 
For normoxic culture, 1x106 cells were cultured on the third day for 24 hours. The 
normoxic and hypoxic cells were trypsinised together on the fourth day, and the pellet 
was obtained. It was resuspended in fresh medium, and cells were counted. 10,000 
cells for MSTO -211H and 50,000 for JU77 were taken per sample and transferred to 
2 ml PBS. The solution was centrifuged at 1200 r.p.m for 5 minutes. The pellet was 
resuspended in 50 µL serum-free media and mixed very well, and it was then topped 
up with 1.95 µL serum-free media and mixed well. Unlike migration, Boyden chamber 
was coated with matrigel for invasion. The gel aliquot for coating was prepared using 
stock (200ul) gel dilution of 1:15 with serum-free media. It was mixed well using cold 
tips, and 200 µL of the mixture was aliquoted in the Boyden chambers and incubated 
overnight. 
The coated Boyden chambers were placed in 24 well plates. 200 µL of SFM and cells 
were transferred to the chamber. 700 µL of serum-containing media was transferred 
to the well in which Boyden chamber placed, to immerse the chamber in serum-
containing media from the bottom. The hypoxic cells treated with 25 nM of PLGA-
DS, which was added in 700 µL of the serum-containing medium. So, one cell line 
had four samples per condition, i.e. Normoxia, hypoxia and Treated. The plates were 
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incubated overnight. Following day media was removed from the chambers, and the 
chamber containing cells were transferred to another 24 well plates containing 700 µL 
of crystal violet/well. Crystal violet was prepared in the ratio of 1:3 with PBS. The 
chamber was left untouched for 20 minutes. They were then washed twice with water 
and left to dry. The dried chambers were placed back in the fresh 24 well plates and 
observed under the microscope. The cells were counted for different conditions and 
analysed using INNOVA graph pad. 
 
2.2.13. Cytotoxicity Assay 
 
 
Stock MTT solution 
 
500 ml of MTT working reagent (5mg/ml MTT solution) prepared by adding 2.5 gm 
of 3-(4,5- Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in 500 mL of sterile 
PBS solution. The mixture is sparingly soluble in water. Therefore, magnetic stirrer 
was used to dissolve it further. Since MTT is sensitive to light, the bottle was carefully 
covered with the foil and left overnight to dissolve completely. The following day, the 
MTT solution was filtered with the sterile vacuum flask, the opaque mixture is 




MTT assay is a renowned method to check the effect of drugs on cell viability. Cells 
were counted and seeded equally into 96 well flat-bottomed microtiter plates overnight 
at 37 °C—the outermost wells were filled with sterile water to maintain humidity. The 
following day, cells were checked for proper seeding number in each well. The cells 
were exposed to various concentrations of anticancer drugs, i.e. PMTXD, 
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CISPLATIN, PLGA-DS/Cu. It was prepared by a two-fold serial dilution using RPMI 
culture medium, i.e. 10µM, 5µM, 2.5 µM, 0.625 µM, 0.3125 µM. One side of the 
column was used as a negative control in which one column contained medium 
without cells, the second column contained medium, and cells (i.e. the far left) and the 
other side of the column (i.e. the far right) was used as a carrier control PLGA 
microparticles. The media used for seeding the cells for 24 hours was aspirated and 
replaced by 200 µL of a fresh drug-containing medium of different concentrations. 
The plates were incubated at 37°C for 72 hours. The experiment was done in triplets 
for each drug concentration with the same cell line, after 72 hrs. The cells were dosed 
with 25 µl of MTT reagent, and the plates are wrapped with foil paper and incubated 
for 3h at 37°C. The solution was removed and was followed by addition of 80 µl of 
99.9% DMSO and 20 µl of Sorensen's buffer (to maintain a pH at 10.5) by 96 well 
multi-drop, in each well. The OD values were further calculated by using multi-well 
plate reader spectrophotometer at a wavelength of 540 nm. The viability percentage 
(%) calculated after treatment to determine the IC - 50 values of each drug. The mean 
and standard deviation was calculated, followed by Isolobologram.  
 
MTT Assay for hypoxic cells 
 
MTT assay for hypoxic cells involves culturing of the cells in the hypoxic conditions 
(oxygen level 1% as compared to Normoxia, i.e. oxygen level 21%) for 96 hours. The 
cells were trypsinised, seeded for the required density and incubated again for 48 hr. 
in the hypoxic condition. The cells were then treated with the desired concentration of 
drug/combination of drugs and incubated for 72 hrs. in hypoxia. It was then subjected 




Isobologram analysis  
Isobologram was used to measure the synergistic effect of two first-line anticancer 
drugs used for combinational chemotherapy for treating malignant mesothelioma. 
MTT assay investigated if PLGA-DS/Cu significantly enhanced the cytotoxicity of 
anticancer drugs, i.e. PMTXD and Cisplatin. The experiment was done in three 
dilutions respectively, e.g. dilution1 of PMTXD alone, dilution 2 PLGA-DS/Cu alone, 
dilution 3 PMTXD in combination with PLGA-DS + Cu. The same was done for 
Cisplatin. After incubating these drugs for 72 hours, cell cytotoxicity was calculated 
by MTT assay as mentioned above.  
The synergy between two drugs was calculated using combination Index (CI). The CI 
index provided a quantitative measure and calculated using software CalcusynTM. The 
data for individual drugs and in combination, was processed in constant and non-
constant ratios. CalcusynTM gives a detailed report of drug interaction which includes 
CI value at effective dose x (EDx), i.e. ED50, ED75 and ED90. A CI value <1 show 
synergy.  
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Hypoxia induces chemoresistance 







3.1 Introduction  
Mesothelioma is a highly chemoresistant neoplasm; only 40% of patients respond to 
standard chemotherapy causing median survival to be only 12 months (Hudson et 
al.,2014). Regardless of severe drug toxicities, chemotherapy for MM patients remains 
primary treatment choice, which can increase the median survival from 9 to 12 months 
in progressed stage for MM patients who cannot undergo surgery (Rossini et al., 
2018). The root cause for this chemoresistance is cancer stem cells (CSCs) which are 
found to resist conventional chemotherapies and cause a relapse. Emerging studies 
suggest that these CSCs reside in a hypoxic/necrotic tumorous CSC niche (Triscott, 
Rose Pambid and Dunn, 2015). It has been shown that hypoxia plays a major role in 
the maintenance of the stemness in CSCs (Peng Liu et al.,2014). 
Recent research has further shown that MM also contains hypoxic regions, which 
explains the link between tumour hypoxia and low therapeutic efficacy. However, the 
underlying mechanism of hypoxia in MM remains mostly unknown. The present study 
showed that hypoxia promotes aggressive phenotypes in MM cells. By inhibiting 
apoptosis and inducing drug resistance, hypoxia enhances in vitro clonogenicity, 
migration, invasion in MM cells (Kim at al.,2018). Mechanistically, hypoxia was 
shown to impact invasive and migratory behaviour of cancer cells via EMT, a process 
which alters their gene expression prior to migration (Barbara Muz et al.,2015).HIF's 
can induce epithelial plasticity and migratory phenotype by direct or indirect 
regulation of transcription factors related to EMT such as Snail, Slug and Zeb. 
Invasion of the surrounding extracellular matrix (ECM) can also be enhanced by HIF 
signaling by upregulation of enzymes such as MMPs to support the initial stages of 
metastasis by remodeling the ECM. Hypoxia is a critical microenvironmental factor 
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that contributes to metastatic tumour progression at the primary and distant tissue sites. 
HIF signaling can also be activated within tumour stromal cells through a variety of 
mechanisms, including hypoxia and secreted factors produced by tumour cells 
(Rankin et al.,2017). Hypoxic regions are found to be associated with increased 
genetic instability during malignant growth and more aggressive phenotype, which 
correlates with tumour metastasis risk (Challapalli et al.,2017).  
Research studies has shown that EMT not only assist cells with migratory and invasive 
properties but also with stem cell properties. Moreover, EMT promotes the generation 
of stem-like cells from differentiated neoplastic cells (Han.,2015). Various molecular 
mechanisms and signaling network suggests the aggressive biological behaviors of 
MM cells is also dependent on EMT. Therefore, exploiting tumour hypoxia may be an 
alternative therapeutic strategy to reduce the aggressive behaviour of MM cells (Kim 
at al.,2018). Hypoxia causes slow-proliferation in stem-cell-like cells, reduce 
senescence, creates dysfunctional blood vessels, and promotes metastasis, which 
altogether results in causing resistance to various therapies (Barbara Muz et al., 2015).  
Hypoxia plays a significant role in causing resistance to cancer treatments, such as 
reduced drug penetration, intrinsic chemoresistance and resistance to ionising 
radiation. Further, by supporting highly tumorigenic stem cell microenvironment, 
hypoxia, and HIF 1a cause treatment resistance. It is achieved by inducing cell cycle 
arrest (quiescence) and making drugs that target cycling cells ineffective. During 
adverse conditions such as prolonged or severe hypoxia, many cells undergo 
programmed cell death. But, some of the cancer cells get adjusted to the environmental 
stress and survive by avoiding necrosis, inhibition of apoptosis, and decreasing 
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senescence of cells, mediated by HIF alpha, resulting in an aggressive phenotype and 
resistance to treatment (Challapalli et al.,2017).  
Hypoxia leads to the failure of chemotherapy in most solid tumours. Hypoxia in 
tumours can reduce the production of reactive oxygen species (ROS) in tumour cells 
and limit the efficacy of cytotoxic chemotherapeutic drugs through intracellular 
reactive oxygen species. Hypoxia can also downregulate the DNA repair pathways 
while upregulating resistance-related genes, thus reducing the sensitivity to p53-
mediated apoptosis, thereby decreasing cell proliferation. Considerable evidence 
indicates that elevating oxygen levels in hypoxic tumours can overcome hypoxic-
related chemoresistance (Chen et al.,2020). 
We hypothesise that hypoxia is responsible for cancer stem cell characteristics and 
maintenance of cancer cell stemness. This study replicates the in vivo tumour 
microenvironment in 2D cultures subjected to hypoxic condition (1%). It determines 
the role of hypoxia to induce cancer stem-like cells in the fully differentiated cancer 
cell. By using this model, the study also intends to understand the resistance 
development to first-line drugs in MM. This study further aims to determine that the 
migration and invasiveness in MM is caused by cancer stems like cells when subjected 
to hypoxic conditions.  
 
3.2 Material and Methods  
This section describes the methods used within this specific study and any observed 




3.2.1. Culture methods 
In this study, two MM cell lines, MSTO-211H and JU77 were established as mono-
layered cultures and maintained following standard subculture methods. Additionally, 
attached mono-layered cell line cultures were incubated under hypoxia. Cell lines 
cultured using RPMI were seeded at a density of ~5×104 cells/mL and incubated using 
tissue culture incubators maintained at 37°C, 5% CO2, 1% O2, for four days. The 
culture conditions were initially maintained for three days and later standardised for 
four days as the markers well expressed on day four.  
 
3.2.2 Measurement of the hypoxic cell population  
The HypoxyprobeTM-1 Plus Kit was used to identify and quantify the hypoxic cell 
population in MM MSTO-211H and JU77 cell lines hypoxic cultures as compared to 
normoxic cultures, respectively. The two methods used for determination were 
immunocytochemistry and flow cytometry analysis as detailed in chapter 2.2.10  
 
3.2.3 MTT cytotoxicity assay  
The MM MSTO-211H and JU77 normoxic and hypoxic cultures were subjected to 
MTT cytotoxicity assay, as mentioned in 2.2.13 The first-line drugs for treating MM 
and highest concentrations used in this study are as follows: PMT (1μM) and CIS 
(10μM). The cell cultures were serially diluted with anti-MM first-line drugs for 72 
hours in their respective cell culture incubators. After the treatment, cells were 
subjected to MTT reagent, and the percentage cell viability was determined.  
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3.2.4 Invasion Assay 
The MM MSTO-211H and JU77 normoxic and hypoxic cell cultures were subjected 
to invasion assay as detailed in chapter 2.2.12 The normoxic and hypoxic MSTO-
211H, and JU77 cell lines were seeded in Boyden chamber with nutrient-deprived 
RPMI medium whereas the chamber was surrounded by nutrient-rich RPMI medium. 
Matrigel was used to coat the bottom of the chamber, which acts as collagenase in-
vitro to study the effect of invasion in MM cell lines. After that, the plate was incubated 
in the respective normoxic and hypoxic conditions for 24 hours at 37°C. The culture 
conditions were initially maintained for 12 hours and later standardised to 24 hours. 
The cells were fixed and stained with crystal violet after incubation; the number of the 
stained cell was counted manually. The comparison of the number of invaded cells in 
normoxic conditions, as compared to hypoxic conditions was made by using statistical 
analysis.  
 
3.2.5 Migration Assay  
The MM MSTO-211H and JU77 normoxic and hypoxic cell cultures were subjected 
to migration assay as detailed in chapter 2.2.11. The normoxic and hypoxic MSTO-
211H and JU77 cell lines were seeded in Boyden chambers in nutrient-deprived RPMI 
medium whereas the chamber surrounded by nutrient-rich RPMI medium. The plates 
were then incubated in respective normoxic and hypoxic conditions for 24 hours. The 
culture conditions were initially maintained for 12 hours and standardised to 24 hours. 
The cells were fixed and stained with crystal violet after incubation, the number of 
cells was counted manually, and comparison was made between migration in 
normoxia as compared to hypoxia.  
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3.3 Results 
3.3.1 Determination of the hypoxic status in hypoxia-cultured MM cell 
lines 
The hypoxic status of normoxia and hypoxia cultures were determined using 
hypoxyprobe kit. Figure 3.1 (A) represents the positive hypoxic cell population as 
there is a visual increase of green fluorescence. Additionally, these findings were 
quantified by using flow cytometer analysis, which further confirms the result by 
showing a statistically significant increase in the hypoxic population for cells 























































                                      
 
Figure 3.1 Hypoxic cell population in hypoxia cultured MM cells. 
Immunocytochemistry staining of MM cells subjected to normoxic and hypoxic 
conditions respectively, by using Hypoxyprobe TM-1 kit. (A) In Situ Detection of hypoxic 
cells in MM cells stained by green-FITC HPP and PI (red) counterstained nucleus 
(40x magnification) (B) Flow cytometric analysis used to measure the proportion of 
the hypoxic population in MM hypoxic cultures. (C) The bar chart displays the 
percentage of hypoxic cells detected in the cell population. n=6, *p<0.05, **p<0.01.  
 
3.3.2. Hypoxia-cultured MM cell lines are resistant to anticancer drugs  
Studies have demonstrated that hypoxia induces resistance to fully differentiated 
neoplastic cells and induces resistance to anti-MM drugs in vitro. The cell lines were 
tested for cell viability after exposure to the first line anti-MM drugs, i.e. PMT and 
CIS, for 72 hours in normoxia and hypoxia respectively. MTT assay was used to 
**  
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determine the cytotoxicity and cell viability after treatment. Figure 3.2 demonstrated 
cell viability curves. It depicts that the percentage of cell viability decreases with the 
increase in anti-MM drug concentration. To compare the effect of hypoxia on 
chemoresistance, IC-50 values, shown in Table 3.2, were calculated. The anti-MM 
drug was able to eradicate cells grown in normoxic condition, and their IC-50 values 
calculated accurately. Nevertheless, the cells subjected to hypoxia developed 
resistance to these first-line drugs and did not reach IC-50 values as shown by the 
plateau on the cell viability curves.  
 



































    
  Figure 3.2 MM hypoxic cultures are resistant to first line anticancer drugs.   
  The cell viability curve shows the effect of first-line anti-MM drugs on normoxic    
  and   hypoxic cultures of MSTO-211H and JU77 cell lines. The cells were treated    
  with (A) PMT (B) CIS for 72 hours and then subjected to MTT assay.  
  Table 3.1: IC-50 values for MSTO-211H and JU77 cell lines under normoxia and      
   hypoxia after 72 hours of treatment with anticancer drugs (where nM = Nano Molar.,    
   ± = Mean + Standard deviation)  
 
                                        Pemetrexed IC50 (nM)                Cisplatin IC50 (nM) 




31.78 ± (8.81) 
 
52.77 ± (21.14) 
 













































3.3.3 Hypoxic cells have higher migratory potential. 
 
The migration potential of hypoxic cells was determined using a migration assay. 
Figure 3.4 shows the increased number of cells in the hypoxic cultures as compared 
to normoxia. The hypoxic cells were more aggressive and metastasised as a nutrition-
rich medium drove them outside the Boyden chamber. The migrated cells were then 
fixed and counted by staining with crystal violet; the number of cells was manually 
counted and standardised using the normoxic conditions.  
 








         
   
 Figure 3.3 MM hypoxic cells have more migration potential in vitro. 
   The potential of MM cells was detected using migration assay with Boyden inserts      
   (A) Microscopic pictures of the migrated MM cells (40x magnification). (B) The    
bar chart is   representing the mean number of migrated MM cells in hypoxia as  



















































3.3.4 Hypoxic cells are more invasive  
The invasive properties of hypoxic cells were determined using invasion assay. Figure 
3.3 shows the increased number of cells in the hypoxic cultures as compared to 
normoxia. In order to migrate hypoxic cancerous cells, need to invade by degrading 
extracellular matrix, which is presented by Matrigel coating in vitro. The invaded cells 
were then fixed and counted by staining with crystal violet; the number of cells was 
manually counted and standardised using the normoxic conditions.  
 











Figure 3.4 MM hypoxic cells shows increased migration.  
The potential of MM cells was detected using Matrigel invasion assay with Boyden 
inserts (A) Microscopic pictures of the invaded MM cells (40x magnification). (B) The 
bar chart is representing the mean number of invaded MM cells in hypoxia as 





























































3.4 Discussion  
This study investigated the use of hypoxic cultures to mimic the hypoxic environment 
of tumour in vivo and to examine the chemoresistant potential of MM. It encouraged 
the study to investigate further if MM cells when subjected to the hypoxic environment 
can induce resistance and related properties in the fully differentiated neoplastic cells. 
The findings in this study indicate that cells in hypoxic conditions are more resistant 
and aggressive as compared to the cells in normoxic conditions. It also gives rise to 
speculation for the presence of cancer stem-like cells as the findings suggest that after 
initial treatment with first line drugs, the cancer cells subjected to hypoxia were still 
resistant. It further confirms the possibility of specialised residual cells, which can be 
CSCs leading to relapse of MM. This study also mimics the in vivo state in MM 
patients, who experience either resistance or relapse, as the first-line drugs are not 
capable to selectively target cancer stems like cells. 
Hypoxia has implicated in resistance to multiple therapeutic modalities. As well as 
driving tumour progression through increased migration and dissemination, reduced 
apoptosis, and enhanced angiogenesis, hypoxia also links to treatment resistance 
through multiple mechanisms. The downstream processes driven by hypoxia can 
generate resistance to therapy, including EMT, aerobic glycolysis and autophagy 
(Redfern et al.,2019). Research also suggest that several hypoxia-inducible genes have 
the capacity to play an important role in promoting the breast to bone metastasis 
(Gikes.,2016).  Hypoxia generates intra tumoural oxygen gradients, contributing to the 
plasticity and heterogeneity of tumours and promoting a more aggressive and 
metastatic phenotype (Jing et al.,2019). Although both acute and chronic hypoxia 
correlates with poor patient outcome and an aggressive tumour phenotype (Williams 
et al., 2001; Vaupel and Harrison, 2004). Acute hypoxia is found to be associated with 
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more aggressive tumour phenotype through the induction of spontaneous metastasis 
(Barbara Muz et al.,2015)  
Hypoxia is a very dynamic and heterogenous feature and observed in many solid 
tumours. These hypoxic cells and hypoxia responsive mechanisms make these 
tumours resistant to both chemotherapy and radiotherapy leading to tumour 
progression (Zonneveld et al.,2019). Hypoxia induces activity and expression of 
MMP-2 and MMP-9 via HIF-1-dependent process, and increased levels of MMP-2 in 
breast cancer biopsies were associated with poor prognosis (Gikes.,2016). HIF-1α 
protects the tumour microvasculature from radiation-induced endothelial apoptosis 
during radiotherapy by inducing vascular endothelial growth factor (VEGF) and other 
pro-angiogenic factors and aid in the survival of tumour cell by increasing the 
antioxidant capacity of tumours to counteract radiation-induced oxidative stress. The 
irradiation further induces changes in the tumour microenvironment such as vascular, 
stromal, and immunological changes which may promote radioresistance and tumour 
recurrence. These effects eventually lead to the resistance of tumour cells to 
chemotherapy and radiation (Challapalli et al.,2017). The expression level of HIF-1α 
in oesophageal squamous cell carcinoma (ESCC) under hypoxic condition increased 
significantly, which boosted migration and invasion ability of ESCC (Jing et al.,2017). 
A meta-analysis of hypoxia-modifying modalities indicated that lowering tumour 
hypoxia increases treatment response and patient survival. To contribute to tumour 
regrowth after treatment or metastasis development, hypoxic cells must reoxygenate 
at some time (Zonneveld et al.,2019) A HIF-1α transcription factor is a central player 
in the hypoxic adaption of tumour cells, therapeutic resistance (Kim and Lee.,2017). 
HIFs coordinately regulate numerous signalling pathways in hypoxic cancer cells, 
which mediate invasive and metastatic phenotypes, including: (i) EMT pathway (ii) 
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basement membrane disruption and ECM remodelling, leading to intravasation; (iii) 
inhibition of anoikis (iv) extravasation (v) establishment of premetastatic niches (vi) 
transition from mesenchymal to epithelial phenotype for clonal expansion (Schito and 
Gregg.,2016). Therefore, hypoxia can induce many pathways and EMT is of utmost 
importance. The effect of this pathway on MM will be discussed in the next chapter. 
The findings in this chapter showed a remarkable effect of hypoxic condition on the 
cancer cell to become resistant to anticancer drugs. Many MM cancer patients 
experience relapse due to the development of chemoresistance, and this in vitro study 
indicated that conventional anti - MM drugs cannot eliminate highly resistant hypoxic 
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As discussed in the previous chapter hypoxia is a significant factor responsible for 
causing chemoresistance in MM cell lines. The underlying reason speculated to be is 
specialised cells that are resistant to all the therapies and termed as stem-like cells or 
cancer stem cells (CSCs). It is based on the findings that a small proportion (1%) of 
cancer cells possess typical stem cell markers, for example, CD133, Nanog, Oct4, 
Sox2 and ALDH and is shown to be responsible for tumour initiation (Clevers, 2011). 
Hypoxia in the stem cell and tumour microenvironment also promote CD133 
expression via hypoxia-inducible factor-1α (HIF-1α) upregulation (Glumac and 
LeBeau.,2018). As a standard marker of CSCs, ALDH also possesses the 
responsibility to catalyse the oxidation of aldehyde, subsequently contributing to 
cellular homeostasis, which is identified to be related to the function as stem cells, 
such as self-renewal capability and stress-resistant properties (Xia et al.,2018).  
The stemness status of CSCs is extremely microenvironment dependent as recent 
studies have indicated that hypoxia and some hypoxia-regulated transcription factors 
are the contributing factors for the stemness of CSCs (Conley et al., 2012). Hypoxia 
may be a major component of the CSCs niche, providing the CSCs with the 
maintenance of an undifferentiated state. The standard niche of hematopoietic stem 
cells (HSC) is hypoxic compared to other tissues, and normal HSCs represent a 
hypoxic population. Both normal bone marrow stem cells and normal brain stem cells 
are reported to reside in a hypoxic environment. Furthermore, human embryonic stem 
cells and adipocyte precursor cells differentiate unless cultured under hypoxic 
conditions (1–5% O2) (Marie-Egyptienne et al.,2012). 
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HIFs target CSC-associated genes and mediate transcriptional responses to hypoxia 
during normal embryonic development, tumour growth, and stem cell differentiation 
(Yeo et al.,2017) Morel et al. showed that cancer cells possessing both stemness and 
tumorigenic characteristics of CSCs could be derived by EMT induction (Yeo et 
al.,2017). Moreover, CSCs has been shown to arise in part by EMT, and that hypoxia 
induced EMT lead the way to an increase in CSCs during tumour progression, which 
subsequently enhances invasion and metastasis (Yeo et al.,2017).  
EMT is involved in cancer progression and metastasis, and HIF-1α has been identified 
as a regulator of EMT in human cancers. EMT can be adjusted by HIF, which regulates 
the expression and functional activity of principal transcription factors, including 
Twist, Snail, Slug, and ZEB1. Amongst which ZEB1 drives the induction of EMT 
with activation of stem cell traits, immune evasion and epigenetic reprogramming 
(Zhang et al.,2019). The promoter region of twist holds an HRE, which can be bound 
by HIF. Hypoxic microenvironment induces EMT master regulators that encourage 
EMT changes, such as E-cadherin attenuation by Snail up-regulation, and besides 
matrix metalloproteinase (MMP) production through activation of Slug (Yeo et 
al.,2017). Research has also suggested that hypoxia and HIF-1α upregulate the 
expression levels and activities of MMP-2 and MMP-9. Collagen is vital for cell 
migration during the invasion. When tumour size increases, collagen fibers straighten 
and align, which facilitates cancer cell invasion (Gao et al.,2016).  
In addition to EMT, cancer stemness plays a role in metastasis and treatment 
resistance, which are associated with poor prognosis (Yeo et al.,2017). Hypoxia is also 
a significant factor for the development of tumour cell resistance to therapy, which is 
in part due to the generation of cancer stem cells (CSCs) (Terry et al.,2018). Hypoxia 
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is not only a significant feature of the tumour microenvironment but is also a potential 
contributor to the multidrug resistance (MDR) and enhanced tumorigenicity of CSCs 
(Ibrahim et al.,2018). Both EMT and stemness are linked with resistance to 
chemotherapy in tumours. ABC transporter genes included in chemoresistance can be 
upregulated by EMT-inducing transcription factors, such as Twist, Snail, and Slug, by 
their ability to induce EMT. The EMT process plays a role in generating the stem cell 
phenotype, and expression of CD44 or CD133 stemness genes confers 
chemoresistance (Yeo et al.,2017).  
Among ABC transporters that are well known to cause MDR, ABCG2 is particularly 
interesting for its potential role in protecting cancer stem cells (Jian and Zhang et 
al.,2012). Many genes implicated in various processes are critical for cancer 
progression (such as angiogenesis, epigenetic changes, erythropoiesis, pH regulation, 
glycolysis, metastatic spread and undifferentiated phenotype) are affected by these 
transcription factors. Therefore, hypoxia, by modifying critical molecular pathways, 
allows the survival and proliferation of tumour cells under harsh conditions creating 
hypoxia tolerance. The highly dynamic hypoxic gradients in tumours provoke the 
manifestation of diverse mechanisms which can promote stemness, metastasis and 
treatment resistance (Marie-Egyptienne et al.,2012).  
CSCs may indicate the microenvironment-dependent heterogeneity and EMT within 
tumour tissues. Although the role of CSCs in tumorigenesis is still debatable, the 
cancer cells expressing stem cell markers are widely accepted as highly resistant to 
radio and chemotherapy and are the sources of cancer recurrence. Also, the cells with 
CSC markers are resistant to all dissimilar anticancer drugs. Remarkable expression 
of the embryonic stem cell-associated genes Sox2, Oct4, and Nanog haven been 
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detected in the resistant cell line (Conley et al., 2012). CSCs possess the critical 
survival mechanisms and properties crucial for the maintenance and propagation of 
the tumour (Marwa M.,2018). Although CSCs are very small in number, they are 
believed to possess pluripotent and self-renewal capacity, which generates a 
heterogeneous cell population of the originating tumour, seeding at distant sites and 
driving the formation of macro metastasis (Han.,2015). We hypothesised that the 
hypoxic microenvironment/stress of the tumour is responsible for maintaining 
stemness in CSCs. This study aims to replicate the hypoxic tumour environment in 
vitro and elucidate the causal relationship between hypoxia and CSCs and EMT status 
in MM cell lines.  
 
4.2 Materials and Methods  
This section describes methods used for this and specifies any observed changes 
concerning the general detailed methods explained in chapter 2.  
 
4.2.1. Culture Methods  
In this study, two MM cell lines, MSTO-211H and JU77 were established as mono-
layered cultures and maintained following standard subculture methods. Additionally, 
attached mono-layered cell line cultures incubated under hypoxia. Cell lines cultured 
using RPMI were seeded at a density of ~5×104 cells/mL and incubated using tissue 





4.2.2.  Detection of CSC markers  
The expression of CSC markers, i.e. CD 133, ABCG2, ALDH and CD 24 was 
measured by Flow cytometry technique in MM MSTO-211H and JU77 cell lines. A 
comparison made between hypoxic and normoxic cultures, respectively. The detailed 
methods are detailed in chapters 2.2.10 respectively.  
 
4.2.3. Detection of ESC markers  
Quantitative RT-PCR method used to determine the mRNA expression of SOX2, 
OCT4 and NANOG in MM MSTO-211H and JU77 cell lines and a comparison was 
made to the normoxic and hypoxic cell cultures, respectively. The RT-PCR procedure 
followed as detailed in chapter 2.2.9 respectively.  
 
4.2.4. Detection of EMT and invasiveness related markers  
Quantitative RT-PCR method used to determine the mRNA expression of EMT 
markers, i.e. Snail, Zeb, Slug, Twist, E-Cadherin, N-cadherin, Vimentin and 
invasiveness markers MMP-2, MMP-7, MMP-9 in MM MSTO-211H and JU77 cell 
lines and a comparison was made to the normoxic and hypoxic cell cultures, 








4.3.1. Hypoxia-cultured MM cells express CSC markers  
MM cells exposed to hypoxic conditions developed stress-induced alterations such as 
expression of CSC characteristics. MM cell lines MSTO-211H and JU77 were 
incubated at 37 ̊C, 5% CO2, and <1% O2 for four days respectively to study the effect 
of hypoxia on CSC markers. Flow cytometry analysis of hypoxic MM cells, is shown 
in figure 4.1, compares the expression level of ABCG2, CD 24 and CD 133. Both the 
cell lines MSTO-211H and JU77 show a statistically significant increase in the cells 
incubated under hypoxia as compared to normoxia. 
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 Figure 4.1 MM cells in hypoxic microenvironment demonstrate increased   CSC 
characteristics.  
 
The expression level of CSC markers was analysed by using flow cytometry in MSTO-
211H and JU77 cell lines. (A) ABCG2 using APC conjugated anti-ABCG2 (B) CD 133 




4.3.2 Hypoxia-cultured MM cells show increased ESC expression.  
MM cells exposed to hypoxia developed cancer stem cell characteristics which were 
further confirmed by expression of ESC markers such as SOX-2, Nanog and OCT 4. 
MM cell lines MSTO-211H and JU77 incubated at 37 ̊C, 5% CO2, and <1% O2 for 
four days respectively to study the effect of hypoxia on CSC markers. The qRT-PCR 
analysis technique was used to compare the relative mRNA expression level of SOX2, 
Nanog and OCT4 of hypoxic and normoxic cultures shown in figure 4.2. Both the cell 
lines MSTO-211H and JU77 shows a statistically significant increase in the expression 
level of Nanog, whereas SOX-2 showed an insignificant increase in the expression 
level in both MSTO-211H and JU77 cell line when MM cells were compared between 
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Figure 4.2 MM hypoxic cultures demonstrates increased of Nanog but decrease 
in SOX-2 expression.  
The relative mRNA expression of ESC markers SOX2, OCT4, NANOG was analysed 
in (A) MSTO-211H (B) JU77 cell lines, using RT-PCR 2-∆∆Ct method. n=4, 
**p<0.01, ns denotes no- significance (p ≥ 0.05) 
 
 
4.3.3 Hypoxia-cultured MM cells show increased expression of EMT 
markers 
The increased expression level of Epithelial to Mesenchymal transition (EMT) and 
related markers such as Snail, Slug, Twist, Zeb, E-cadherin, N-Cadherin and Vimentin 
were compared between MM cells in the hypoxic and normoxic microenvironment. 
MM cell lines MSTO-211H and JU77 cell lines were incubated at 37 ̊C, 5% CO2, and 





































































technique used to compare the relative mRNA expression level of EMT related 
markers in figure 4.3. Both the cell lines MSTO-211H and JU77 shows statistically 
increased expression level of Snail 1, Twist 1, Zeb,1 N-cadherin and Vimentin in 
hypoxia. MSTO-211H cell lines showed a non-significant increase in Snail 2, and 
there was no expression of for E-cadherin. Whereas JU77 cell line showed a decreased 
expression level of E-Cadherin when the two cell lines were compared to normoxic 





































































































Figure 4.3. MM hypoxic cultures demonstrates increased expression of EMT 
markers but decrease in the expression of E - Cadherin.  
The relative mRNA expression of invasion related markers, i.e. Snail 1. Snail 2, Twist, 
Zeb 1, E cad, N cad and Vimentin, were analysed in (A) MSTO -211H (B) JU77 cell 
lines, using RT- PCR 2-∆∆Ct method. n=4, **p<0.01, *p<0.05, ns denotes no - 




































































4.3.4 Hypoxia-cultured MM cells show increased expression of 
invasiveness related genes 
 
The expression level of invasiveness related markers such as MMP-2, MMP-7 and 
MMP-9 was compared between MM cells in hypoxic and normoxic 
microenvironment. MM cell lines MSTO-211H and JU77 were incubated at 37 ̊C, 5% 
CO2, and <1% O2 for four days respectively in hypoxic conditions. qRT-PCR analysis 
technique was used to compare the relative mRNA expression level of invasion related 
markers in figure 4.3. Both the cell lines MSTO-211H and JU77 shows statistically 
significant increase in the expression level of MMP2, and MMP-9, whereas MSTO-
211H showed non-significant increase in MMP-7, in hypoxia as compare to normoxia 
respectively. 
 


















































Figure 4.4. MM hypoxic cultures demonstrates increased expression of 
invasiveness related markers.  
The relative mRNA expression of invasion related markers i.e. MMP-2, MMP-7 and 
MMP-9 were analyzed using RT- PCR 2-∆∆Ct method. n=4, **p<0.01, *p<0.05, ns 













































4.4. Discussion  
This study demonstrated the effects of hypoxia on the expression level of CSC and 
EMT pathway-related markers in MM. The experimental conditions mimicked tumour 
microenvironment in acute and hypoxic conditions. The results confirm that hypoxia 
induces significant changes on the molecular level and increases the expression of 
CSC, ESC and EMT related markers. CSCs are capable of uncontrolled self-renewal 
and metastasis, chemoresistance and tumour recurrence (Marwa M.,2018) 
Hepatocellular Carcinoma (HCC) has shown that hypoxia induce EMT transition, a 
typical character of CSCs involving in metastasis (Wang et al., 2017) 
Tumours are "abnormal organs" encouraged by a CSC, enriched with the capacity to 
self-renew and with multipotent differentiation capacity to yield a heterogeneous cell 
progeny (Montreo et al.,2018). In this study, we showed the increased expression of 
CD133, ABCG2 and CD 24 in hypoxic conditions as these markers have shown a 
prominent role in maintaining stemness in CSCs. The expression of CD133 on the cell 
surface is known to be a specific marker for CSCs in several malignancies (Barzegar 
et al.,2019). Studies have also shown that CD24 expression induces increased cell 
proliferation, migration, and invasion, leading to rapid tumour spread, properties 
fostered by the EMT program and stemness capabilities (Montreo et al.,2018).  
Among ABC transporters that are well known to cause multidrug resistance (Mo and 
Zhang.,2012). High expression levels of ABC transporters and aldehyde 
dehydrogenase (ALDH) may also cooperate in the development of drug resistance in 
CSCs (Wang et al., 2018). Drug resistance is associated with expression of various 
pluripotency markers, including NANOG, OCT4, and SOX2, since these genes further 
lead to a decrease in differentiation status (Weina and Utikal.,2014) Poorly 
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differentiated tumours shows preferential overexpression of genes usually enriched in 
embryonic stem cells, such as downstream targets of Nanog, Oct4 and Sox2 (Ben-
Porath et al., 2008). Oct4 is most crucial transcription factor since it can reprogram 
adult stem cells to induced pluripotent cells (iPS) cells as an individual factor. 
Aberrant expression of Oct4, Nanog, and Sox2, is associated with abnormal tissue 
growth or tumorigenesis (Kumar et al.,2012) Sox2 is also linked to stemness through 
modulation of Oct4 levels in CSCs (Sun et al.,2019). This might also explain the 
decreased level of SOX 2 and insignificant increase of Oct 4 in MSTO-211H cell lines. 
Nanog regulates several aspects of cancer development such as tumour cell 
proliferation, self-renewal, motility, epithelial-mesenchymal transition, immune 
evasion, and drug-resistance, which are all defined features for cancer stem cells 
(Wang et al.,2013). EMT transcription factors and regulators transform the cancer 
cells from epithelial-cell like to mesenchymal-cell like by suppressing epithelial 
markers and upregulating mesenchymal markers. It leads to cancer metastasis, drug 
resistance and features of cancer stem cells. 
Furthermore, the cancer cells undergoing EMT show increased resistance to apoptosis 
and chemotherapeutic drugs and traits expressed by stem cells (Shih and Yang.,2011). 
EMT initiated by overexpression of specific proteins, e.g. Snail, Slug, twist, and ZEB 
(1and 2) in cells which have been observed in progression from in situ to invasive 
forms (Grzegrzolka et al.,2015). EMT can also be defined by events such as the 
formation of specific epithelial cells, degradation of the basement membrane, 
disruption of epithelial tissue constitution, and development of a novel mesenchymal 
form (Koujan et al.,2015). The hallmark of EMT in cancer is the downregulation of 
E-cadherin, which is thought to be a repressor of invasion and metastasis. Several 
transcription factors are implicated within the transcriptional repression of E-cadherin, 
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including zinc finger proteins, Snail, Slug, Zeb1, and Zeb2 (Shih and Yang.,2011) In 
breast cancer cells, many studies have demonstrated that hypoxia leads to an increased 
expression of two transcriptional repressors of E-cadherin, SNAIL1 and SLUG, by the 
modulation of NOTCH1 signaling pathway (Gikes.,2016) 
Fusion oncogenes generated as a result of chromosomal abnormalities associated with 
mesenchymal tumours block differentiation and have the ability to activate target 
genes such as Slug (also known as Snail-2, which promotes survival and migration of 
the defective target cells into different environments (Mancera et al.,2005). Slug 
enhances chemoresistance of several types of cancer, including malignant 
mesothelioma (Shih and Yang.,2011). The expression of Slug is linked to cancer stem 
cell formation, cell cycle regulation and apoptosis as well as invasion and metastasis 
(Wu et al.,2012) TWIST is also a predominant regulator of EMT, involved in the 
promotion of cellular differentiation, motility, and proliferation, and is associated with 
cancer stem cell phenotype (Grzegrzolka et al.,2015). HIF-1α has also shown direct 
binding to TWIST by HRE in the TWIST proximal promoter in hypopharyngeal and 
breast cancer cell lines (Tam et al.,2020) Snail, another gene studied in this study is a 
zinc-finger transcription factor, triggers EMT providing epithelial cells with migratory 
and invasive properties by both embryonic development and tumour progression 
(Vega et al.,2004) Snail mediates an increase in expression of mesenchymal markers 
such as vimentin, and matrix metalloproteinases (MMPs) (Smith and Mrah.,2012). 
Snail and ZEB also suppress other epithelial markers and activate mesenchymal genes 
(Cho et al.,2019).  
Zeb-1 acts as an oncogene in metastatic and invasive lung cancer cells, in which 
ZEB1-induced EMT enhanced the loss of epithelial cell adhesion and polarity, induces 
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drives growth and cytoskeleton remodelling, migration, metastasis, and invasion 
(Zhang and Han.,2019). Vimentin's overexpression in cancer correlates well with 
increased tumour growth, invasion, and poor prognosis (Satelli and Li,2011) N-
cadherin, as a marker of ongoing EMT, is not expressed in normal epithelial cells. 
However, its expression has demonstrated in several forms of carcinomas. Aberrant 
N-cadherin expression is related to various processes in tumour metastasis, such as 
angiogenesis, heterotypic adhesion, and invasion (Zhan-qi et al.,2019). 
MMP's are capable of cleaving type IV basement membrane collagen (MMP-2 and -
9) and add value for drug development (Brehmer et al.,2003). MMP-7 can deteriorate 
laminin, type IV collagen, and entactin, which are the main element of the basement 
membrane, and activate other important MMPs (MMP-1, MMP-2, and MMP-9)(Bavi 
et al.,2011) MMP-2 and MMP-9 are related to tumour invasion and metastasis and 
involved in tissue remodelling by ECM as well as basement membrane degradation 
and induction of angiogenesis. Thus, MMP-9, together with MMP-2, activate 
transforming growth factor β (TGF-β) signalling to promote the invasion of the 
tumour, angiogenesis, and metastasis (Gialeli et al.,2011). Although MMP-2 is mainly 
responsible for the regulation of inflammatory response, MMP-7 takes part in the 
degradation of the peritumoral stroma whereas MMP-9 may have an impact on the 
formation of the new blood vessels (Pryczynicz et al.,2016) Hypoxia induces activity 
and expression of MMP-2 and MMP-9 via HIF-1-dependent process, and increased 
levels of MMP-2 in breast cancer biopsies were associated with poor prognosis 
(Gikes.,2016).  
Hypoxia is a major factor responsible for chemoresistance. This study confirms the 
elevated expression of CSC markers, metastasis and invasion related markers in 
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correlation with hypoxia. Studies have demonstrated the role of CSCs in the growth 
of tumours and inducing resistance to chemotherapeutic drugs and radiation therapy. 
Hence, the detection and targeting of CSCs could be examined as a therapeutic 
strategy in the future (Barzegar et al.,2019). It is highly convincing that tumour 
recurrence can be prevented if CSCs are specifically targeted. Development of drugs 
to target and eliminate CSCs represents a major challenge since they are resistant to 
all modes of conventional therapies (Jagupilli and Elkord.,2012) 
This study demonstrated that hypoxia-induced CSC, ESC and EMT characteristics in 
MM cell lines. These characteristics are responsible for causing chemoresistance in 
MM. The next chapter will demonstrate the effect of Pemetrexed, Cisplatin, PLGA-


















PLGA-DS and copper targeted MM 
CSCs, reversed chemoresistance and 







5.1 Introduction  
 
MM treatment is not guided by histological or molecular features of the tumour. It 
mainly depends on the clinical stage and patient characteristics. Moreover, there are 
no other approved regimens for relapsed or refractory MM, as platinum-based 
chemotherapies have also failed to show improvements in survival benefits. There is 
no alternative when MM patients fail this treatment option as the combination confers 
a median progression-free survival (PFS) of 5.7 months (Porpodis et al., 2013). 
Moreover, the overall response rate of combination chemotherapy is approximately 
40%; almost half of all the patients are primary resistant, and all develop resistance 
ultimately (Kim et al.,2018). As discussed earlier, CSCs may reflect the 
microenvironment-dependent heterogeneity and epithelial-mesenchymal transition 
within tumour tissues. Although the role of CSCs in tumorigenesis is still debatable. 
But it is widely accepted that the cancer cells expressing stem cell markers are highly 
resistant to radio and chemotherapy and are the sources of cancer recurrence. Also, 
the cells with CSC markers are immune to all different anticancer drugs (Conley et al., 
2012). Chapter 3 and 4 demonstrated that hypoxic stress stimulated the expression of 
CSC traits and significantly induced chemoresistance.  
Given the high costs and time duration for producing new medicines, the repurposing 
of already existing drugs to combat both rare and common disease is an attractive 
approach (Pushpakom et al., 2019). The anticancer activity of DS was reported as early 
as 40 years ago, since then DS is widely considered as a strong candidate for 
repurposing due to its relatively good safety profile and reasonable financial cost (Li 
et al., 2015). DS repurposing is considered as an anticancer medication to decrease 
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tumour development as a consequence of high-throughput cell-based drug screening 
(Turanli et al., 2018). Despite its diverse range of pharmacologic activities, prolonged 
treatment with DS has negligible, reversible, adverse effects and is considered a safe 
drug (Rae et al., 2013). But the major drawback of DS is that it instantly reduces to 
DDC in the bloodstream in vivo, which is also very unstable and promptly converted 
into the irreversible downstream metabolites. Till date, various studies have 
successfully entrapped DS by different formulations in vitro and in vivo to achieve 
high antitumour efficacy. However, these systems could not trap DS with high drug 
load and also, they were not apt for the treatment of lung cancers, due to their low 
delivery ability to lungs in oral or intravenous administration (Wang et al., 2017). Our 
previous publication demonstrates that the new formulation significantly improves the 
half-life of DS. Our group developed a PLGA encapsulated DS. The PLGA-DS plus 
Copper showed very promising anticancer efficacy in liver cancer mouse model 
(Wang et al., 2017). These encouraging results prompted me to examine the cytotoxic 
effect of PLGA-DS and Copper (Cu) in MM cell lines.  
The research aims to establish the cytotoxicity of PLGA-DS on MM cell lines in 
conjunction with Cu. We previously identified that hypoxic stress promotes CSC 
characteristics and chemoresistance in MM. This study will examine the ability of 
PLGA-DS/Cu to inhibit CSC traits leading to reversed chemoresistance. It will also 
confirm if PLGA-DS/Cu can synergistically enhance the cytotoxicity of conventional 
anti-MM drugs. To direct our in vivo MM analysis and potentially transform PLGA-
DS into MM patient care, this research aims to provide preliminary in vitro 
cytotoxicity results.  
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5.2 Materials and Methods  
In this analysis, the following section explains the primary methods used and defines 
any methodological improvements in comparison to the broadly comprehensive 
methods described in Chapter 2.  
  
5.2.1 Detection of CSC markers  
Flow cytometric analysis was used to measure the presence of CSC markers such as 
CD24, CD133 and ABCG2 after treatment with PLGA-DS (500 nM) in combination 
with CuCl2 (10 µM) for 24 hours in MM MSTO-211H and JU77 cell lines hypoxic 
cultures, respectively. A comparison was made between hypoxic and normoxic 
cultures, respectively. The detailed methods of staining and detection are detailed in 
chapters 2.2.10.  
 
5.2.2. Sphere reformation assay  
The MM MSTO-211H and JU77 spheroid cultures we subjected to sphere reformation 
assay as detailed in chapter 2.2.6. The specific drugs and doses used in this study are 
as follows: Cu (10 µM), CIS (10µM) PMT (1µM), PLGA-DS (1µM), and PLGA-DS 
in combination with CuCl2 (PLGA-DS/Cu). The spheroid cultures were treated for 48 
hrs. at 37°C, 5% CO2. After treatment, the samples were seeded at a low cell density 
in drug-free medium and incubated for seven days. The total numbers of spheres 
formed were manually counted, and images were taken at 4× magnification.  
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5.2.3 Migration Assay  
The MM MSTO-211H and JU77 hypoxic cell cultures were subjected to migration 
assay as detailed in chapter 2.2.11. The hypoxic MSTO-211H and JU77 cell lines were 
seeded in Boyden chamber with nutrient-deprived RPMI medium whereas the 
chamber has surrounded by nutrient-rich RPMI medium containing PLGA-DS/Cu 
(25nM/10 µM). The plate was then incubated in hypoxia for 24 hours at 37 ºC. After 
incubation, the cells were fixed and stained with crystal violet; the number of stained 
cells were counted manually. The comparison of the number of migrated cells in 
hypoxia was compared to normoxia and hypoxia PLGA-DS/Cu, followed by statistical 
analysis. 
 
5.2.4 Invasion Assay 
The MM MSTO-211H and JU77 hypoxic cell cultures were subjected to invasion 
assay as detailed in chapter 2.2.12. The hypoxic MSTO-211H and JU77 cell lines were 
seeded in Boyden chamber with nutrient-deprived RPMI medium, whereas the 
chamber was surrounded by nutrient-rich RPMI medium containing PLGA-DS/Cu 
(25nM/10µM). To study the effect of MMP's on basement membrane degradation, in 
MM cell lines, the bottom of the chamber was coated with matrigel, which acts as 
collagenase/ECM in vitro. The plate was then incubated in hypoxia for 24 hours at 37 
ºC. After incubation, the cells were fixed and stained with crystal violet; the number 
of stained cells were counted manually. The comparison of the number of invaded 





5.2.5. Detection of ESC markers  
Quantitative RT-PCR method was used to determine the mRNA expression of SOX2, 
OCT4 and NANOG in PLGA-DS/Cu treated MM MSTO-211H and JU77 cell lines. 
The hypoxic MM cells were treated with PLGA-DS/Cu (500nM/10μM) for 24 hrs and 
a comparison made to the hypoxic and PLGA-DS/Cu treated cell cultures, 
respectively. The RT-PCR procedure was followed as detailed in chapter 2.2.9. 
respectively. 
 
5.2.6 Detection of EMT and invasiveness related markers  
Quantitative RT-PCR method was used to determine the mRNA expression of EMT 
markers, i.e. Snail, Zeb, Slug, Twist, E-Cadherin, N-cadherin, Vimentin and 
invasiveness markers MMP-2, MMP-7, MMP-9 in MM MSTO-211H and JU77 cell 
lines. The hypoxic MM cells were treated with PLGA-DS/Cu (500nM/10μM) for 24 
hrs. And comparison was made to the hypoxic and PLGA-DS/Cu treated cell cultures, 
respectively. The qRT-PCR procedure was followed as detailed in chapter 2.2.9. 
respectively.  
 
5.2.7 MTT cytotoxicity assay  
The MM MSTO-211H and JU77 normoxic and hypoxic cultures were subjected to 
MTT cytotoxicity assay as detailed in section 2.2.13. The first-line drugs for treating 
MM and highest doses used in this study are as follows: PMT (1μM), CIS (10μM), 
PLGA-DS (1μM) and (PLGA-DS/Cu) (1μM/10 μM)) as a combination. The cell 
cultures were incubated with serially diluted anti-MM drugs for 72 hours and placed 
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in their respective cell culture incubators. After the treatment, cells were treated with 
MTT reagent, and percentage cell viability was calculated.  
 
5.2.8. Isobologram analysis  
To measure the synergistic effect of the first line anti-MM drugs in combination with 
PLGA-DS/Cu, isobologram analysis was used. Hypoxic-cultured cell lines were 
seeded as described for the MTT cytotoxicity assay. Three serial drug dilutions were 
performed for each experiment as follows; anti-MM drug alone, PLGA-DS/Cu alone 
and anti-MM drug in combination with PLGA-DS/Cu. For analytical purposes this 
study required drugs to be added in a ratio of 1:1 or 1:10; the specific drugs and highest 
doses used were as follows: PMT (1μM), CIS (10μM), PLGA-DS (1μM) with copper 
supplementation at a consistent concentration of 10 μM. Cells were incubated in a 
drug-containing medium for 72 hours. After incubation, measurement of cell 
cytotoxicity was determined as above for the MTT assay, and the results were used to 








5.3 Results  
5.3.1. PLGA-DS/Cu inhibits CSC markers in hypoxic culture.  
The expression of CSC markers was induced by MM hypoxic cultures and were 
subjected to PLGA-DS in combination with copper. The flow cytometric analysis 
determined the expression levels of CSC markers, i.e. CD133, ABCG2 and CD24, as 
shown in Figure 5.1. MSTO-211H and JU77 hypoxic cultures showed a significant 
reduction in the expression of positive CSC population after treating with (500 nM) in 
combination with CuCl2 (10 μM). The results indicate that the treatment with PLGA-
DS/Cu inhibits hypoxia-induced CSC traits. The cytotoxicity of PLGA-DS/Cu on 
normoxia and hypoxic MM cells were determined using MTT assay. The IC 50 table 
5.1 shows cytotoxic response of normoxia and hypoxia-cultured MM cell lines to 
PLGA-DS/Cu treatment. Additionally, MTT assay determined that a very low 
concentration of PLGA-DS/Cu in combination with copper is required to show its 

























                             
 



















































































































































                                                                                                          





                     
                                   




























































MSTO -211H  JU77 
Figure 5.1. PLGA-DS/Cu inhibits MM CSC characteristics in hypoxic cultures.  
The above results indicate the effect of PLGA-DS with CuCl2 on CSC markers i.e., ABCG2, 
CD133 and CD24. Results showed that CSC characteristics were increased in MSTO-211H 
and JU77 cell lines and statistically reduced in both MSTO-211H and JU77 cell lines after 
treatment with PLGA-DS 500nM and CuCl2 10 μM. PLGA DS in the figure represents PLGA-




Table 5.1. IC50 values for MSTO 211H and JU77 cell lines under normoxia 
and hypoxia after 72 hours of treatment with PLGA-DS/Cu.  
                                                             
 
5.3.2 PLGA-DS/Cu inhibits sphere reformation  
 
MSTO-211H and JU77 spheroid cultures also showed sensitivity to PLGA-DS/Cu as 
compared to other first line drugs available for MM treatment. Additionally, PLGA-
DS/Cu treatment eradicated the sphere reforming ability of MM cells. Figure 5.3 
shows that the sphere reformation ability was not affected when the cells were treated 
with PLGA-DS (1 μM) or CuCl2 (10 μM) alone and with anti-MM drugs. Whereas, 
the sphere-reformation was completely inhibited after treatment with PLGA-DS + Cu. 
The bar chart depicts that the number of spheres after the treatment. The result shows 
that the spheres treated with PLGA-DS/Cu lost the ability of sphere reformation. The 
results from this experiment indicate that PLGA-DS/Cu actively targets the CSC 
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Figure 5.2. PLGA-DS/Cu inhibits sphere reformation in MM cell line.  
The Normoxia and hypoxia cultures of MSTO-211H and JU77 cell lines were treated 
with PMT (1µM), Cisplatin (10 µM), CuCl2 (10 μM), PLGA-DS (1µM) and PLGA-
NEGATIVE PMT (1µm)   CIS (10µm)  

























































DS in combination with CuCl2 for 48 hours. After treatment, MM cells were reseeded 
at a low density and maintained in respective conditions for sphere formation. (A) 
Images of sphere reformed for MSTO-211H cell lines with bar chart (B). Images of 
sphere reformed for JU77 cell line with bar chart. n=3, ns denotes no- significance (p 
≥ 0.05), **p<0.01 
 
5.3.3 PLGA-DS/Cu inhibits migration in hypoxic culture. 
Results from chapter 3 showed that hypoxia increases the migration potential of MM 
cells. To demonstrate that PLGA-DS/Cu inhibit migration in MM cell lines, Boyden 
chamber assay was performed. The cells were subjected to hypoxic conditions at 37 C̊, 
5% CO2, and <1% O2. Hypoxia negative/untreated culture were used as a control, and 
hypoxic cells were treated with an extremely low dose of PLGA-DS/Cu, i.e. 25 nM in 
combination with 10µM of copper. Figure 5.4 (A) shows representative microscopic 
images of the cells stained with crystal violet, showing migration under hypoxia 
(negative) and hypoxia (treated) conditions. The results demonstrated that the 
migration potential of hypoxic cells was remarkably reduced after treatment with 
PLGA-DS/Cu at a very low dosage of 25 nM, as compared to untreated (hypoxic) cells 
in MSTO-211H and JU77 cell lines respectively. The number of cells that migrated 
through 8 µm pore size in the PET membrane was counted. The bar chart in Figure 
5.4 (B) represents the mean number of migrated cells under each condition. The 
number of migrated cells was reduced after the treatment of PLGA-DS/Cu under 
hypoxic conditions. This number varies between each cell line and further depends on 












Fig 5.3. PLGA-DS/Cu inhibits migration potential of MM hypoxic culture in vitro 
The potential of MM hypoxic cells was reduced after the treatment with a very low 
dose of PLGA-DS/Cu, i.e. 25 nM in combination with 10 µM of copper. (A) 
Microscopic pictures of the reduced migrated MM cells (40x magnification). (B) The 
bar chart is representing the mean number of migrated MM cells in hypoxia as 
compared to normoxia. PLGA DS in the figure represents PLGA-DS/Cu. n=12, (p ≥ 













































5.3.4 PLGA-DS/Cu inhibits invasion in hypoxic culture. 
Results from chapter 3 showed that hypoxia increases the invasion potential of MM 
cells. To demonstrate that PLGA-DS/Cu inhibits invasion in MM cell lines, Boyden 
chamber assay performed. The cells subjected to hypoxic conditions at 37 ̊C, 5% CO2, 
and <1% O2. Hypoxia negative/untreated cells were used as a control, and hypoxic 
cells were also treated with a very low dose of PLGA-DS/Cu, i.e. 25 nM in 
combination with 10µM of copper. Figure 5.5 (A) shows representative microscopic 
images of the cells stained with crystal violet, showing invasion under hypoxia 
(negative) and hypoxia (treated) conditions. The results demonstrated that invasion 
potential of hypoxic cells was remarkably reduced after treatment with PLGA-DS/Cu 
at a very low concentration, as compared to untreated (hypoxic) cells in MSTO-211H 
and JU77 cell lines respectively. The number of cells that invaded through the coated 
gel matrix chamber were counted. The bar chart in Figure 5.5 (B) represents the mean 
number of invaded cells under each condition. The number of invaded cells reduced 
after the treatment of PLGA-DS/Cu under hypoxic conditions. Interestingly, this 






























Figure 5.4. PLGA-DS inhibits invasion potential of MM hypoxic culture in vitro. 
The potential of MM hypoxic cells was reduced after treatment with a very low dose 
of PLGA-DS/Cu, i.e., 25 nM in combination with 10µM of copper. (A) Microscopic 
pictures of the reduced invaded MM cells (40x magnification). (B) The bar chart is 
representing the mean number of invaded MM cells in hypoxia as compared to 
normoxia. PLGA DS in the figure represents PLGA-DS/Cu. 
 
5.3.5 Hypoxia induced ESC traits are inhibited by PLGA-DS/Cu 
Results from chapter 4 demonstrated that MM cells exposed to hypoxia develop cancer 
stem cell characteristics which was further confirmed by expression of ESC markers 
such as SOX-2, Nanog and OCT 4. MM cell lines MSTO-211H and JU77 were 
incubated at 37 ̊C, 5% CO2, and <1% O2 for five days respectively to study the effect 
of hypoxia on CSC markers and normoxia was used as a control. The other set-in 
hypoxic condition was treated with 500 nM of PLGA-DS/Cu for five days. The 
(B) 
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consumed media was changed with fresh medium after every three days. The qRT-
PCR analysis technique was used to compare the relative mRNA expression level of 
SOX2, Nanog and OCT4 of hypoxic negative and hypoxic treated cultures shown in 
figure 5.5. JU77 showed a statistically significant decrease in the expression level of 
Nanog, SOX 2 and OCT 4. MSTO-211H showed a non-significant increase in SOX2 
and OCT4 after treatment and a significant increase in Nanog when MM cells were 
treated with 500 nM of PLGA-DS/Cu in combination with copper 
 










































                                                                     
Figure 5.5. PLGA-DS/Cu inhibits hypoxia induced ESC characteristics in MM 
cell lines. 
The relative mRNA expression of ESC markers SOX2, OCT4, NANOG was analysed 
using RT-PCR 2-∆∆Ct method in (A) MSTO -211H (B) JU77 cell lines respectively. 
Results showed that ESC characteristics were increased in MSTO 211H cell lines and 
reduced in JU77 cell lines after treatment with PLGA-DS 500nM and CuCl2 10 μM. 
n=3, ns denotes no- significance (p ≥ 0.05), *p<0.05 **p<0.01 
 
5.3.6. PLGA-DS/Cu inhibits EMT related markers in hypoxic culture. 
Results from chapter 4 demonstrated that MM cells exposed to hypoxia showed 
increased expression level of EMT related markers such as Snail, Slug, Twist, Zeb, E-
cadherin, N-Cadherin and Vimentin. MM cell lines MSTO-211H and JU77 were 
incubated at 37 ̊C, 5% CO2, and <1% O2 for five days respectively and normoxia was 





























days. The consumed media was changed with fresh medium every three days. The 
qRT-PCR analysis technique was used to compare the relative mRNA expression level 
of EMT related markers for hypoxic negative and hypoxic treated cultures shown in 
figure 5.6. The expression level of Snail 1 and ZEB 1 was statistically increased in 
both MSTO-211H and JU77 cell lines. Whereas E-cadherin was increased only in 
JU77 and no expression of E cadherin was found in MSTO-211H. Both the cell lines 
MSTO-211H and JU77 showed a statistically significant decrease in the expression 
































Figure 5.6. PLGA-DS/Cu inhibits hypoxia induced EMT characteristics in MM 
cell lines. 
The relative mRNA expression of EMT markers Snail, Slug, Twist 1, ZEB-1, E-
Cadherin, N-Cadherin and Vimentin was analysed using qRT-PCR 2-∆∆Ct method in 
(A) MSTO -211H (B) JU77 cell lines respectively. Results indicated that the expression 
level of Snail 1 and ZEB 1 were statistically increased in both MSTO-211H and JU77 
cell lines. Whereas E -cadherin was increased in only in JU77 and there was no 
expression of E cadherin in MSTO 211H cell line. Both the cell lines MSTO-211H and 
JU77 showed a statistically significant decrease in the expression level of Snail 2, 
Twist and Vimentin when MM cells were treated with 500 nM of PLGA-DS/Cu. n=3, 


























5.3.7 PLGA-DS/Cu inhibits invasiveness related markers in hypoxic 
culture. 
Results from chapter 4 demonstrated that MM cells exposed to hypoxia showed 
increased expression level of invasiveness related markers such as MMP-2, MMP-7 
and MMP-9 in MM cell lines. MSTO - 211H and JU77 cell lines were incubated at 
37 ̊C, 5% CO2, and <1% O2 for five days respectively and normoxia was used as 
control. The other set was treated with 500 nM of PLGA-DS/Cu for five days. The 
consumed media was changed with fresh medium every three days. The qRT-PCR 
analysis technique was used to compare the relative mRNA expression level of 
invasiveness related markers for hypoxic negative and hypoxic treated cultures shown 
in figure 5.7. Both the cell lines MSTO -211H and JU77 showed statistically non- 
significant decrease in the expression level of MMP-7 and MMP-9 and a significant 
decrease in the level of MMP 2 when MM cells were treated with 500 nM of PLGA-










































Figure 5.7. PLGA-DS/Cu inhibits hypoxia induced invasive characteristics in 
MM cell lines. 
The relative mRNA expression of invasiveness related markers MMP-2, MMP-9 and 
MMP-7 were analysed using RT-PCR 2-∆∆Ct method in (A) MSTO -211H (B) JU77 
cell lines respectively. Results showed that both the cell lines MSTO-211H and JU77 
showed statistically no-significant decrease in the expression level of MMP-7 and 
MMP-9 and a significant decrease in the level of MMP 2, when MM were cells treated 
with 500 nM of PLGA-DS/Cu in combination with copper. ns denotes no- significance 
(p ≥ 0.05), *p<0.05 **p<0.01 
 
5.3.8.  PLGA-DS/Cu enhances the cytotoxicity of the anti-MM drugs in 
MM cell lines 
MM cell lines have demonstrated earlier that they are more sensitive to PLGA-DS in 
combination with copper as compared to conventional anti-MM drugs. The 









































cytotoxicity of conventional drugs in vitro. The cell viability curves represent the anti-
MM drugs in combination with PLGA-DS/Cu in Figure 5.8 These curves depicts the 
effect of various anti-MM drugs alone and in combination with PLGA-DS/Cu on 
MSTO-211H and JU77 cell lines. Treating MM cells alone with conventional drugs 
shows drug-resistance as depicted in chapter 3. However, when these drugs were 
combined with PLGA-DS/Cu, a significant decrease in the number of MM cells at a 
very low dosage was observed. These results indicate that PLGA-DS/Cu, when 
combined with anti-MM drugs, improves the cytotoxicity by reducing the required 
dose for killing the cells. To determine the synergy of the drug combinations, 
CalcusynTM software used, and the Combination Index (CI) value calculated. A CI 
value of less than one is considered synergistic. Table 5.2 shows the calculated IC50 
and CI values of anti-MM drugs in combination with PLGA-DS/Cu. The IC50 values 
show the dose required to kill 50% of the cell population. Table 5.3 shows the CI 
values were calculated using the Effective Dose (ED) at three points of the curve, 
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Figure 5.8. PLGA-DS/Cu enhances the anticancer activity of conventional anti-
MM drugs.  
The cell viability curves show the synergistic effect of PLGA-DS/Cu on the cytotoxicity 
of anticancer drugs on hypoxic cultured MM cell lines (A) JU77and (B) MSTO -211H. 
The cells were incubated with PLGA-DS and supplemented with CuCl2(10 μM) in 
combination with anticancer drugs:  PMT (1µm) and CISPLATIN (10 µM) for 72 



































MSTO MSTO (B) 
 155 
Table 5.2. IC 50 values of anti-MM drugs after 72 hours of treatment on 





Table 5.3. Isobologram analysis of anti-MM drugs in combination with PLGA 
DS/Cu after 72 hours on MSTO 211H and JU77 hypoxic cultures: Combination 







Pemetrexed (nM)  
1.08 
MSTO 211H   Hypoxia   
Drug in 
combination with 
PLGA-DS/Cu (nM)  CI values  
CI values  
ED90 ED75 ED50  ED75 ED90 ED50  
1.43 1.21 1.09 0.84 0.89 0.94 






   11802.42 ± 5839.23  
 
 822.99± 486.30 
 
Cisplatin + PLGA - DS (nM) 
   52.77 ± 21.14 
 
JU77 hypoxia 
   4385.49± 3650.86  
 
<10,000 
Pemetrexed + PLGA-DS (nM)   43.13± 17.26 
 
    472.20 ± 130.9 
 




The prognosis of MM is poor due to late diagnosis, rapid progression, high 
invasiveness and the lack of effective treatment (Zhang et al.,2015). A front-line 
regime for this disease is the combination of Pemetrexed and Cisplatin, resulting in a 
response rate of 41% and a median survival of 12.1 months. Despite continuous efforts 
to implement new therapeutic modalities, none of these, have prolonged patient 
survival primarily due to chemoresistance. It is hypothesised that tumour relapse may 
be associated with the drug resistance caused by CSC. Hence, the identification and 
complete elimination of  CSC looks promising for treating MM (Dericks et al.,2017) 
Although there is an improved understanding of the biology of MM, response to 
targeted therapies is hampered by intra-tumour heterogeneity, and it is still unclear 
whether most of the mutations constitute clonal or sub-clonal driver events (Cantini et 
al.,2020) 
It has been shown that combination chemotherapy is superior to monotherapy, with 
higher response rates to Platinum-based regimens. But several complications have 
been associated with the treatment strategies and can result in significant morbidity 
(Murphy and Gill.,2017) There is no single drug or combination therapy that can be 
considered as the standard treatment for MM. A variety of single-agent and 
combination regimens have been tried in clinical trials with response rates of between 
0% and 45% (Moore, Parker and Wiggins., 2008) 
The findings from chapter four showed a strong detection of hypoxia-induced CSC 
traits which induces resistance to anti-MM drugs in hypoxic cultures. Hence, 
indicating that conventional anti-MM drugs do not selectively target the CSC 
population. This study demonstrates the significant anti-CSC activity of PLGA-DS in 
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combination with Cu in MM cell lines, which suggests that conventional drug 
combinations with PLGA-DS/Cu may provide better outcomes for patients. This 
anticancer property of Disulfiram and copper has been shown in lung cancer, prostate 
cancer, leukaemia, breast cancer and cervical adenocarcinoma and depends on copper 
(Cu), as Cu plays an important role in the redox reactions and triggers generation of 
reactive oxygen species (ROS) which induces apoptosis in human cells (Boyd et 
al.,2014) 
In this study, PLGA-DS/Cu treatment inhibits the expression of CSC markers CD133, 
CD 24 and ABCG2 in MSTO-211H and JU77 hypoxic cultures. Current studies have 
established ALDH and CD44 as putative CSC markers that exhibit elevated 
chemoresisitive properties in solid cancers, making them potential indicators of drug 
tolerance in MM (Dericks et al., 2017). High ALDH activity has been shown to 
maintain a drug-resistant phenotype in cancer cells (Triscott, Rose Pambid and Dunn, 
2015). ALDH inhibition with DS, by modulation of reactive oxygen species, could 
overcome this drug-resistant phenotype and delay disease recurrences (Rezk et al., 
2015) Wang et al demonstrated that hypoxia increased CSC population in 
Hepatocellular carcinoma (HCC) cell lines, and DS-PLGA/Cu significantly inhibited 
the ALDH and CD133 positive CSC population in both hypoxic and spheroid HCC 
cultures. DS-PLGA/Cu also showed very strong anti-metastatic effect on HCC in vitro 
and in vivo (Wang et al.,2017) 
This study also demonstrates that after treatment with PLGA-DS/Cu, the detection of 
specific CSC markers was significantly reduced in MM hypoxic cultures. Despite the 
current evidence linking CSC markers such as ALDH and CD44 to drug resistance in 
solid tumours, the variability in the different studies still warrants further investigation 
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to delineate the present roles of these potential CSC markers (Dericks et al.,2017). DS 
has been reported to downregulate tumour growth through the inhibition of 
proteasome activity, induction of apoptosis, blockage of drug resistance, inhibition of 
invasion and angiogenesis and suppression of stem cell-like properties. Moreover, DS 
shows high toxicity to cancer cells in a Copper (Cu)-dependent manner and inhibits 
cancer stem cells (Li et al., 2015). It has shown that the DS-Cu complex is highly 
cytotoxic to the cancer cells but not the normal cells (Yang et al., 2017). 
The intact sulfhydryl group is essential for the anticancer function of DS. The 
degradation of DS in the bloodstream destroys the sulfhydryl group making DS lose 
its cancer-targeting ability. The degradation of DS in the serum kinetically results from 
a covalent interaction of this drug with the free sulfhydryl of serum albumin. The half-
life of DS pH 7.4 is 1-1.5 minutes. It may introduce the discrepancy between the 
anticancer activities in vitro and in vivo and in the clinic. Nanomedicine can protect 
and deliver drugs in the bloodstream. The in vivo anticancer efficacy of DS can be 
improved by liposomal encapsulation (half-life~25 min). Therefore, our group has 
successfully extended the half-life of DS to ~7 h by encapsulation of DS into PLGA 
(Zhipeng Wang et al.,2017)  
DS-loaded PEGylated liposomes have relatively smaller sizes, and significantly lower 
polydispersity index (PI) than those of conventional liposomes (Najlah et al.,2019) 
The cytotoxicity of Lipo-DS/Cu is ROS dependent. ROS induces apoptosis by 
damaging DNA, RNA and protein. Cancer cells possess and also tolerate significantly 
higher levels of ROS due to the balance of anti-apoptotic mechanisms, e.g. NFκB 
(Peng Liu et al.,2014). Copper plays a key role in redox reactions which induces ROS 
to trigger apoptosis. DS can chelate Cu (II) to form a DS/Cu complex that enhances 
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Cu transport to cancer cells and is a much better inducer of ROS than Cu alone. Drug-
induced ROS accumulation is usually counterbalanced due to the activation of NF-kB, 
an anti-apoptotic factor inhibiting ROS and ROS-induced cytotoxicity. However, DS 
is also capable of inhibiting the activity of NF-kB. Furthermore, it has been 
demonstrated that DS can potentiate the cytotoxic effect of other anticancer drugs and 
ionising radiation. These characteristics and its low toxicity make DS an attractive 
candidate for treating orphan diseases like MM (Zembko et al.,2014) 
This study confirms that the cytotoxic activity of PLGA coated Disulfiram is 
dependent on copper supplementation. The results have clearly shown that CSC traits 
have inhibited by PLGA-DS/Cu in MM cell lines. CSCs can form spheres, which 
retain their stem cell properties for several passages, while most differentiated cells 
die from anoikis (Liu et al.,2020). PLGA-DS/Cu blocked the sphere reformation 
ability of CSCs after treatment in vitro. The combination of PLGA-DS/Cu was able to 
reduce the invasion and migration in MM at a very low concentration in vitro. It further 
suggests that if a potential target is identified, it may elucidate the underlying 
anticancer mechanism of DS to reverse chemoresistance. PLGA-DS/Cu has shown to 
enhance the cytotoxicity of first-line drugs in MM hypoxic cultured cell lines. 
Although combination therapy, consisting of Cisplatin (CIS) and Pemetrexed (PMT), 
has demonstrated promising prognostic outcomes and a response rate of 41.3%, 
making it the standard treatment for mesothelioma, overall survival has been a low 
16.6 months (Tolani et al.,2018). Therefore, urgent treatments are required for MM. 
We hypothesise that PLGA-DS/Cu, in combination with anti-MM drugs, can reduce 
the cytotoxic effects of conventional therapies. These results show that PLGA-DS/Cu 
enhance anti-MM drugs in cell lines on the graphs (Figure 5.8) but due to high standard 
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Hypoxia changes cancer cell metabolism and contributes to therapy resistance by 
inducing cell quiescence. Hypoxia stimulates a complex cell signalling network in 
cancer cells, including the HIF, PI3K, MAPK, and NF-ĸB pathways, which interact 
with each other causing positive and negative feedback loops and enhancing or 
diminishing hypoxic effects. Hypoxia causes slow-proliferating stem-cell-like 
phenotype of cells, decreases senescence, creates chaotic and malfunctioning blood 
vessels, and augments metastasis, which all together induces therapy resistance. 
Currently, the assessment of tumour oxygenation and HIF expression pattern helps 
determine tumour chemo and radio-sensitivity (Barbara Muz et al.,2015). The measure 
of ROS has shown to be increased in cancer cells exposed to hypoxia. ROS can also 
activate the differentiation of cancer stem cells, thus encouraging EMT and influence 
metabolic reprogramming contributing to the resistance of cancer cells (Jing et 
al.,2019). PI3K/AKT/mTOR, MAPK, and NFĸB signalling pathways are also 
stimulated in a hypoxia-independent manner by several factors such as cytokines, 
chemokine, and growth factors (Barbara Muz et al.,2015). The pathways controlling 
survival and cell proliferation include MAPK, PI3K-Akt, and NF-κB (Lin et al.,2010). 
NF-κB protects DNA-damaged cells from apoptosis and stimulates cell proliferation, 
which at least partly contributes to its role in promoting cell transformation (Lin et 
al.,2010). Also, in many types of cancer, chemotherapy and radiotherapy induce 
constitutive activation of NF-κB, thereby making the tumour non-responsive to the 
treatment (Chaturvedi et al.,2011). 
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NF-κB activities are often regulated by its upstream kinase known as Inhibitory kB 
Kinase (IKK), and activated IKK phosphorylates IkB alpha and beta, the endogenous 
inhibitors of NF-κB. The phosphorylated IkB alpha and beta gets ubiquitinated and 
degraded by the proteasome, allowing NF-κB nuclear translocation and transcriptional 
activation functions (Cheriyan et al., 2014) The half-life of NF-κB is less than 30 min, 
and maintenance of its activity requires ongoing protein synthesis and continuous 
stimuli. Thus, the high NF-κB activity in drug-resistant cells is a constitutive and 
intrinsic feature of the resistant cell lines, IkB degradation is thought to be the main 
reason for induction and maintenance of high nuclear NF-κB activity (Wang et 
al.,2013). Although NF-κB is an attractive molecular target for therapeutic 
intervention, inhibition of NF-κB alone only induces limited cell death (Liu et al., 
2012).  
 
Although much of the precise mechanism of the pathogenesis of mesothelioma 
remains unknown, the involvement of chronic inflammation in the pathogenesis has 
been proposed. Although the uptake of asbestos often induces cytotoxicity and results 
in the apoptosis of affected cells, TNF-α produced by macrophages may rescue 
mesothelial cells from cell death through nuclear factor-κB (NF-κB) dependent 
pathway. Crucial roles of NF-κB signalling in both malignant transformations have 
been identified. However, direct evidence regarding NF-κB in triggering 
mesothelioma formation has been insufficient in clinical cases (Nishkawa et al.,2014). 
Research has shown increased expression of genes with NF-κB binding sequences in 
the regulatory regions of lungs and cells in vitro after exposure to crocidolite asbestos 
in lung cancer, and mesothelioma. The fibrous nature of asbestos is essential for 
activation of NF-κB (Yvonne et al.,1997). The in vitro studies evaluating the impact 
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of asbestos on cell cycle regulation and survival have discovered a significant 
relationship between activation of NF-κB pathways and cellular protection from the 
asbestos-induced cell. This effect is further confirmed by selective inhibition of NF-
κB, which subjects the exposed cells to programmed cell death (Chandra et al.,2011). 
We hypothesised that NF-κB drives chemoresistance in MM. 
 
6.2 Materials and Methods  
The following section elaborates the specific methods used within this particular study 
and specifies any experimental changes concerning the general detailed methods 
explained in chapter 2. 
 
6.2.1 NF-κB -P65 overexpression  
6.2.1.1 Culture methods  
In this study, MSTO-211H cell line transfected with NF-κB-p65. Amongst fifty clones, two 
overexpressed clones selected. The transfected clones (C12 and C15) along with MSTO-211H 
mock, were maintained in RPMI medium containing 50 Pg/mL hygromycin and incubated at 
37°C and 5% CO2.  
 
6.2.1.2 Stable transfection  
MSTO-211H cell lines were stably transfected with NF-κB -P65. The cDNA of NF-
κB-p65 and recombinant vector constructed by inserting the cDNA into 
pcDNA3.1(+)/hygromycin vector for mammalian expression. The MSTO-211H cells 
were incubated at a density of 0.4×105 cell/well in a 6-well plate for overnight culture. 
To determine the efficiency of transfection negative (no plasmid) and mock (empty 
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vector) was used as a control. The pcDNA3.1 NF-κB-p65 and the empty pcDNA3.1 
construct was incorporated inside the cells by using lipofectamineTM 2000 reagent and 
incubated for 24 hours at 37°C and 5% CO2. The cells were then transferred into the 
fresh RPMI media containing 50 Pg/mL hygromycin as the selecting agent for 
successfully transfected cells. The media was changed after every three days to remove 
dead cells. After seven days, the successfully transformed colonies were selected and 
picked carefully. The clones were then screened for ectopic expression by qRT-PCR 
and western blot analysis. In this study, MSTO-211H cell lines were transfected with 
an empty vector identified as mock, and the selected MSTO-211H clones with high 
NF-κB-p65 expression were C12 and C15.  
 
6.2.1.3 Detection of hypoxia-induced proteins by RT-PCR  
qRT-PCR was used to measure the mRNA expression of NF-κB-p65 transfected 
clones C12 and C15 as compared to mock. The qRT-PCR procedure was followed as 
detailed in chapter 2.2.9.  
 
6.2.1.4. Detection of NF-κB-p65 by Western blot analysis  
Flow cytometric analysis was used to measure the presence of CSC markers ALDH, 
CD133 and ABCG2 in the NF-κB -p65 transfected cells, respectively. A comparison 
made between NF-κB overexpressed clones and mock, respectively. The detailed 
methods of staining and detection listed in chapters 2.2.10.  
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6.2.1.5.  Detection of CSC markers 
Quantitative RT-PCR method was used to determine the mRNA expression of ESC 
markers, i.e. SOX-2, NANOG, OCT 4 in NF-κB overexpressed clones. The 
comparison was made between the overexpressed clones and mock, respectively. The 
RT-PCR procedure was followed as detailed in chapter 2.2.9. respectively. 
 
6.2.1.6.  Detection of EMT markers  
Quantitative RT-PCR method was used to determine the mRNA expression of EMT 
markers, i.e. Snail, Zeb, Slug, Twist, E-Cadherin, N-cadherin, Vimentin and 
invasiveness markers MMP-2, MMP-7, MMP-9 in NF-κB overexpressed clones. The 
comparison was made between the overexpressed clones and mock, respectively. The 
RT-PCR procedure was followed as detailed in chapter 2.2.9. respectively.   
 
 
6.2.1.7.  MTT Cytotoxicity assay  
 
The NF-κB P65 transfected cells were subjected to MTT cytotoxicity assay as detailed 
in section 2.2.13. The over expressed clones were exposed to serially diluted first line 
drugs PMT and CIS for 72 hours and placed in their respective cell culture incubators. 
After incubation the cells were treated with MTT reagent and percentage cell viability 





6.2.2. Knockout of NF-κB -P65 using CRISPR Cas 9 technology  
MSTO-211H cell line was stably transfected with CRISPR Cas-9 lentiviral vectors 
containing different target sequences of NF-κB p65 gene, i.e. T1, T2 and T3 (Detailed 
in chapter 2.2.13) purchased from Abm (Canada) by using lipofectamineTM 2000 
reagent. The clones were then screened for NF-κB -p65 knock out by RT-PCR and 
western blot analysis. The MSTO-211H cells were also transfected with a scrambled 
vector which was used as control. 
 
 
6.3 RESULTS  
 
6.3.1. Hypoxic culture induced expression of NF-κB  
The expression of NF-κB-p65, HIF-1α and HIF-2α examined in hypoxia and normoxia 
cultured MM cell lines. Figure 6.1 identifies the relative mRNA expression of NF-κB-
p65, HIF-1α and HIF-2α, and shows that in comparison with the normoxia-cultured 
counterparts, the hypoxia-cultured MSTO -211H cells expressed high levels of NF-
κB-p65 and HIF-2α. Furthermore, the expression of NF-κB-p65 protein was 
examined. The overexpression of NF-κB -p65 was detected in the hypoxia-cultured 













Figure 6.1. Hypoxic cultures demonstrate increased mRNA and protein 
expression of hypoxia-induced NF-KB-P65. The relative mRNA and protein 
expression of hypoxia-induced proteins. (A) mRNA expression in normoxia and 
hypoxia cultures of MSTO-211H cells. (B) Protein expression in normoxia and 
hypoxia culture of MSTO-211H cells. n=3, **p<0.01 
 
6.3.2. Stable transfection of NF-κB-p65 into MSTO-211 cell line  
Stable transfection of pcDNA3.1 NF-κB-p65 was performed on MSTO-211H cell line 
to overexpress NF-κB-p65. Two successfully transfected clones, C12 and C15, with 
high NF-NB-p65 expression were selected. Figure 6.2. (A) To confirm the success of 
NF-κB-p65 transfection western blot analysis was performed to identify the whole 
protein expression of NF-κB-p65. Western blot determined the final screening for the 
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both C12 and C 15 compared to mock.  Figure 6.2 (A) shows an increase in the 
detection of NF-κB-p65 whole protein signals for both C12 and C15 as compared to 
the mock. β-Actin used as a loading control for whole protein detection. Figure 6.2 
(B) displays a significant increase in the relative mRNA expression of NF-κB-p65 in 
both C12 and C15 compared to mock, and the results further verify the success of NF-
κB-p65 transfected cell lines.  








Figure 6.2. Successful stable transfection of NF-κB-p65 in MSTO 211H 
cell line.  
(A)  Western blot analysis used to screen the NF-κB-p65 overexpressed in NF-κB-p65 
transfected MSTO-211H cell lines, C12 and C15 demonstrated ectopic expression as 
compared to mock. β-actin has used as a loading control (B) The relative mRNA 
expression of NF-κB-p65 was analysed using RT-PCR 2-∆∆Ct method for further 

































6.3.3. NF-κB-p65 transfected cell lines does not induce CSC traits  
 
Hypoxic cultures significantly promote the expression of CSC related proteins, but 
NF-κB-p65 transfected cell lines did not demonstrate an increase in the detection of 
CSC markers. Figure 6.3. shows the flow cytometric analysis of CSC markers in 
ALDH, CD133 and ABCG2 in NF-κB-p65 transfected clones C12 and C15 compared 
to the mock. The transfected cell lines demonstrated statistically no significant  
increase in the expression of ALDH, ABCG2 and CD133.  
 
                                                                                                  




























































































 Figure 6.3. NF-κB-p65 overexpression does not induce expression of 
CSC markers. 
The expression of CSC markers was analysed using flow cytometry. (A) ABCG2 using 
APC conjugated anti-ABCG2, (B) CD133 using FITC conjugated anti-CD133 and (C) 
ALDH activity using ALDEFUOR. The bar chart displays the population of cells 
expressing CSC markers. 
 
6.3.4. NF-κB-p65 transfected cell lines does not induce ESC traits  
To further identify if NF-κB-p65 expression correlates with CSC characteristics, the 
relative mRNA expression of ESC transcription factors SOX2, OCT4 and NANOG 
were analysed by qRT-PCR and shown in Figure 6.4 The bar charts signify non-
significant increase in relative mRNA expression for all targets in C12 and C15 



























                             
Figure 6.4. NF-κB-p65 transfected MSTO 211H cells demonstrate non-
significant increase in the expression of ESC markers. 
The relative mRNA expression of ESC markers SOX2, OCT4, NANOG analysed using 
RT-PCR 2-∆∆Ct method. n =3, ns denotes no- significance (p ≥ 0.05) 
 
6.3.5.  NF-κB-p65 transfected cell lines does not induce EMT and 
invasiness related markers.  
Hypoxic cultures significantly promoted the expression of EMT characteristics, but 
NF-κB-p65 transfected cell lines did not demonstrate statistically significant increase 
in the expression of EMT markers. Figure 6.5. shows the relative mRNA expression 
of (A) EMT markers i.e. Snail 1, Snail 2, ZEB, Twist, E-cadherin, N cadherin, 
Vimentin and (B) Invasiveness related markers i.e. MMP2, MMP9 and MMP7 in NF-






































     













                                                                 
 
 
 Figure 6.5. NF-κB-p65 transfected MSTO 211H cells demonstrate non-
significant increase    in the expression of EMT and invasiveness related 
markers.  
The relative mRNA expression of (A) EMT markers i.e., Snail 1, Snail 2, ZEB, Twist, 
E-cadherin, N cadherin, Vimentin and (B) Invasiveness related markers i.e. MMP2, 
MMP9 and MMP7 in NF-κB-p65 transfected clones C12 and C15 compared to the 
mock was analysed using RT-PCR 2-∆∆Ct method. n=3, ns denotes no- significance 

















































































































6.3.6.  NF-κB-p65 transfected cell lines did not show chemoresistantance 
Hypoxia stimulated stress drives NF-κB pathway and hypoxic cultures in chapter 3 
showed a significant effect of hypoxia on resistance to first line drugs.  Figure 6.6. 
shows the cell viability curves and compares the cytotoxic effect of first line drugs 
between NF-κB-p65 transfected cell lines. These results demonstrated that the mock 
showed more resistance to NF-κB -p65 transfected clones, as the curve for the clone 
declines at lower drug concentration. Table 6.1 shows the calculated values for Mock 
are greater than the IC50s calculated for the clones C12 and C15 and demonstrate 




























Figure 6.6. NF-κB-p65 transfection does not induces chemoresistance. 
The cell viability curves depict the effect of first line drugs on NF-κB-p65 transfected 
MSTO 211H cell lines, C12 and C15 as compared to mock. The cells were incubated 
with (A) PMT (B) CIS for 72 hours and then subjected to MTT assay. 
 
Table 4.1. IC50 values for MSTO 211H pcDNA3.1 NF-κB-p65 cell lines 
(mock, C12 and C15) after 72 hours treatment with anticancer drugs.  
 
 
NF-κB -P65 transfected clones    
C12 Mock  C15 
Pemetrexed    





















29.41 ± 1.25 
 
25.22 ± 0.73 
 
20.22 ± 4.73 
 
1179.84 ± 572.36 
 
1036.85 ± 544.34 
 
909.87 ± 626.18 
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6.3.7. Stable knockout of NF-κB-p65 in MSTO-211 cell line  
 
In order to determine the effect of NF-NB-p65 on MM cells, I also used CRISPR - 
Cas9 technology to knock out NF-κB-p65 in MSTO-211H cell line. Three successfully 
transfected clones were selected C2, C13 and C16 during a screening procedure to 
determine the expression and activity of NF-κB-p65 compared to the scramble vector 
transfected control cell line. Figure 6.7. (A) To confirm the success of NF-κB-p65 
knock out and screening by western blot analysis was performed to identify the whole 
protein expression of NF-κB-p65 knock out. (B) To confirm an increase in the relative 
mRNA expression of NF-κB-p65 C2, C13 and C 16 were compared to mock.  Figure 
6.7. (A) shows no expression of NF-κB-p65 whole protein signals for both C2 and 
C16 compared to the scrambled. β-Actin was used as a loading control for whole 
protein detection. Figure 6.7 (B) displays a significant decrease in the relative mRNA 
expression of NF-κB-p65 in C2, C13 and C16 compared to scrambled, these results 






(A) (B)  
 
Figure 6.7. Successful stable transfection of NF-κB-p65 knock out in 
MSTO 211H cell line.  
(A) Western blot analysis was used to determine NF-κB-p65 knock out in NF-κB-p65 
transfected MSTO-211H cell lines, C2, C13 and C16 demonstrated decreased 
expression of NF-κB -p65 as compared to mock. β-actin was used as loading control 
(B) The relative mRNA expression of NF-κB-p65 was analysed using RT-PCR 2-∆∆Ct 






































The previous study identified the hypoxic stimulus as a major contributing factor to 
the development of CSC traits and chemoresistance in MM. In this chapter, it was 
shown that MM hypoxic cultures equally demonstrate a significant increase in the 
expression of transcription factors related to metastasis. Hypoxia generates intra-
tumoural oxygen gradients, contributing to the plasticity and heterogeneity of tumors 
and promoting a more aggressive and metastatic phenotype (Jing et al., 2019). 
Hypoxia induces NF-κB activation in a wide range of cells and NF-κB plays important 
role in cell survival, proliferation, invasion, migration and chemoresistance (Liu et 
al.,2014). NF-κB and its target genes have been implicated as mediators in all of the 
hallmarks of cancer (Hanahan and Weinberg, 2011). Research have shown increased 
expression of genes with NF-NB binding sequences in their regulatory regions in lungs 
and cells in vitro after exposure to crocidolite asbestos in lung cancer, and 
mesothelioma. The fibrous nature of asbestos is essential for activation of NF-ΚB 
(Yvonne et al.,1997). In vitro models evaluating the impact of asbestos on cell cycle 
regulation and survival have discovered a significant relationship between activation 
of NF-κB pathways and cellular protection from asbestos induced cell. This effect has 
been verified by selective inhibition of NF-κB, which subjects the exposed cells to 
programmed cell death (Chandra et al.,2011). 
 
Malignant cells are “addicted” to NF-κB signaling, which drives oncogenesis, disease 
recurrence and therapy resistance in both solid and hematological malignancies, where 
it induces transcriptional programmers sustaining all hallmarks of cancer (Verzella et 
al.,2020). As NF-κB is the key transcription factor involved in the inflammatory 
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pathway, NF-κB is constitutively active in most cancers, and many of the signaling 
pathways implicated in cancer are likely to be networked to the activation of NF-κB. 
The cell signaling intermediates that are frequently mutated in human cancers have 
been directly/indirectly networked with NF-κB pathway (Chaturvedi et al.,2011). NF-
κB target genes play an important role in the regulation of many of the pathways 
involved in the hallmarks of cancer (Godwin et al.,2013). Cheng et al. concluded that 
HIF-1α-activated NF-κB could promote EMT in pancreatic cancer cells by inhibiting 
E-cadherin and promoting N-cadherin (Tam et al.,2020) The p65/p50 is the most 
common NF-κB dimer and plays a major anti-apoptotic role in anticancer drug treated 
mammalian cells (Wang et al.,2003). The p65 transactivator subunit of NF-κB, RelA, 
was recognized earlier as the potential oncogene. The p50-p65 heterodimer interacts 
with many other transcription factors that are regulated by epigenetic modifications at 
the promoters of responsive genes (Chaturvedi et al.,2011). The canonical pathway for 
NF-κB activation involves the re-localization of NF-κB p65-p50 dimers to the nucleus 
(Samuel et al., 2014) 
 
Various oncogenic insults such as in Ras, P53 and EGFR leads to the activation of 
NF-κB pathway in tumor cells. Due to inflammatory environment and several 
oncogenic mutations a significant number of neoplasms have constitutive NF-κB 
activity. As a corollary, the frequent up-regulation of the NF-κB signaling pathway in 
multiple forms of carcinoma establishes a complimentary microenvironment, which 
is critical for either tumor initiation or tumor development, or both. (Xia et al.,2014). 
Our previous work has shown that High NF-κB activity has been identified in drug-
resistant cancer cells and ectopic over-expression of NF-κB can block anticancer drug-
induced apoptosis (Yip et al.,2011). Exposure of cancer cells to anticancer drugs, 
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cytokines and radiation can induce the nuclear translocation and DNA binding activity 
of NF-κB. Human cancer cells with induced NF-κB nuclear activity have 
demonstrated resistance to apoptosis induced by chemotherapy or radiotherapy (Wang 
et al.,2003) The mechanism by which NF-κB is induced by drugs or how the genes 
driven by NF-κB causes drug resistance are not completely understood. The drug 
driven damage to cancer cell DNA is believed to trigger NF-κB by the protein IKK-
gamma. DNA-damage activates ATM kinase, which in turn activates NF-κB essential 
modifier (NEMO), a component of the IKK complex that induces nuclear 
translocation of the p65/p50 transcription factor complex (Verzella et al.,2020) 
Regulation of gene expression is essential for cell maintenance. Transfection is 
performed to understand the function of gene by enhancing or inhibiting its expression 
in cells (Kim and Eberwine.,2010) Liu et al transfected Breast cancer (BC) cells with 
NFκB p65 to determine the importance of NFκB with respect to CSC traits. The 
transfected clones expressed high levels of BC stem cell markers and were highly 
resistant to Doxorubicin and Paclitaxel. Therefore, NFκB certainly conferred CSC 
traits upon BC cells (Liu et al.,2014) 
 
In order to understand the transcriptional activity of NF-κB in MM, stable transfection 
of NF-κB-p65 over expression and NF-κB p65 knockout was performed on MSTO-
211H cell lines. The former study identified specific CSC markers to be overexpressed 
in hypoxic cultures. Research has revealed that in the bulk of tumors in which NF-κB 
is constitutively active, it frequently provides cancer cells with a survival advantage 
by upregulating antiapoptotic genes. Cancer stem-like cells, which utilize the NF-κB 
pathway, may be responsible for resistance and for re-seeding of the tumor mass after 
initially effective chemotherapy or radiation (Verzella et al.,2020). We hypothesized 
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that persistent activation of the NF-κB-p65 pathway drives the maintenance of the 
stem-like phenotype in MM. This study did not recognize a statistical increase in the 
expression of CSC, EMT and ESC markers in NF-κB -p65 overexpressed transfected 
cell lines, indicating NF-κB-p65 may be not be responsible for the generation of CSC 
in MM. The findings suggest that NF-κB-p65 might not play a pivotal factor in driving 
CSCs in MM.  
 
 It has been shown that in many types of cancer, that chemotherapy and radiotherapy 
induce constitutive activation of NF-κB, thereby making the tumor non-responsive to 
the treatment (Chaturvedi et al.,2011). In addition, the previous study demonstrated 
that the detection of specific CSCs confirms chemoresistant properties in MM hypoxic 
cultures. NF-κB is also heavily implicated in the development of resistance to 
platinum-based chemotherapies, such as Cisplatin. Therefore, NF-κB represents an 
attractive target for anti-cancer therapy particularly as an adjuvant to overcome 
resistance to platinum-based chemotherapeutics (Godwin et al.,2013). Therefore, we 
overexpressed and knocked-out NF-kB-P65 to confirm its role in causing 
chemoresistance in MM. The NF-κB-p65 over expressed transfected cell lines did not 
demonstrate CSC traits along with no increase in resistance to first line drugs. The 
MTT assay in this study clearly shows NF-κB-p65 over expressed cell lines did not 
display a significant increase in resistance to PMT and CIS treatment. One of the 
reasons speculated here can be that first line drugs elicit their effects in various ways 
which may not induce apoptosis, therefore, may not be directly affected by NF-κB-
p65 overexpression.  
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Transfection with CRISPR/Cas9 system has been extensively used in easy‐to‐
manipulate cells (Saber et al.,2018). CRISPR/Cas9 is a very powerful gene editing 
tool for exploring the function of defined genes in cell signalling pathways, 
proliferation, migration, invasion and potentially chemotherapy resistance (yang et 
al.,2019). NF-κB -p65 gene was successfully knocked out in MSTO-211H cell line by 
using CRISPR - Cas9 technology. The result obtained by over expression should be 
further confirmed by NF-κB -p65 knock out cytotoxicity assay and expression of CSC 
markers, which would further reconfirm that NF-κB  does not drive chemoresistance 
in MM. Due to time constraints further experiments on NF-κB -p65 knock out could 
not be performed. This study implicates the possibility if NF-κB-p65 induce CSC traits 


































Malignant Mesothelioma is a highly malignant disease that most often occurs in the 
pleura of the thoracic cavity, followed by the peritoneum, pericardium, and tunica 
vaginalis testis (Levy et al.,2019). The standard first-line chemotherapy includes a 
combination of Cisplatin and Pemetrexed. However, median survival is 12.7 months, 
and most patients become resistant to chemotherapy and relapse quickly. Currently, 
there are no second-line treatment options for relapsed patients (Staumont et al. ,2020). 
Recent research has further shown that MM contains hypoxic regions, which explains 
the link between tumour hypoxia and poor therapeutic efficacy. However, the 
underlying mechanism of hypoxia in MM remains largely unknown.  
 
The present study showed that hypoxia promotes aggressive phenotypes in MM cells. 
By inhibiting apoptosis and inducing drug resistance, hypoxia enhances in vitro 
clonogenicity, migration, invasion in MM cells (Kim at al.,2018). It promotes EMT 
associated CSC properties, including self-renewal in which CSC enrichment occurs 
upon exposure to hypoxia-inducible factor HIF-1α in vivo; and promote resistance to 
chemotherapy (Najafi et al.,2019). HIF-1α is commonly expressed in MM and play a 
significant role in keeping with its aggressive behaviour and chemoresistant phenotype 
(Klabatsa et al.,2006). Mesotheliomas are particularly hypoxic solid tumour masses. 
Imaging evidence from [F-18] fluoromisonidazole (FMISO) PET-CT scanning 
confirms hypoxia being integral to mesotheliomas (Nabavi et al.,2016). Therefore, we 
observed the effect of hypoxia on chemosensitivity and invasiveness in MM. The 
results of this study have confirmed that the hypoxic status in MM promotes CSC traits 




Studies have suggested that hypoxia and some hypoxia-regulated transcription factors 
are the determinants for the stemness of CSCs (Conley et al., 2012). CSCs are a small 
subpopulation of tumour bulk, but they are mainly responsible for tumour mass 
renewal, recurrence and chemoresistance (Milosevic et al.,2020). Hypoxia functions 
to increase CSC number and helps in maintaining their stem-like state allowing the 
subsequent growth and metastasis and hence considered as a critical physiological 
component of CSC niche (Yadav and Desai.,2019). Recent research has shown that 
the generation of CSCs occurs in part as a result of EMT. This hypoxia-induced EMT 
leads to an increase in CSCs during tumour progression, which subsequently enhances 
invasion and metastasis (Yeo et al.,2017). EMT is also involved in progresson of 
cancer and metastasis, and HIF-1 has been identified as a regulator of EMT in human 
cancers (Zhang et al.,2019).  CSCs possess the critical survival mechanisms and 
properties crucial for the maintenance and propagation of the tumour (Marwa 
M.,2018).). Both EMT and stemness are associated with resistance to chemotherapy 
in tumours (Yeo et al.,2017).  
 
We hypothesized that the hypoxic microenvironment/stress of the tumour is 
responsible for maintaining stemness in CSCs. To further study the effects of hypoxia 
on MM cell lines, attached monolayer cultures were incubated under hypoxic 
conditions. The results demonstrated a strong correlation to the hypoxic environmental 
stress and the expression of CSC specific markers. Chronic, diffusion-limited hypoxia 
due to an increase in diffusion gap with tumour growth results from excess in oxygen 
supply and demand (Tameemi et al., 2019). Activation of stem genes along with 
dedifferentiation, under hypoxic conditions, advances stemness in the cells (Yadav 
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and Desai.,2019). Also, the hypoxic microenvironment maintains the undifferentiated 
state of cancer cells and enhances their cloning rate. CSCs can also adapt to a new 
method of cell energy metabolism and avoid apoptosis caused by hypoxia (Yang et 
al.,2019). There is growing evidence that CSC are innately resistant to radiation, 
redistributing the cells in the cell cycle, by stimulating the repair of DNA damaged, 
increasing activation of the DNA damage checkpoint, and repopulating and 
reoxygenating areas of hypoxia in the tumour. The reversible conversion capacity of 
CSCs also attributes to protect themselves from chemo-radiotherapeutic insults (Das 
et al.,2020). This study confirms the elevated expression of CSC markers, metastasis 
and invasion related markers in correlation with hypoxia. 
 
The results from this study also demonstrate that CSCs cause chemoresistance in MM 
cell lines and thus can be potential targets to overcome chemoresistance. Strong 
preclinical evidence supports the role of hypoxia and MM cancer stem cells (CSCs) in 
determining tumour resistance to therapies. Indeed, studies have observed that MM 
includes hypoxic regions and that several signaling pathways are involved in tumour 
initiation, growth and maintenance, as well as chemo-radio-resistance, are known to 
trigger the hypoxic microenvironment. Hypoxia also modulates gene and microRNA 
expression, which are also associated with stemness and to resistance to therapies 
(Abbott et al.,2020). The CSC and ESC markers were studied in monolayered cultures, 
and the specific markers studied were CD133, CD24, ABCG2, SOX2, NANOG and 
OCT 4. CD24 is considered the primary marker of MM in many cases (Yamazaki et 
al.,2012). It has been shown that Mesothelioma stem cells (MSC) increase and become 
more resistant after chemoradiation (Wu et al.,2018). Also, elevated levels of OCT4 
and other stemness markers in MM cells derived from mesosphere are paralleled by 
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an increased tumour-initiating capacity (Blum et al.,2017). Overall MM cultures 
demonstrated a significant increase in the detection of the above markers, and the 
expression of these markers is associated with poor survival in MM. Also, studying a 
variety of CSC markers further confirm the significant changes in the phenotype and 
is beneficial in understanding the molecular interactions and response to anti - MM 
drugs. The anti-MM drugs used in this study include first-line cytotoxic agents 
Pemetrexed and Cisplatin. Surgical therapy is only for patients who can handle 
surgical risks and who have a low tumour stage. Radiation therapy (RT) has a role in 
MM treatment as well, as it can be in conjunction with chemotherapy and can provide 
local tumour control if the patient has a good performance status. Toxicity, however, 
is significant, and thus RT alone has little benefit unless it aims to relieve specific 
symptoms such as chest pain. Modern targeted therapies have shown benefit in other 
human tumours - e.g., lung cancers-have so far failed in MM. Although combination 
therapy, consisting of Cisplatin and Pemetrexed, has shown promising prognostic 
outcomes and a response rate of 41.3%, making it the standard treatment for MM, 
overall survival has been a low 16.6 months (Tolani et al.,2018). In the present study, 
the hypoxic cultured MM cells showed similar traits and demonstrated resistance to 
anti-MM drugs. When hypoxic MM cells were exposed to high drug concentrations 
by MTT cytotoxicity assay, the cells showed resistance and demonstrated stemness 
properties and formed resistant colonies after treatment.  
 
The focus of this study is the betterment of the patient’s life and improve current 
treatment regimes. Therefore, this study focuses on the improvement of first-line anti-
MM drugs by synergistically enhancing their efficacy with PLGA-DS + Cu, which 
can potentially provide the best therapeutic outcomes for MM patients. Drug 
 
 188 
repurposing has the potential to surpass many challenges associated with de-novo drug 
discovery. Repurposing of an existing drug guarantees quick clinical trials due to 
already established pharmacokinetics, tolerability and toxicity profiles (Kaushik et 
al.,2020). This study also focused on drug repurposing to target mechanisms 
responsible for causing chemoresistance in MM. DS/Cu has shown to cause regression 
of mesothelioma growth in vivo in part by stimulating apoptosis (Cheriyan et al.,2014). 
DS generates oxidative stress through the inhibition of NF-κB activation (Tesson et 
al., 2017) (Triscott, Rose Pambid and Dunn, 2015) (Li et al., 2017). This study focused 
on repurposing DS in combination with copper chloride, which demonstrated 
significant cytotoxicity in MM cell lines. Copper has a crucial role in redox reactions 
and triggers the generation of ROS in human cells. DS/Cu is a potent ROS inducer 
and proteasome-NF-κB pathway inhibitor (Chen et al., 2006). Combination of DS with 
Cu may target cancer cells by simultaneously tackling both ROS and NF-κB (Yip et 
al., 2011). DS also showed synergy with first-line drugs Pemetrexed and Cisplatin by 
targeting CSCs and EMT pathway. Conventional anticancer drugs target the 
proliferating and differentiated tumour bulk but fail to eradicate the CSCs, which 
become the source of tumour recurrence (Yip et al., 2011). The use of DS in the clinics 
is limited due to its very short half-life in the blood. It inhibits the ability of intact DS 
to reach distant tissues and organs due to metabolism in the liver which hampers its 
chelation with Cu (II) rendering it unfavourable for treating cancer. Therefore, our 
group coated DS with PLGA nanoparticles and extended its half-Life in the blood, 
allowing it to chelate Cu (II) at the target site (Wang et al.,2016). The nano-
encapsulation protects the thiol groups in DS and extends its half-life in the serum 
from less than 2 min to over seven hrs. and successfully delivers the intact DS to cancer 
tissues (Butcher et al., 2018). Our results show that PLGA-DS/Cu enhance anti-MM 
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drugs in cell lines and can potentially improve treatment options for MM patients with 
negligible side effects.  
 
MM is a heterogeneous neoplasm. Recent classifications take into account the 
heterogeneity between patient tumours but not the heterogeneity inside the tumour of 
each patient (Blum et al.,2019). Tumour heterogeneity can significantly affect drug 
penetration and distribution (Abbott et al.,2020). Therefore, cancer stemness is highly 
heterogeneous. Different pathways may express at different times in different tumour 
types, resulting in distinct stemness characteristics. Activation of stemness pathways 
can identify in cells expressing distinct CSC markers (Lathia, Liu and Matei.,2020). 
CSCs has implicated in contributing to tumour heterogeneity and metastasis. For these 
reasons, CSCs may represent the “root of cancer”, and their elimination represents a 
promising yet investigational therapeutic strategy (Castagnoli et al.,2020). 
Traditionally, CSCs has been described as preferring hypoxic conditions, and the CSC 
niche is described as hypoxic and acidic (Steinbichler et al.,2020). Research has shown 
that CSCs that can form spheres to retain their stem cell properties for many passages, 
while most differentiated cells die from anoikis (Liu et al.,2020). CSCs can create 
spheroids in blood circulation. The ability to form spheroids is considered a unique 
feature of CSCs. These CSC containing spheroids in the blood of cancer patients might 
generate a “micro‐niche” that support CSC survival and adaptation in the bloodstream 
(Steinbichler et al.,2020). The most commonly used method of function-based CSC 
enrichment is the sphere reformation assay, in which spheres form CSCs which can 
grow as non-attached in serum-free medium and form non-adherent 3-dimensional 
(3D) tumour sphere structures which is characteristic reminiscent of the ability of 
CSCs to initiate tumours and maintain tumour progression (Liu et al.,2020). This study 
 
 190 
used suspension culture and kept it additionally with growth factors and other essential 
nutrients, which helped to promote the cell aggregation and encouraged the spheroid 
formation of different shapes and sizes. These spheroids were then treated with 
different drugs, i.e. Pemetrexed, Cisplatin, Copper, PLGA-DS and PLGA-DS+ Cu. 
The results showed that the spheroids aggregated again when treated with first-line 
drugs and Copper and PLGA-DS separately. Still, the combination of PLGA-DS + Cu 
was able to eliminate sphere reformation in MM cell lines.  Therefore, the sphere 
reformation assay shows that MM spheroid cells are resistant to first-line MM drugs. 
The results also indicate that certain culture conditions are required to promote CSC 
expression and induce chemoresistance since the MM cells which survived after 
treatment again generated spheroid cultures. 
 
Our previous work has shown that hypoxia drives CSCs by activating NF-κB pathway, 
which also regulates many genes associated with CSC maintenance. The NF-κB 
pathway has also implicated in EMT and metastasis by transcriptionally up-regulating 
master-switch transcription factors required for EMT, such as Slug.  There is 
accumulating evidence for an essential link between EMT and the invasion, metastasis 
and self-renewal traits of cancer cells. Among all the known factors involved in the 
EMT, the transforming growth factor-beta 1 (TGF-b) signalling pathways have taken 
centre stage. Coordinated activation of NF-κB and TGF-b signalling cascades 
effectively induces EMT and the expression of genes related to stemness and cell 
invasion (Li et al., 2017; Benedetti et al.,2015). High NF-κB activity is identified in 
drug-resistant cancer cells, and ectopic overexpression of NF-κB can block anticancer 
drug-induced apoptosis (Wang et al., 1998, 1999, 2004). The p65/p50 subunit is the 
most common NF-κB dimer and plays a significant anti-apoptotic role in anticancer 
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drug-treated mammalian cells (Wang et al.,2003). NF-κB induction frequently 
contributes to a dysregulated apoptotic response in response to chemotherapy, which 
could mediate chemoresistance (Godwin et al., 2013). Hypoxia induces several 
complex intracellular signalling pathways such as the major HIF pathway. Other 
hypoxia-associated pathways include PI3K/AKT/mTOR, MAPK and NF-ĸB 
pathway. These pathways have involved in cell proliferation, survival, apoptosis, 
metabolism, migration, and inflammation (Barbara Muz et al.,2015).  
Research has shown increased expression of genes with NF-κB binding sequences in 
their regulatory regions in lungs and cells in vitro after exposure to crocidolite asbestos 
in lung cancer, and MM. The fibrous nature of asbestos is essential for the activation 
of NF-κB (Yvonne et al.,1997). Upon contact with asbestos fibres, macrophages 
produce Tumor Necrosis Factor-alpha (TNF-α), which is a key cytokine involved in 
inflammatory processes such as acute-phase reaction, systemic inflammation, and 
chronic inflammation. TNF-α binds to TNF-α Receptor 1 located on mesothelial cells, 
thereby activating NF-κB. Activation of the NF-κB pathway allows mesothelial cells 
with DNA damage as a result of exposure to asbestos fibres to survive and proliferate 
(Hiriart et al.,2019). In vitro models evaluating the impact of asbestos on cell cycle 
regulation and survival have discovered a significant relationship between activation 
of NF-κB pathways and cellular protection from the asbestos-induced cell. This effect 
is verified by selective inhibition of NF-κB, which subjects the exposed cells to 
programmed cell death (Chandra et al.,2011). In line with the previous studies, the 
hypoxia cultured cells express a high level of NF-κB-p65. Therefore, we hypothesized 
that hypoxic tumour microenvironment promotes the existence of CSCs by activation 
of the NF-κB pathway in MM. Extensive bidirectional crosstalk between HIF and NF-
κB has also been described, highlighting the influence that hypoxia may have on the 
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sub adjacent pathways. NF-κB subunits are located in the cytoplasm in an inactive 
form, allowing a rapid response following an activating stimulus (Tirpe et al.,2019). 
Since hypoxia activates NF-κB, this study compared the mRNA and protein 
expression of NF-κB-p65, in attached/normoxic and hypoxic cultures. The results 
showed an increased expression of NF-κB-p65 in hypoxic cultures as compared to 
normoxia in both protein level and mRNA levels. Therefore, these findings suggest 
that hypoxia-induced stress can increase the expression of NF-κB in MM cell lines. 
NF-κB showed significant support for cancer development and maintenance. 
Additionally, NF-κB is important for metastasis through epithelial to mesenchymal 
transition EMT. Hence, the NF-κB pathway is a promising target for cancer therapy 
(Pires et L.,2018).  
A large body of evidence exists to support the rationale of pursuing novel therapies 
which modulate the NF-κB pathway (Godwin et al., 2013). NF-κB protects DNA-
damaged cells from apoptosis and stimulates cell proliferation, which at least partly 
contributes to its role in promoting cell transformation (Lin et al.,2010). Also, in many 
types of cancer, chemotherapy and radiotherapy induce constitutive activation of NF-
κB, thereby making the tumour non-responsive to the treatment (Chaturvedi et 
al.,2011). We hypothesized that NF-κB drives chemoresistance in MM. Cisplatin is 
the first-line drug used as combination chemotherapy for the treatment of MM.  
Platinum-based drugs cause apoptosis by forming DNA adducts. Cisplatin causes the 
chronic activation of apoptotic MAPK and c-Jun N-terminal kinase (JNK) pathways. 
NF-κB can also be activated by this mechanism, resulting in selective apoptotic 
signalling. By this mechanism, the NF-κB activation can be driven by MAPK pathway 
in response to Cisplatin treatment. It means that inactivating mutations in the JNK 
pathway could lead to signalling only via NF-κB pathway in response to Cisplatin 
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treatment, thereby providing a potential mechanism of resistance (Godwin et al.,2013). 
Therefore, NF-κB represents an attractive target for anticancer therapy, particularly as 
an adjuvant to overcome resistance to platinum-based chemotherapeutics (Godwin et 
al.,2013).  
Since NF-κB is shown to be activated in tumour progression, therefore, to understand 
its role in depth, MSTO-211H cell lines were transfected with pcDNA 3.1 and NF-
κB-p65 was successfully overexpressed. Two positive clones were selected based on 
the relative increase in the mRNA expression determined by qRT-PCR and the 
increase in protein concentration by western blot analysis. NF-κB proteins are involved 
in the dimerization of transcription factors, regulate gene expression and affect various 
CSC biological processes, including inflammation, stress responses, growth, and 
development of CSCs (Yang et al.,2019). This study did not identify any association 
between increased expression of NF-κB and CSC traits. 
 
The overexpressed clones did not demonstrate resistance to anti-MM drugs as 
compared to the mock, and the expression level of CSC markers did not increase as 
compared to the mock. Therefore, NF-κB did not depict a clear association with 
chemoresistance caused by CSC traits. Also, the complex mechanism of 
chemoresistance makes it challenging for finding a promising therapeutic target. 
Although many previous publications, including our group, has demonstrated that 
NFNB is responsible for cancer stemness and chemoresistance, I did not have the same 
findings in MM cell line. Therefore, the role of NFNB may be dependent on cancer 
type. To further confirm the obtained results from ectopic expression in MM, 
CRISPR-Cas 9 technology was used to knock out NF-κB-65. Similar to the 
overexpression, two knocks out clones were selected and compared to scrambled for 
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cytotoxicity. However, I was not able to carry out further studies because of the time 
constraints. My findings from the results suggest that NF-κB does not play a prominent 
role in causing chemoresistance in MM. The current proven therapy for MM is 
combination chemotherapy and is widely practised along with surgery and 
radiotherapy where possible, considering the age and status of the disease. Also, this 
study and recent other studies have shown the importance of CSCs in causing 
chemoresistance. Therefore, the development of drugs targeting CSC along with 
conventional anticancer drugs suggests improving the response rate in MM patients.   
 
Drug repurposing promises a quicker and cost-effective alternative for new drugs, 
especially for orphan cancers like MM. This study focused on repurposing PLGA-DS 
in combination with Copper to treat MM cell lines. The results of the treatment showed 
reversed chemoresistance by targeting CSCs. DS could be a way to hit the “Bullseye" 
given the fact that it not only kills CSCs but also seems to do so by targeting multiple 
pathways (Triscott, Rose Pambid and Dunn, 2015). Since DS is a bivalent metal ion 
chelator, DS forms a complex with Cu (DS/Cu) which is more readily taken up by 
cells (Wu et al., 2018) DS/Cu is a potent ROS inducer (Yip et al., 2011). MTT assay 
and sphere reformation assay clearly showed that the anticancer activity of DS is 
directly dependent on Copper in MM cell lines. PLGA-DS/Cu reversed 
chemoresistance in the hypoxic cultures and inhibited resistant sphere reformation 
after treatment. The results from my study demonstrated that PLGA-DS/Cu inhibited 
known MM stemness markers, i.e. CD 24, ABCG2 and CD 133 in MM hypoxia-
induced CSC cells. Additionally, PLGA-DS/Cu was able to inhibit ESC markers and 
eradicated spheroid cultures which further confirmed its ability to target CSCs in MM 
cell lines. These results confirm that PLGA-DS/Cu demonstrate significant inhibition 
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of CSC traits, including self-renewal, proliferation and chemoresistance. The 
successful in vitro data from this study and our previous research showing the evidence 
of PLGA-DS/Cu to target CSCs in NSCLC, glioblastoma and breast cancer makes 
PLGA-DS/Cu as a potential chemotherapeutic treatment for MM. Further, data from 
our group has also shown that initial reaction of PLGA-DS chelation with Cu (II) 
generates extracellular ROS as a byproduct which is lethal to cancerous cells, this is 
followed by transport of DDC-Cu (a byproduct of PLGA-DS/Cu) which causes 
intracellular ROS. Thus, making PLGA-DS/Cu work in biphasic reaction and 
directing the cell towards apoptotic cell death (Tawari et al., 2015). 
 
Remarkably PLGA-DS/Cu also enhanced the cytotoxicity of anti-MM drugs 
synergistically which improve the efficacy and reduce the toxicity. Further, the study 
on the key structure of DS, which is responsible for the anti-cancerous activity will 
aid in the translation of PLGA-DS to the clinic. Our previous study has also shown 
that PLGA-DS formulation administration by intravenous injection in combination 
with oral CuGlu significantly improved the efficacy of DS in liver cancer xenografts 
without causing any side effects (Wang et al., 2017). In line with our previous work, 
the in vivo data based on our study in MM demonstrated significant anti-cancerous 
activity of PLGA-DS in MM xenograft models. Therefore, the in vivo and in vitro data 
confirms the successful combination of DS with Cu as a potential anti-MM drug with 
little or no known toxicity. It also makes PLGA-DS/Cu as an excellent candidate for 
combination chemotherapy with conventional anti-MM drugs. It can contribute to the 









































8.1 Conclusion  
 
To conclude, hypoxic tumour microenvironment plays a significant role in inducing 
CSC traits and chemoresistance in MM cell lines in vitro. CSCs are resistant to all 
modes of therapies including radio and chemotherapy and possess the ability of self-
renewal, proliferation and metastases. Hypoxia generates intra tumoural oxygen 
gradients which increases the plasticity and heterogeneity in the tumours forming an 
aggressive phenotype resistant to treatments. Hypoxia induces NF-kB pathway, and 
many of the target genes transcribed by NF-kB play an essential role in the regulation 
of various pathways involved in the hallmarks of cancer. DS is a known drug to target 
cancer stem cells in a copper-dependent manner, with negligible side effects. DS/Cu 
synergistically enhanced the cytotoxicity of first-line drugs in chemoresistant hypoxic 
cultures in vitro. The intact sulfhydryl group is imperative for DS mechanism of Cu 
(II) chelation to generate ROS and target cancer cells. Therefore, the success of DS in 
vivo largely depends on copper supplementation along with intact sulfhydryl group to 
the diseased tissue without getting metabolised. The half-life of DS in the bloodstream 
is less than 4 minutes. Therefore, our group encapsulated DS with biodegradable 
polymer PLGA and extended its half-life to ~7 hrs in serum. The encapsulation 
ensured an adequate ratio of DS to react with the Cu at a distant targeted site. DS is an 
FDA approved drug for more than 60 years with no known side effects. PLGA-DS/Cu, 
in combination with anti-MM drugs, can reduce the cytotoxic effects of conventional 
therapies. This data is consistent with our previous work in treating various other 
cancers with PLGA-DS/Cu and support translation of PLGA-DS for treating cancer. 
The successful translation of PLGA-DS to clinics will significantly improve overall 
survival and quality of life for MM patients.  
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8.2 Future work 
In support of my in vitro studies, CRISPR-Cas9 technology would further elucidate 
the role of NF-kB in causing chemoresistance in MM cell lines. Due to time 
constraints, I was not able to further perform experiments on NF-kB-p65 knock out 
clones to determine the definitive role of NF-kB in MM. I would have also investigated 
the expression level of EMT and CSC markers on protein level by western blot which 
would further confirm my results obtained on mRNA level by qRT-PCR. I would also 
suggest investigating the effect of PLGA-DS on healthy epithelial cells which would 
indicate that this therapy is selective for malignant cells and not healthy cells. The 
effect of PLGA-DS Cu and its enhancing effect on conventional anticancer drugs, e.g., 
cisplatin and pemetrexed on NF-kB transfected cells should also be determined. My 
results also suggest the active role of HIF 2D in causing chemoresistance in MM. I 
successfully overexpressed HIF 2D in MSTO 211H cell lines and further experiments 
would confirm the resistance mechanisms with respect to HIF signalling in MM. 
The results obtained in this study showed promising in vitro results and was further 
considered for animal studies which showed valuable insights. But, the translation of 
PLGA-DS to clinics require various guidelines and mandatory clinical studies.  Since 
mesothelioma is a rare and orphan localised neoplasm, we propose PLGS-DS 
administration by i.v injection. The ICH guidelines provide the recommendations to 
support nonclinical evaluations of an anticancer drug before proceeding to clinical 
trials (ICH Topic S9, 2008). Hence,  for clinical trial approvals, we must recognise the 
detailed pharmacological and toxicological profile of PLGA-DS.  This will establish 
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Appendix 2: Hypoxia cultured MM cell lines E -58 and 2591 are resistant to first 



































































































      The cell viability curve shows the effect of first-line anti-MM drugs on normoxic   
      and hypoxic cultures of E -58 and 2591 cell lines. The cells were treated with (A)  
     Cisplatin (B) Pemetrexed for 72 hours and then subjected to MTT assay (C) IC-50  
     values for E -58 and 2591 cell lines under normoxia and hypoxia after 72 hours of   
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 drug in combination 
with PLGA-DS/Cu(nM) 
CI values 
E58 Hypoxia 2591 Hypoxia 
ED50 ED75 ED90 ED50 ED75 ED90 
Cisplatin (nM) 2.51 0.92 4.81 
 0.73 0.94 1.21 
0.98 0.21 0.50 
0.61 0.51 0.43 
The above results indicate the effect of PLGA-DS with CuCl2 in hypoxia cultured cell lines. 
The cells were treated with serial dilution of PLGA-DS μM + CuCl2 μM (1:1) and 
incubated for 72 hours and then subjected to MTT assay. Combination index (CI) values 
for hypoxic cultures treated with drug combinations. The effective dose at 50% (ED50) in 
both cell lines showed a greater synergistic relationship with PMT+PLGA-DS/Cu (1:10) 




Appendix :3 NF-κB-p65 knock out clones did not alter the drug sensitivity in MM  
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The above results indicate the effect of Pemetrexed (1µM) in NF-kB-p65 
overexpressed clones. The cells were treated with Pemetrexed (1µM) and 
incubated for 72 hours and then subjected to MTT assay.  
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Appendix 4: NF-κB-p65 knock out MSTO-211H cells did not demonstrate    
significant decrease in the expression of (A) ESC markers (B) Invasiveness and    
 (C) EMT related markers.  
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